



Time for united action on depression: a Lancet-World Psychiatric Association commission

LSE Research Online URL for this paper: <http://eprints.lse.ac.uk/114299/>

Version: Accepted Version

Article:

Herrman, Helen, Patel, Vikram, Kieling, Christian, Berk, Michael, Buchweitz, Claudia, Cuijpers, Pim, Furukawa, Toshiaki A., Kessler, Ronald C., Kohrt, Brandon A., Maj, Mario, McGorry, Patrick, Reynolds, Charles F., Weissman, Myrna M., Chibanda, Dixon, Dowrick, Christopher, Howard, Louise M., Hoven, Christina W., Knapp, Martin ORCID: 0000-0003-1427-0215, Mayberg, Helen S., Penninx, Brenda W.J.H., Xiao, Shuiyuan, Trivedi, Madhukar, Uher, Rudolf, Vijayakumar, Lakshmi and Wolpert, Miranda (2022) Time for united action on depression: a Lancet-World Psychiatric Association commission. *The Lancet*, 399 (10328). 957 - 1022. ISSN 0140-6736

[https://doi.org/10.1016/S0140-6736\(21\)02141-3](https://doi.org/10.1016/S0140-6736(21)02141-3)

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

**TIME FOR UNITED ACTION ON DEPRESSION:
A LANCET-WORLD PSYCHIATRIC ASSOCIATION
COMMISSION**

Suggested citation: Herrman H, Patel V, Kieling C, Berk M, Buchweitz C, Cuijpers P, Furukawa TA, Kessler RC, Maj M, McGorry P, Reynolds III CF, Weissman MM, Chibanda D, Dowrick C, Howard LM, Hoven CW, Knapp M, Kohrt BA, Mayberg HS, Penninx BWJH, Xiao SY, Trivedi M, Uher R, Vijayakumar L, Wolpert M. Time for united action on depression: a Lancet-World Psychiatric Association Commission. Lancet. 2021; in press.

*Helen Herrman, MD – Orygen and Centre for Youth Mental Health, The University of Melbourne, Australia

h.herrman@unimelb.edu.au

*Vikram Patel, PhD – Harvard Medical School, USA; Sangath, India

vikram_patel@hms.harvard.edu

*Christian Kieling, MD – Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

ckieling@ufrgs.br

\$Michael Berk, PhD – Deakin University, Melbourne, Australia

Michael.berk@deakin.edu.au

\$Claudia Buchweitz, MA – Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

cbuchweitz@hcpa.edu.br

\$Pim Cuijpers, PhD – VU University Amsterdam, Amsterdam, the Netherlands

p.cuijpers@vu.nl

\$Toshiaki A. Furukawa, MD, Full Professor – Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan

furukawa@kuhp.kyoto-u.ac.jp

\$Ronald C. Kessler, PhD, Full Professor – Harvard Medical School, Boston, USA

Kessler@hcp.med.harvard.edu

\$Mario Maj, PhD, Full Professor – University of Campania L. Vanvitelli, Naples, Italy

majmario@tin.it

\$Patrick McGorry, MD, Full Professor – Orygen, The National Centre of Excellence in Youth Mental Health and The University of Melbourne, Melbourne, Australia

pmcgorry@unimelb.edu.au

\$Charles F. Reynolds III, MD, Full Professor – University of Pittsburgh School of Medicine, Pittsburgh, USA

reynoldscf@upmc.edu

\$Myrna M. Weissman, PhD, Full Professor – Columbia University Vagelos College of Physicians and Surgeons, New York State Psychiatric Institute, New York, USA

myrna.weissman@nyspi.columbia.edu

Dixon Chibanda, PhD – University of Zimbabwe, Harare, Zimbabwe

dichi@zol.co.zw

Christopher Dowrick, MD – University of Liverpool, UK

cfd@liv.ac.uk

Louise M. Howard, PhD, Full Professor – King's College London, UK

louise.howard@kcl.ac.uk

Christina W. Hoven, DrPH, Full Professor – Columbia University, New York State Psychiatric Institute, New York, USA
ch42@columbia.edu

Martin Knapp, PhD – London School of Economics and Political Science, UK
m.knapp@lse.ac.uk

Brandon A. Kohrt, MD – George Washington University, Washington, D.C., USA
bkohrt@gwu.edu

Helen S. Mayberg, MD – Icahn School of Medicine at Mount Sinai, New York, USA
helen.mayberg@mssm.edu

Brenda W.J.H. Penninx, PhD, Full Professor – Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands
b.penninx@vumc.nl

Shuiyuan Xiao, MD – Central South University Xiangya School of Public Health, Changsha, China
xiaosy@csu.edu.cn

Madhukar Trivedi, PhD – The University of Texas Southwestern Medical Center at Dallas, USA
madhukar.trivedi@utsouthwestern.edu

Rudolf Uher, PhD, Full Professor – Dalhousie University, Halifax, Canada
uher@dal.ca

Lakshmi Vijayakumar, PhD – Sneha, Suicide Prevention Centre and Voluntary Health Services, Chennai, India
lakshmi@vijayakumars.com

Miranda Wolpert, PsychMD, Full Professor – The Wellcome Trust, London, UK
m.wolpert@wellcome.ac.uk

*Editors – equal contribution

\$Lead Writing Group (alphabetical order)

All other authors listed in alphabetical order.

Corresponding author:

Professor Helen Herrman

Orygen and Centre for Youth Mental Health, The University of Melbourne
35 Poplar Road, Parkville, Victoria 3052, Australia

h.herrman@unimelb.edu.au

EXECUTIVE SUMMARY

Depression is a disorder of mood, so mysteriously painful and elusive in the way it becomes known to the self—to the mediating intellect—as to verge close to being beyond description. It thus remains nearly incomprehensible to those who have not experienced it in its extreme mode.

William Styron, *Darkness Visible*, 1990

Evidence has accumulated over decades that depression is a leading cause of avoidable suffering in the world. Yet too few people in communities, governments, and the health sector understand or acknowledge depression as distinct from the other troubles that people face. Too little is done to avoid and alleviate the suffering and disadvantage linked with it. And few governments acknowledge the brake that depression places on social and economic development.

By aligning knowledge about depression from many fields, this Commission has synthesised evidence from diverse contexts and, in consultation with people with lived experience, generated action-oriented recommendations for a variety of stakeholders: communities and those affected by depression and their families; clinicians and public health practitioners, and researchers who work to understand and address it; policy makers and financiers of health and long-term care; and those responsible for motivating decision makers and politicians to act on the evidence. Our aim is to promote concerted and united action to reduce the burden of depression and ensure that greater attention is paid to the millions of people who live with it across the globe.

Our task has never felt more urgent. The potentiation by the COVID-19 pandemic of adverse societal factors such as deep-seated structural inequalities and personal impacts such as social isolation, bereavement, sickness, uncertainty, impoverishment, and poor access to health care has had negative impacts on the mental health of millions of people. It has generated a “perfect storm” that requires responses at multiple levels. This underscores the need to make the prevention, recognition, and treatment of depression an immediate global priority, which we address through a number of key messages and recommendations.

First, depression is a common health condition. It is distinct from the sadness experienced by most people from time to time and from the misery or despair experienced by people in adversity. It brings profound suffering to individuals and families, impairs social functioning and economic productivity, and is associated with premature mortality from suicide and physical illnesses.

Second, even though biomedicine uses a single word to designate this condition, depression is a heterogeneous entity experienced with various combinations of signs and symptoms, severity levels, and longitudinal trajectories. We consider depressive disorders (or simply “depression”) in this report as well as symptoms of depression causing distress or social impairment (although depression as experienced by people diagnosed with bipolar disorder is outside the scope of the report).

Third, core features of the condition have been described over thousands of years, well before the advent of contemporary classifications, and in diverse communities and cultures. This belies the myth that depression is a modern condition, an invention of biomedicine, or restricted to certain cultural groups.

Fourth, depression is the result of a unique combination of factors for each person affected. Proximal adversities act as triggers for the onset of an episode. They typically interact with genetic, environmental, social and developmental vulnerabilities and resilience factors. Embracing the complexity of the disorder involves recognizing the human brain/mind as an interface connecting our conscious selves to the world around us. This requires going beyond a brain-based or a social-environmental paradigm and recognizing that our biology is inseparable from our environment across our life course.

Fifth, at the individual level, detecting and diagnosing depression early in its course, based on recognising the signs and symptoms of illness and functional impairment over time, is a crucial first step. A clinical formulation co-designed by the person with lived experience, caregivers as appropriate, and clinicians sets the foundation for person-centred care. This accommodates the heterogeneous presentations and unique personal stories. A formulation will vary in complexity depending on the individual and family needs, the resources available, and the platform of care. Adopting a staged approach to treatment is a pragmatic strategy for reaching clinical decisions about interventions that are evidence-based and proportional. The staged approach encompasses low-intensity, early interventions aimed at interrupting an emerging episode of depression, long-term multi-modal care for people with recurrent or persistent depression, and a range of interventions in between. Collaborative care models offer an evidence-based way for health systems to implement the staged approach to prevention and care, realizing a vision of personalized interventions for delivery at scale.

Sixth, the great majority of individuals with depression recover from an episode if they obtain adequate support and treatment, even though for a significant minority there are recurrences. We call on communities and professionals to support the empowerment of people with the lived experience of depression. The active role of people with this experience, alongside families, practitioners, policymakers and civil society, is essential in ensuring that the unacceptably high levels of unmet needs are addressed: through sharing their experience to reduce stigma; supporting others with information about the condition and possibilities for help; and advocating for greater resources for evidence-based approaches.

Seventh, a public health approach to depression is needed, taking into account both its social structural determinants and the severity, breadth, and (for many people) durability and persistence of its consequences. The consequences include the loss of lives and the diminution of educational and work opportunities and social connections, even extending to harms to future generations. Preventive and health promoting actions at population and individual levels have a critical role in lowering the prevalence of depression. Early detection and sustained care as needed for people experiencing depression are essential to reducing distress, disability, and suicide. Together these interventions can contribute substantially towards both promoting the health of individuals, families, and communities, and achieving the Sustainable Development Goals for a country.

We encourage health care practitioners to consider depression as a condition that affects people of all ages in a number of different ways. It frequently accompanies other multifactorial illnesses such as diabetes, heart disease, cancer and dementia, and infectious diseases such as HIV and COVID-19, and is likely to complicate and prolong the course of these associated conditions. Practitioners will be rewarded by efforts to integrate depression care with their practice, leading to better outcomes, giving priority to the therapeutic alliance, and addressing the rights and needs of people with depression and their families.

Public health practitioners, policymakers, and researchers need to integrate depression prevention and care into their broader agendas. It is vital to make mental health a central aspect of universal health coverage, and to recognize the need for policies and interventions across sectors, beyond the health sector alone. Researchers should be encouraged to adopt a life course perspective to understanding depression and devise novel methods to optimize prevention, care and recovery, using approaches that are accessible in diverse resource contexts. Decision makers must respond appropriately using the best available evidence and acting on the knowledge that depression has especially profound effects on people living in poverty and adversity. All these stakeholders must also strive to actively engage people with lived experience of depression, including families and caregivers, in the design and implementation of services, policies, and research.

The multi-disciplinary contributions to this report and its synthesis of evidence across fields generate a new focus on several aspects of the experience of depression. The heterogeneity of depression, the universality of the experience even while influenced by culture and context, the uniqueness of the experience for each person, the importance of intervening early, and the consequent need to stage and personalise care are described and justified. We emphasise the need to move beyond health care to consider what is required across societies to reduce the burden of depression. Economics arguments are presented alongside evidence derived from clinical, scientific, and lived experience to reflect on and recommend actions across policy, research and practice.

While there remains much that we do not know about depression, for which we advocate a cutting-edge science agenda, there is much that we *do* know, and which is not utilized optimally. The imperative is, therefore, to invest in translation of knowledge into practice. There is abundant evidence for the efficacy of preventive and therapeutic interventions for depression. However, most communities still do not benefit and most people affected by this condition globally still do not receive these interventions because of a range of demand and supply barriers. Our response to depression will require whole-of-society and whole-of-government engagement, with united action to reduce exposure to adversity and enhance protective factors as well as engage with one of the most private of all human experiences in its diverse aspects, and to ensure that people needing help can find it. Never before has this ambitious agenda been as urgent or necessary.

Panel 1. Key messages of the Lancet WPA Commission on Depression^a**1. Depression is a common but poorly recognized and understood health condition**

Depression can cause profound distress, impair social functioning and economic productivity, and lead to premature mortality; it has substantial impacts on significant others and on society. Yet these impacts are neither well understood nor acknowledged, and there is an insufficient response at local and international levels. There is still a lot we don't know about the prevention and treatment of depression, about what works for whom and why, and we need further scientific discovery as well as better use of what we know if we are to transform the lives of the millions and their families and communities held back by it.

2. Depression is a heterogeneous condition

Although usually classified as a binary disorder, depression has a diversity of clinical presentations, severity levels, and longitudinal courses; it extends beyond the boundaries imposed by current classifications and commonly overlaps with other conditions.

3. Depression is universal, but culture and context matter

Depression has been described across the aeons of human civilization. Depressed mood, loss of interest, and fatigue are common features of the condition across populations. At the same time, there is also considerable variability in types and prevalence of depressive symptoms and signs among cultures and contexts.

4. Prevention is essential to reducing the burden of depression

Whole-of-society strategies are required to operate on adversities early in life and across the subsequent life course. Interventions are also needed at the individual level, focusing on current life habits and risk factors. More efficient prevention of depression is likely to have powerful impacts on the Sustainable Development Goals for a country and the health of individuals and families.

5. The experiences of depression and recovery from it are unique for each individual

Depression is the result of a set of factors, typically the interaction of proximal adversities with genetic, social, environmental and developmental vulnerability and resilience factors. There is a frequent and complex association between depression and physical health. No two individuals share the exact same life story and constitution, which ultimately lead to a particular experience of depression and different needs for help, support, and treatment in recovery.

6. Closing the gap requires engagement of people with lived experience

Preventive efforts across the world are rarely used to best effect and the vast majority of people with depression globally do not receive effective care due to a range of demand and supply barriers. Empowerment of individuals, families, and communities, to work with professionals who can learn from their experience and help demand the implementation of known preventive and therapeutic strategies and to hold health care systems and decision makers accountable is vital.

7. A formulation is needed to personalize care

Detection and diagnosis of depression based on symptoms, function, and duration should be accompanied by a clinical review or formulation for each person that takes into account individual values and preferences, life stories, and circumstances. Formulation identifies characteristics aiding personalised treatment. The complexity and sophistication of the formulation may vary depending on the context of care and availability of resources.

8. A staged approach to care addresses the heterogenous nature of depression and its impacts on individual, family and community functioning

A staged approach offers a pragmatic tool to translate the heterogenous clinical nature of depression for management and to ensure that interventions are comprehensive and yet proportional to the severity of the condition; this facilitates a focus on intervening early in the course of the condition and graduating the intensity of interventions, tailored to the specific needs of the person and the stage of illness.

9. Collaborative delivery models are a cost-effective strategy to scale up depression interventions in routine care

Collaborative care offers an evidence based approach for the delivery of interventions by diverse providers, tailored to the specific stage of the illness, and always including participatory decision

making with patients and engagement with families and communities, greatly increasing the chances of quality rights-based care and remission and recovery.

10. Higher investment with whole-of-society engagement is a priority to translate what we already know into practice and policy and to upgrade the science agenda

While there remains much that we do not know about depression for which we advocate a cutting-edge science agenda, there is much that we do know, and which is not utilized optimally; the most important immediate imperative is to invest in translation of this rich body of knowledge into practice and policy.

^a Encompassing depressive disorders as well as symptoms of depression causing distress or social impairment. Depression as experienced by people diagnosed with bipolar disorder is outside the scope of the report.

INTRODUCTION

When you have other diseases, they are considered normal. Why is depression not considered a normal disease?

- Vidushi Karnatic, 20, Haldwani, India

Over the past decades, much has been achieved in the field of global mental health.¹ The suffering consequent on mental health problems is recognised globally, and promising strategies have been devised to address them, even in low-resourced contexts. The value of mental health and its interconnections with sustainable development are better understood. Mental health is central and intrinsic to overall health, exemplified by the inclusion of mental health in the UN Sustainable Development Goals.¹ Innovative ways of engaging communities and implementing services hold promise for expanded health promotion, prevention and treatment opportunities around the world.

But many challenges remain. Despite robust evidence of the effectiveness of several intervention strategies at multiple levels of promotion, prevention, treatment and support, poor understanding of mental health and mental ill-health and high levels of stigma and discrimination continue to hamper public action. There is no compelling evidence of a reduced burden of these conditions in any society, and the vast majority of persons affected by mental health problems do not receive appropriate interventions.

No mental health condition captures the complexity of these challenges as emphatically as depression, the leading mental health contributor to the Global Burden of Disease.² Metaphors such as “low spirits”³ or “sadness and dejection”⁴ have been used throughout human history to describe the experience of depression. This reflects the omnipresence of the experience, as well as the difficulty in a narrow, discrete framing of the features associated with a condition comprising diverse sets of deeply personal experiences.⁵ Operational definitions and classification systems have been essential in creating a common language for science and practice. Using these definitions and systems nonetheless can be seen to deflect attention from the unique journey of each individual affected by the disorder and to give insufficient weight to the voices of people with lived experience.

The concept of depression as used in medicine and health care refers to a condition that arises from multiple constellations of factors that operate in various ways with widely different outcomes. Different combinations of factors predispose to and precipitate the onset of an episode; lead to different experiences and clinical presentations of the disorder with diverse trajectories; and respond to a wide range of prevention and treatment strategies, although with little indication so far of which works better for whom and in what circumstances. In this report we use two expressions to denote the lived experience of depression—“people with depression” and “patients”—the latter designating persons in clinical encounters and, therefore, constituting a subgroup of the former.

Several core features of depression are identified across various geographies and cultures. The heterogeneity is evident, however, from the multiple ways in which symptoms combine to produce a variety of clinical phenotypes.⁶ At the extreme, two individuals can meet criteria for a diagnosis of major depressive disorder without sharing any single symptom.⁷ Such variability leads to the question of whether depression is one disorder with shades of severity and multiple presentations, or whether it is a common name for a number of loosely related problems.⁸ This diversity is further complicated by the fact that many of the core features of depression are also

part of the normative human response to adversity, without a clear defining line between everyday sadness or distress and the clinical condition.

Unsurprisingly, the quest for a mono-causal aetiology for depression has been unsuccessful. Approaches to understanding the multi-causal aetiology of the condition analogous to those used in other non-communicable diseases have been much more fruitful and appropriate.⁹ While the biological underpinnings of depression must be acknowledged, and depression can be conceptualised ultimately as an illness of the brain,¹⁰ it is essential to recognize the tangible and intangible environmental influences on brain development and function across the lifespan. Recent research on childhood abuse and neglect, for instance, emphasises the lasting effects on the risks for depression not only in childhood and adolescence, but also later in life and in subsequent generations.¹¹ These results make it clear that the pathways to experiencing depression can begin many years before the condition is manifest. The journey almost always involves environmental influences on neurodevelopment, psychological functioning and neural circuits and networks, which in turn mediate the specific phenomena associated with the condition.¹²

Researchers, practitioners, and those with lived experience have long worked to build a knowledge foundation for our understanding of this complex and heterogeneous human experience. Depression has profound effects on a person regardless of sex, background, social class, or age. It is associated with suffering and multifaceted disability, with the early age of onset contributing to difficulties in adult functioning. A proportion of those affected have a recurrent or persistent course, frequent co-occurrence of other health conditions, and an elevated risk of premature death from a range of causes including suicide. Beyond the individual, depression can have a significant impact on families and communities and is an important barrier to the sustainable development of nations. Given the degree of individual suffering and the deleterious impacts on public health and society, it is reasonable to assert that depression is everybody's business and a global health priority. Yet, despite the abundant evidence reviewed later in this report that much can be done to prevent depression and facilitate recovery, only a small minority of the world's population benefits from this knowledge. In this regard, depression is a global health crisis.

This crisis is due in part to the controversies that rage around the nature of depression, its significance as a biomedical condition, and how depression should be managed. There is a tension between depression constituting a *bona fide* medical entity and a leading cause of disability worldwide versus the construct of depression as an extreme of the normative emotional experience that should not be pathologized.¹³ Critical voices question the application of the concept of depression and associated treatment science, mostly developed in European contexts, in diverse cultural settings around the world.¹⁴ Still other critiques question the extent to which conceptualising depression as a biological disorder with implications for use of medications is simply a ploy for reification of normal human suffering under a medical model and promotion of the pharmaceutical industry.¹⁵

Recognising depression as a central yet neglected global health problem led to the creation of this Commission. This Commission has a mandate to present a unifying and balanced view of the available evidence on these and other core questions, indicating also the grey areas and knowledge gaps requiring further research. Its audiences include people with the lived experience of depression and their families, clinical and public health practitioners, researchers, and policymakers. The Commission aims to advance understanding of the nature of depression, laying to rest nihilistic debates — such as the idea that depression is simply sadness or that it

is a creation of biomedicine or that its roots are either biological or social — and providing evidence that depression can be prevented and treated if we move beyond a “one size fits all” approach, which does not work well for depression nor a range of other health conditions. Recognizing the subtleties of each person’s experience of depression and the varying patterns in different population groups and cultural settings across the world is an essential step. This in itself improves the ability to communicate about the disorder to a broader audience,¹⁶ enhancing understanding and reducing stigma. It brings the prospect of facilitating prevention and access to collaborative care strategies, even in resource-limited settings. In doing so, we stand on the edge of an historic opportunity for united action by all stakeholders, across sectors, to work together and reduce the global burden of suffering due to depression.

WHAT IS DEPRESSION?

People have described forms of suffering that resemble depression over thousands of years. Across cultures that developed written medical text—Chinese medicine, Ayurveda, Q’uranic medicine, Western classical antiquity—symptoms of depression are described and remedies outlined. These are underpinned by varied concepts of causation and vulnerability (Figure 1).

Figure 1. Depression across the ages



10,000 BCE

Studies with contemporary hunter-gatherer groups document accounts of prolonged grief, social withdrawal, and loss of vitality,¹⁷⁻²⁰ which are treated with shamanic practices. These practices include symbolic healing, herbal remedies, and collective rituals.²¹

1500 BCE – 6th Century CE

The foundations of the *Ayurveda* healing tradition in South Asia includes some of the first written descriptions resembling depression. The Vedas describe imbalance in humours and lifestyle with manifestations including *vishada*, *avasada*, *manodhukaja*, *adhija unmada*, and *kaphaja unmada*: with characteristics ranging from apprehension-induced despondency and inertia to more severe manifestations of staying in one place, reduced activities, lack of self-care, preferring to be alone, and disgust feelings.²² Descriptions of states resembling depression are found in the Hindu epics, the *Ramayana* and *Mahabharatha*.²²



5th Century BCE – 6th Century CE

During Western Classical Antiquity, Hippocrates (370-460 BCE), then later Plato, Aristotle, and Galen²³ describe melancholia, an accumulation of black bile, characterized as an aversion to food, despondency, sleeplessness, irritability, restlessness²⁴; according to Berrios, “the meaning of melancholia in classical antiquity is opaque and has little in common with 20th-century psychiatric usage (...) Symptoms reflecting pathological affect (e.g. sadness) were not part of the concept.”²³



2nd Century BCE – 8th Century CE

Early Traditional Chinese Medicine writings, such as the *Huangdi Neijing* including the *Suwen* and *Lingshu* text, described health in terms of balance, such as between the macrocosm and microcosm, which reflects Taoist philosophy.²⁴ Imbalance and disturbances of ‘wind’ are associated with a variety of conditions, including symptoms of depression. The term *yu* in early writings referred to “a depressed content of *qi*”, and latter uses of *yu* also referred to depressed mood.²⁵ In the classics of Traditional Chinese Medicine, depression could be a symptom or other conditions or a cause of disease.²⁴

3rd – 9th Centuries CE

Archaeological findings from the Mayan Classical Period and documentation of current populations suggest a range of terms related to depression, with a prominent metaphor referring to the sensation that the body is being eaten and vitality is lost.²⁶ Mayan ethnobotanical preparations are considered to have antidepressant properties.²⁷ Shamanic healing practices were likely used to treat individuals with this suffering, and some practice may be reflected in current *Curandero* healings in Central and South America.²⁸




4th Century CE

The early Christian monastic community, in particular the monks Evagrius Ponticus (360-435 CE), described *acedia* as a state of idleness or restlessness, as well as psychic exhaustion, dejection, resentment, and boredom. Early descriptions focused on experiences of monks in the Egyptian desert near Alexandria.²⁹ *Acedia* was characterized as spiritual failing of those who could not maintain the monastic lifestyle of solitude and devotion, and a succumbing to the Seven Deadly Sins.³⁰ The stigmatization of depression within Christianity is influenced by these early monastic writings. *Acedia* was also considered to be contagious. Eventually, the usage expanded beyond monks, to include the general public.

7th – 13th Centuries CE

During the Islamic Golden Age, scholars of Q'uranic medicine document a range of conditions related to depression and melancholia, depression is a common and treatable illness.^{31,32} Passages throughout the Holy Q'uran and *Mizan al-Hikmah Encyclopedia* (Scale of Wisdom) contain lifestyle and behavioural recommendations considered helpful for preventing and treating depression.³¹



9th– 10th Centuries CE

The Muslim philosopher Al Ash'ath Bin Qais Al-Kindi wrote treatises related to sorrow, describing "a spiritual (*Nafsani*) grief caused by loss of loved ones or personal belongings, or by failure in obtaining what one lusts after."³³ He said that sorrow is not within us we bring it upon ourselves. He used cognitive strategies to alleviate sorrow. Abu Zaid Al-Balkhi compared physical with psychological disorders and showed their interaction in causing psychosomatic disorders. He classified depression into three kinds: everyday normal *huzn* or sadness, as well as forms of endogenous depression and reactive depression.

11th Century

The Four Tantras (also known as Four Treatises, *Rgyud bzhi*) of Tibetan Medicine were composed during the Tibetan Renaissance. In Tibetan Medicine, health is a balance of wind, bile, and phlegm, with wind illness (*rlung*) resembling many aspects of depression.³⁴ Terms related to depression include *skyo snang*, *sems pham pa*, *sems sdug*, which refer to suffering in the *sems*, (heart-mind).³⁵ Treatments include dietary and lifestyle changes, massage, moxibustion and Buddhist spiritual practices, and herbal medicines with anti-depressant properties.³⁶



13th Century

Europe: Thomas Aquinas (Italy, 1225 to 1274) on *acedia*: "It strikes like a recurring fever: it lays the soul low with sultry fires at regular and fixed intervals... a kind of oppressive sorrow."³⁷

14th Century

Europe: After surviving the Black Death, Julian of Norwich (England) became an anchorite. Her writings based on Christian theology had resonance for people devastated by death and turmoil from war, rebellion and plague. She was visited by travellers from across Europe – "all shall be well, and all shall be well and all manner of thing shall be well."

15th Century



Europe: "low spirits" connoted "to bring down in vigour or spirits." Melancholia was also seen to have positive connotations for social status, intelligence, aesthetic refinement. Marsilio Ficino (Florence, Italy): "[B]oth Mercury who invites us to investigate doctrines, and Saturn, who makes us persevere in investigating doctrines and retain them when discovered, are said by astronomers to be somewhat cold and dry just like the melancholic nature according to physicians. And this same nature Mercury and Saturn impart from birth to their followers, learned people, and preserve and augment it day by day."³⁸

16th Century

Yu Zheng, a term widely used in present times to label a group of symptoms similar to the modern concept of depression, was first used by Yu Chuan (1438-1517), a famous doctor in the Ming Dynasty. Yu Chuan published his 8-volume work "Yi Xue Zheng Chuan" (Orthodox of Medicine), which included a chapter on "Yu Zheng." In Yu zheng or yu bing, "Yu" indicates depressed mood, while "zheng" means syndrome and "bing" means disease.³⁹

17th–18th Century

After its publication in 1621, *Anatomy of Melancholy* by Richard Burton dominated European understandings of depression for the following two centuries. In Burton's interpretation, melancholy was seen as both a disease and the essence of the human condition, "a kind of dotage without a fever, having, for his ordinary companions, fear and sadness, without any apparent occasion."⁴⁰

19th Century

In France, Jean Esquirol wrote "melancholy (...) is a cerebral malady characterized by partial, chronic delirium, without fever, and sustained by a passion of a sad, debilitating or oppressive character."^{41,42} The term "nervous erethism" was also terminology used in the French Asylum to refer to irritability, emotional instability, also

association with upper class. In the European cultural context, overlap of melancholia with Romantic concept of *Weltschmerz* (world-weariness), a deep sadness about the inadequacy or imperfection of the world. Around the 1850s, the concept of nondelusional melancholia was introduced, described as “a state of sadness or dejection” – moving the concept away from “the intellect” and closer to “mood.” Delusions were no longer considered the primary symptom in melancholia; the lack of knowledge regarding physiological aspects of the brain/mind led to the proposal of a classification of diseases according to the faculties involved, pushing melancholia away from disorders such as dementia and monomania. After 1860, having established melancholia as a mood disorder, scholars had to propose an explanation for the emergence of delusions in some individuals, and suggested that emotional alterations entailed alterations in intellectual functioning, i.e., the mood disorder spread to other faculties. Delusions would be the consequence, not the cause, of the depressed feeling.^{23,41}

1883

Emile Kraepelin in Germany writes about melancholia that “psychological anguish” arises from “the feelings of dissatisfaction, anxiety and general misery gains such strength that it constantly dominates the mood.” Kraepelin’s work highlights that delusions could arise from depression rather than depression being a result of delusions.



1893

Bertillon Classification of Causes of Death (precursor of International Classification of Disease) published by Jacques Bertillon in Paris.

1900

First international conference to revise *International Classification of Causes of Death*.

1900s - 1920s

In Chinese Medicine, *shenjing shuairuo* is a reference to depletion (imbalance) of qi energy and was translated at that time as neurasthenia in Western medical terms. Ancient methods to improve qi circulation in the body have been incorporated into Tai Chi and Qi gong practices, which have been evaluated as treatments for depression.⁴³

1949

International Classification of Causes of Death (Version 6) renamed as *International Statistical Classification of Diseases (ICD)*, and was the first version of the ICD to include mental disorders.

1952

First version of the *Diagnostic and Statistical Manual of Mental Disorders (DSM-I)* published. Influenced by psychoanalytic concepts, disorders were described according to understandings of their causes and functions: e.g., “Depressive reactions” in relation to psychotic, psychoneurotic, and personality disorders.^{44,45} This approach, rather than symptomatic criteria, continued to be used for DSM-II (1968).



1970

Standardized qualifications for Ayurveda for practitioners and accreditation established in Indian Medical Central Council Act passed by the Parliament of India. Depression-related diagnoses and treatments are made according to a humoral (*dosha*) classification system. Depression symptoms are related to *Vata* and some to *Kapha dosha*.²² Ayurvedic treatments include lifestyle and dietary change, herbal medicines, emesis/purgation, and other practices.⁴⁶

1979

The first edition of the Chinese Classification of Mental Disorders is published. The diagnosis “depression” was considered an equivalent of melancholia in English and not commonly used, with neurasthenia continuing to be the most prominent diagnosis.

1980

Diagnostic and Statistical Manual of Mental Disorders, third version (*DSM-III*) is published with symptomatic based criteria for depression. The DSM-III version is the foundation of the subsequent constellation of symptoms⁴⁵ in DSM-IV (1994) and DSM-5 (2013).

1990s

The term “depression” (*yiyu zheng*) has rapidly replaced neurasthenia as a well-accepted diagnostic label in China, mainly as a reflection of sociocultural changes in the country.⁴⁷

Current diagnostic approaches

The World Health Organization’s 11th revision of its International Classification of Diseases and Related Health Problems (ICD-11)⁴⁸ conceptualizes depression as a syndrome, i.e., a clinically recognizable set of reported experiences (symptoms) and observed behaviours (signs) associated with distress and interference with personal functions.⁴⁹ For a diagnosis of depression, at least five out of a list of 10 symptoms/signs have to be present most of the day, nearly every day, for at least two weeks (Table 1). The presence of either the first or the second symptom/sign is mandatory. The mood disturbance should result in significant functional impairment (“if functioning is maintained, it is only through significant additional effort”). The symptoms/signs are not a manifestation of another medical condition (e.g., a brain tumour), are not due to the effect of a substance or medication, and are not better explained by bereavement.

Table 1. ICD-11 and DSM-5 diagnostic criteria for depressive episode

ICD-11	DSM-5
Depressed mood as reported by the individual (e.g., feeling down, sad) or as observed (e.g., tearful, defeated appearance). In children and adolescents, depressed mood can manifest as irritability.	Depressed mood most of the day, nearly every day, as indicated by either subjective report (e.g., feels sad, empty, hopeless) or observation made by others (e.g., appears tearful). (Note: In children and adolescents, can be irritable mood.)
Markedly diminished interest or pleasure in activities, especially those normally found to be enjoyable to the individual. The latter may include a reduction in sexual desire.	Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day (as indicated by either subjective account or observation).
Reduced ability to concentrate and sustain attention to tasks, or marked indecisiveness.	Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective account or as observed by others)..
Beliefs of low self-worth or excessive or inappropriate guilt that may be manifestly delusional.	Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick).
Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation (with or without a specific plan), or evidence of attempted suicide.	Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide.
Significantly disrupted sleep (delayed sleep onset, increased frequency of waking up during the night, or early morning awakening) or excessive sleep.	Insomnia or hypersomnia nearly every day.
Significant change in appetite (diminished or increased) or significant weight change (gain or loss).	Significant weight loss when not dieting or weight gain (e.g., a change of more than 5% of body weight in a month), or decrease or increase in appetite nearly every day. (Note: In children, consider failure to make expected weight gain.)
Psychomotor agitation or retardation (observable by others, not merely subjective feelings of restlessness or being slowed down).	Psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down).

Reduced energy, fatigue, or marked tiredness following the expenditure or only a minimum of effort.	Fatigue or loss of energy nearly every day.
Hopelessness about the future.	
The presence of at least one of the symptoms in bold is required for a diagnosis according to both ICD-11 and DSM-5. The DSM-5 also states that: at least five symptoms have to be simultaneously present for 2 weeks, and represent a change from previous functioning; the symptoms cause clinically significant distress or impairment in social, occupational or other important areas of functioning; and the episode is not attributable to the physiological effects of a substance or to another medical condition.	

The list of symptoms and signs in Table 1 – almost identical to that proposed by the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM) since its 3rd edition (DSM-III)⁵⁰—is based on the best available evidence. In a sample of people attending outpatient clinics with a range of clinical diagnoses, all symptoms included in the DSM had a positive predictive value above 75%, in differentiating patients with a diagnosis of depression vs. non-depression, with the first two symptoms on the list having the highest values.⁴⁹ “Hopelessness about the future,” the only symptom included in the ICD-11 but not in the DSMs, performed more strongly than about half of the DSM symptoms and signs in differentiating depressed from non-depressed subjects.⁵¹ A further symptom, “diminished drive,” outperformed almost all those that are currently listed, and should probably be added to the list.⁵¹ Other symptoms and signs not included in these definitions – such as lack of reactivity of mood (i.e., the individual’s mood fails to rise even temporarily in response to positive stimuli), anger, irritability, psychic anxiety, and somatic concomitants of anxiety (e.g., headaches, muscle tension) – also discriminated between depressed and non-depressed subjects, but performed less well than the symptoms and signs listed in the DSMs and ICD-11.⁵¹

“Continuous” or “categorical” and the question of severity

More controversial than the list of symptoms and signs defining depression has been the number of symptoms or signs required for diagnosis in both the DSM and the ICD (at least five, one of which must be either depressed mood or diminished interest or pleasure). Several studies^{52,53} have reported that subthreshold depressions (i.e., conditions characterized by the presence of less than five depressive symptoms or signs) did not differ from diagnosable depression with respect to variables such as the risk for future depressive episodes, the family history of mental illness (including depression), psychiatric and physical comorbidity, and functional impairment. Nor has the clinical utility of the five-symptom threshold in predicting response to treatment been confirmed.^{54,55}

Most studies applying latent class analysis⁵⁶ support the notion of a continuity between subthreshold and diagnosable depression. A possible exception is a “nuclear depressive syndrome,”⁵⁷ broadly resembling the melancholic subtype of depression (described later), which does seem to be qualitatively different. Whether melancholia represents a distinct disease entity or corresponds to the most severe manifestation of depression (in which further neural circuits are possibly recruited, so that the clinical picture becomes more complex and with a more significant “biological” component) remains open to debate. However, the fact that several people with recurrent depression experience some episodes which are melancholic and some others which are not⁵⁸ seems to argue in favour of the latter option.

The notion that depression is “continuous” rather than “categorical” does not solve the threshold issue. Should we extend the concept of depression up to include “normative sadness,” i.e., “the sorrow that visits the human being when an adverse event hits his precarious existence”?⁵⁹ This does not seem reasonable, because on the one hand it would reinforce current complaints about the medicalization of “normal sorrow,” driving inappropriate and unnecessary treatment,⁶⁰ and on the other it may mislead people who are really depressed, who could regard their condition as a “normal response to adversity,” thus being discouraged from finding appropriate help.

The need to establish a “threshold” for subsyndromal depression in order to distinguish it from “ordinary feelings of sadness” has been widely acknowledged, and different solutions have been proposed.⁶¹ The most frequently adopted option has been to require at least one “core” depressive symptom (i.e., either depressed mood or loss of interest or pleasure), most of the time for at least two weeks.⁶² Of note, this option is endorsed in the “depression identification questions” of the Guidelines for the Treatment of Depression of the UK National Institute for Health and Care Excellence (NICE),⁶³ although the time frame suggested there is “the last month.” An alternative has been to experience any two depressive symptoms most of the time for at least two weeks, associated with evidence of social dysfunction.⁶⁴

The different levels of severity of depression also remain to be validly characterized. The descriptions provided in the current diagnostic systems, based on the number and intensity of symptoms and the degree of functional impairment, are somewhat generic and lack empirical validation. In fact, the ICD/DSM definitions of “mild,” “moderate,” and “severe” depression are rarely used in ordinary clinical practice worldwide. Clinical trials also do not use these definitions, and assess instead the severity of depression on the basis of the global score on a rating scale, usually the 17-item version of the Hamilton Depression Rating Scale (HAM-D).⁶⁵ Even in clinical trials, there is a variability in how the different levels of severity of depression are defined.^{66,67}

The use of a measurement instrument — such as the 9-item version of the Patient Health Questionnaire (PHQ-9),⁶⁸ based on DSM criteria — has been proposed as a practical approach to addressing the questions of the “threshold” for subsyndromal depression and the assessment of the severity of depression. The PHQ-9 is a brief self-report questionnaire that can be completed by the user in just a few minutes and then rapidly scored by the clinician. It is the most widely used (in the global context) questionnaire for the assessment of nine symptoms of depression, each scored on a four point Likert scale. Scores can be interpreted as a continuous measure of severity or categorized into degrees of severity of depression; scores below 5 signify absence of depression or sub-threshold depression. A recent meta-analysis⁶⁹ reported that sensitivity and specificity was maximized at a cut-off score of 10 or above in studies using a semi-structured diagnostic interview (29 studies, 6,725 participants; sensitivity 0.88; specificity 0.85). Furthermore, using just the first two items which assess the core phenomena of depression (low mood and anhedonia), followed by the remaining questions only if either is endorsed, is associated with similar levels of sensitivity and specificity. 0.85).⁶⁹ Nonetheless, there is some evidence of variation in these psychometric properties across contexts and it is recommended that the instrument, like any other measure of depression, undergo systematic translation and adaptation followed by validation to establish appropriate local cut-offs.⁷⁰ The PHQ-9 has been proposed for routine assessment of depression in primary care settings⁷¹ and shown to be sensitive to treatment response.

In the above-mentioned approaches, the severity of depression is evaluated by adding up the scores for the individual depressive symptoms/signs. However, recent research based on the network perspective on psychopathology (which understands mental disorders as complex networks of interacting symptoms) suggests that the various symptoms and signs may not have the same weight in determining the severity of depression: “depression sum-scores don’t add up.”⁷² Therefore, the nature of the depressive symptoms and signs may also need to be considered. Relevant to this issue, for instance, is the concept of “complicated” vs. “uncomplicated” depression, the former characterized by at least one of the following symptoms or signs: psychomotor retardation, psychotic symptoms, suicidal ideation, and sense of worthlessness or guilt. The complicated/uncomplicated status was found to predict the severity of depression significantly better than the standard number-of-symptoms measures.⁷³ The nature of the depressive symptoms and signs, in addition to their overall intensity might also inform the selection of treatment—for instance, the choice of pharmacotherapy vs. cognitive-behavioural psychotherapy; this is discussed later.⁷⁴

Psychopathological “oversimplification”?

A concern voiced by both mental health and social science researchers^{75,76} is that the recent translation of the concept of depression into operational terms may have involved a psychopathological “oversimplification.” This line of thought argues that the subjective experience of depressed persons is different from “normal forms of negative mood such as despair or sadness.”⁷⁶ Some support for this argument has come from the few studies in which depressed persons were asked to describe their current experience in their own words, or to select from lists of adjectives those which best depicted their state. The most common descriptions provided in one of these studies,⁷⁷ (e.g., “a feeling that the subject was coming down with a viral illness, either influenza or glandular fever, along with descriptions of aches and pains”; “a sense of detachment from the environment”; “a specific inability to summon up effort, a feeling of being inhibited or an inability to envisage the future”), as well as the adjectives they most commonly endorsed (dispirited, sluggish, wretched, empty, washed out, awful, dull, exhausted), do suggest that the nature of the subjective experience of depression may not be fully conveyed by current diagnostic systems, and may involve a more significant “somatic” component than currently maintained.

It remains possible that those descriptions are not relevant to all or most people with depression, but only to a subgroup (i.e., those with melancholia). However, a systematic review of qualitative studies on depression conducted worldwide⁷⁸ found that several somatic symptoms—namely headaches, general aches and pains, problems connected with the heart (e.g., palpitations, heavy heart, heart pain)—were among the features most frequently reported by people with depression across populations. A study based on the “network approach”⁷⁹ also found “sympathetic arousal” (i.e., palpitations, tremors, blurred vision, sweating) to be one of the most central symptoms in the depression network, showing strong connections with other somatic complaints (limb heaviness, pain, headaches).

“Higher-order” dimensions and “specifiers”

Depression often co-exists, at different levels of severity, with anxiety and bodily distress. Studies in primary care settings have indeed suggested that depressive, anxiety, and somatic symptoms may be different presentations of a common latent phenomenon⁸⁰ and may require common therapeutic approaches,⁸¹ leading some to propose a higher-order category of “common mental disorders.”⁸² However, in a subpopulation (more frequently in men), depression may instead be part of an “externalizing” spectrum, also including anger attacks, aggression, substance abuse and risk-taking behaviour.⁸³

This characterization should also consider what current diagnostic systems regard as “specifiers” or “qualifiers” to the diagnosis of depression, such as the presence of melancholic, atypical or psychotic features, a peripartum onset, or a seasonal pattern of occurrence of depressive episodes. In some instances, these features have specific treatment implications, for example, use of antipsychotics in the presence of psychotic features or the use of light therapy in seasonal depression.⁸⁴ In the ICD-11, the qualifier “with melancholia” applies when several of the following symptoms have been present during the worst period within the past month: pervasive anhedonia, lack of emotional reactivity, terminal insomnia, depressive symptoms worse in the morning, marked psychomotor retardation or agitation, marked loss of appetite or loss of weight. The qualifier “with psychotic symptoms” applies when either delusions or hallucinations are present during the episode. Psychotic symptoms may be subtle, they may be concealed by the patient; and the boundary between delusions and persistent depressive ruminations or sustained preoccupations may not be clear. The latest edition of the DSM (DSM-5)⁸⁵ also includes the specifier “with atypical features” (absent in the ICD-11), which pertains to people who have increased appetite, weight and sleep, as opposed to lack of appetite and insomnia.

The DSM/ICD approach, considering melancholic and psychotic features as “specifiers” or “qualifiers” to the diagnosis of depression, rather than assuming that melancholia and psychotic depression are distinct diagnostic entities, is also supported by the evidence that, in many people with recurrent depression, some episodes are either psychotic or melancholic and some others are not.^{58,86}

Since depression occurring within bipolar disorder does not seem to have distinct characteristic features, the history of past manic or hypomanic episodes should be explored in every person presenting with a depressive episode. Bipolar depression⁷ is different from unipolar major depression in several important respects, including treatment needs and prognosis. Ascertaining this history can considerably affect the management plan.⁸⁷ It represents for instance an increased risk of postpartum psychosis in the initial weeks after birth in women.⁸⁸

An issue which remains controversial is that of “mixed” depression, i.e., a depressive syndrome accompanied by symptoms/signs of thought, motor or behavioural overactivation interpreted as “contrapolar.” DSM-5 defines “major depression with mixed features” as a depressive episode with at least three typical manic symptoms/signs – such as expansive mood, inflated self-esteem or increased involvement in risky activities – present on most days. On the contrary, in the ICD-11 characterization, the most common “contrapolar” features are irritability, racing or crowded thoughts, increased talkativeness and psychomotor agitation, in line with both the classic⁸⁹ and recent⁹⁰ literature on this issue.

Both the ICD-11 and DSM-5 provide different codes for “single episode depressive disorder” and “recurrent depressive disorder” (the latter defined in the ICD-11 by a history of at least two depressive episodes separated by several months without significant mood disturbance). Both diagnostic systems acknowledge that the remission after a depressive episode may either be “partial” or “full”. The ICD-11 provides a qualifier indicating that the current depressive episode is “persistent” (i.e., diagnostic requirements have been met continuously for at least the past two years) whereas in the DSM-5, “persistent depressive disorder” is a separate diagnostic entity. “Dysthymic disorder” is yet another variant, characterised by persistent depressed mood, accompanied by typical symptoms of depression but which never meet the diagnostic requirements for a depressive episode.

Age and gender

Depression among preschool children has been recognized only recently; and, although less common than at other ages, preschool-onset depression can display a persistent course through late adolescence, with multiple negative outcomes.⁹¹ Considering adolescents, there is a widespread notion that moodiness, feelings of loneliness, interpersonal sensitivity and negative self-perception are relatively common. This perception has contributed to the neglect or even the denial of the problem of youth depression, despite its importance as a signal of the possibility of recurrent depression throughout the life course.⁹² On the other hand, depressive symptoms may be part of the fluid and nonspecific clinical picture which has been described as a prodromal stage of the development of several mental disorders.⁹³

In the ICD-11 and DSM classifications, the only emphatic difference in the clinical picture of depression among children and adolescents compared with that in adults is that “depressed mood can manifest as irritability.” Beyond that, the ICD-11 text notes that the reduced ability to concentrate or sustain attention may manifest in adolescence as a decline in academic performance or an inability to complete school assignments. Indeed, depressed adolescents are often primarily irritable and unstable, with frequent anger outbursts, sometimes without significant provocation, which may result in a deterioration of their interpersonal relationships.^{94,95} Moreover, they may not report sadness, but complain of feelings of disquiet and malaise that are overwhelmingly painful.⁹⁵ Ruminations about being unable to live up to school demands or about feeling different from others are common. In many cases, conduct problems, eating disorders, substance abuse or inattention at school may be the main focus of relatives’ or teachers’ complaints. Suicidality and self-injurious behaviours are particularly sensitive concerns in young people. Complicating the picture in a young person, depression usually precedes mania in bipolar disorder, so that the index presentation of this disorder in youth is often depression.⁹⁶

As in adolescents, depression among the elderly tends to be under-recognized or minimized. It is often ascribed to normal ageing, or to losses or physical illness. The clinical picture of depression in older people, compared with that in middle-aged adults, includes a higher frequency of somatic symptoms, anxiety, psychomotor retardation or agitation, and psychotic features. Moreover, depression in the elderly is more commonly associated with cognitive impairment (in particular memory disturbances, impaired executive functions and slowed information processing), painful conditions, and physical disability.⁹⁷


Depression is consistently found to be more common in women than in men. This gender difference is first apparent at about 12 years of age, and has been found to peak in adolescence, at about age 16.⁹⁸ Whether the gender gap decreases or not at older age is currently debated.⁹⁹ The clinical picture was reported until recently as similar in women and men although, as noted earlier, “externalizing” features are now recognised as more common in men.⁸³ In addition, appetite changes, fatigue, and poor sleep may be associated with pregnancy and the postpartum, and are less discriminating for depression during the perinatal period.¹⁰⁰

Culture and depression

A challenge to understanding the generalizability of depression to the global context is that the vast majority of research has come from high-income, predominantly English-speaking countries. Some authors critique that the concept of depression conveyed by the ICD is biased towards these populations. Studies of depression across history and cultures (see Figures 1 and 2) suggest that while several core features of depression are clearly identified across

geographies and cultures, there remain significant variations. For instance, the prominence of sadness might not be universal, emotions are expressed in differing ways, and there is overlap between the concepts of social suffering and depression as a biomedical construct.^{101,102}

Figure 2. Depressive symptoms in diverse global populations



Based on analyses by Haroz et al.⁷⁸ of data from 170 study populations and 76 nationalities/ethnicities. Study populations categorized as Western included North American/European/Australian non-native populations (55 study populations). Non-Western population included Sub-Saharan Africa (38 study populations), South Asia (25 study populations), Latin America (21 study populations), East Asia (7 study populations), Southeast Asia (10 study populations), the Middle East/North Africa (11 study populations), and North American/European/Australian Indigenous populations (3 study populations). No studies were identified from Russia or Central Asia. Non-Western populations excluded Northern American/European/Australian non-native populations. *ICD/DSM major depressive episode symptoms.

Cross-national studies using standardized diagnostic tools such as the CIDI support the prevalence of many of the ICD/DSM symptoms across cultures and populations.¹⁰³ However, contextually grounded research draws attention to other symptoms that are not routinely evaluated even though they may be salient for people presenting with depression and their healthcare providers. Examples are loneliness, anger, and headaches. The higher prevalence of somatic symptoms, such as headaches and general aches and pains, among African, Asian, Caribbean, Central and South American and Pacific Islander peoples and Indigenous populations from North America, Europe, and Australia (Figure 2),⁷⁸ may relate to a number of factors. Even though somatic complaints are rarely documented in studies, they may be discussed more readily than cognitive and emotional ones.^{104,105} Irritability and anger are also not included within DSM criteria for adults but are frequently noted across diverse cultural groups.^{78,106,107} The subjective experience of loneliness is also a hallmark symptom in many cultural groups;^{78,108,109} for example, among Aboriginal men in Australia, loss of social

connection was a central feature of the depression experience with less salience of hopelessness and somatic complaints.¹¹⁰ One notable finding contrasts depression as a relatively weak risk factor for suicidal ideation, plans and attempts in low- and middle-income countries with the strong relationship between suicidality and depression in high-income countries.¹¹¹

Cultural idioms of distress have been evaluated for similarities with ICD/DSM classifications of depression. These idioms include *hwa-byung*, *shenjing shuairuo*, and *phiền não tâm thần* in East and Southeast Asia; tension and heart-mind problems in South Asia; *kufungisisa*, *kusuwisia*, and *yo'kwekyawa* in Sub-Saharan Africa; and *susto*, *coraje*, and *nervios*-related conditions in Latin America. A meta-analysis examining the association of these concepts with ICD/DSM depression categories observed that persons endorsing these idioms had 7.55 greater odds than others of meeting the ICD/DSM depression criteria.⁴ The idiom “thinking too much” denotes a broader mental health syndrome, with manifestations such as sadness, lack of motivation, poor concentration, sleep difficulties and irritability, perhaps similar to the construct of ‘common mental disorders’.¹¹²⁻¹¹⁷ Using these idioms and other cultural concepts has been central to the development and adaptation of psychological interventions for depression that are culturally acceptable and reduce risk of stigmatization.¹¹⁸⁻¹²¹ Use of the idioms can also be paired with depression screening tools to reduce screening time and improve accuracy of detection.¹²²

Unfortunately, cultural influences on the experience of depression among children and adolescents have received very limited attention. To date, some studies have suggested that symptoms such as appetite or weight changes do not distinguish between depressed and non-depressed outside of affluent high-resource settings, as evidenced by studies in Turkey, Nigeria, and Nepal.¹²²⁻¹²⁴ Subjective experiences of loneliness are distinctive aspects of the phenomenology of depression among youth across cultural groups in high-income and low- and middle-income countries.¹²⁴⁻¹²⁶

Depression and grief

The affect of grief is different from depressed mood. It consists of feelings of emptiness and loss. Self-esteem is usually preserved. Dysphoria tends to occur in waves, usually associated with thoughts or reminders of the deceased, rather than being persistent.⁵⁶ However, both the ICD-11 and the DSM-5 acknowledge that depression may occur in some bereaved people. The ICD-11 provides a higher threshold for the diagnosis of depression; a longer duration of the depressive state is required (a month or more following the loss, with no periods of positive mood or enjoyment of activities), as well as the presence of some symptoms which are unlikely to occur in “normal” grief (extreme beliefs of low self-worth and guilt not related to the lost loved one, psychotic symptoms, suicidal ideation, or psychomotor retardation). This approach, present in the DSM-IV, has been abandoned in the DSM-5, where the threshold for the diagnosis of depression is the same in bereaved and non-bereaved persons.

The ICD-11 has also introduced the new category of “prolonged grief disorder,” including abnormally persistent and disabling responses to bereavement.¹²⁷ Following the death of a person close to the bereaved, there is a persistent and pervasive grief response characterized by longing for the deceased or persistent preoccupation with the deceased, accompanied by intense emotional pain. Symptoms may include sadness, guilt, anger, denial, blame, difficulty accepting the death, feeling that the person has lost a part of his or her self, an inability to experience positive mood, emotional numbness, and difficulty in engaging with social or other activities. This response must clearly exceed expected social, cultural, or religious norms and, to attract the diagnosis, it must persist for more than six months following the loss. There is

evidence that prolonged grief disorder, characterized as a stress disorder in DSM-5, responds well to a specific type of psychotherapy tailored for the condition.¹²⁸

Although the symptoms of prolonged grief disorder are observed across cultural settings,¹²⁹ grief responses may manifest in culturally specific ways, with wide diversity in the expected norms for duration of grieving.¹³⁰⁻¹³² Of note, studies of cultural concepts of grief among refugees demonstrate that the terms and explanatory models for prolonged grief are distinct from cultural concepts of depression.¹³³

EPIDEMIOLOGY AND BURDEN

Depression doesn't hand you an itinerary.

- Ishita Mehra, 22, Delhi, India

It is estimated that 4.7% (95% uncertainty interval: 4.4-5.0%) of the world's population have an episode of depression in any 12-month time period.¹³⁴ Only about half as many people have depression at a point in time given that average episode duration is about 6 months, although there is wide variation around this average.¹³⁵ Higher estimates have been reported for 12-month and 30-day prevalence of depressive episodes which include those due to bipolar disorder;¹³⁶ up to 20-33% of depressive episodes at a point in time is associated with a history of bipolar spectrum disorder.¹³⁷ This high proportion of bipolar involvement in current depressive episodes exists despite lifetime prevalence of bipolar disorder being much lower than that of depression because depressive episodes are much more persistent and recurrent among people with bipolar disorder than among individuals with depression.¹³⁸

Estimates of depression prevalence within world regions pooled across available data sources were created by the World Health Organization (WHO) for 2015.¹³⁹ These estimates suggest that 12-month prevalence among women was somewhat higher in Africa and the Americas (5.8%) and somewhat lower in the Western Pacific (4.2%) than in the remaining regions of the world (5%). Among men, estimated prevalence was highest in Africa (4.8%), lowest in the Western Pacific (2.8%), and intermediate in other regions (3.5-3.8%). More recent estimates of depression point prevalence in differently defined world regions were created by the Institute for Health Metrics and Evaluation as part of their Global Burden of Disease (GBD) Study 2019.¹⁴⁰ The estimated point prevalence among both women and men was highest in North America (4.4 and 2.5% respectively) and lowest in the Western Pacific (2.3 and 1.3%); it was intermediate in other world regions both for women (2.8-3.6%) and men (1.9-2.0%). The exact reasons for such variations are yet to be understood. They are likely attributed mostly to the varying distribution of risk or protective factors. Methodological aspects, such as differential response to questions assessing depressive symptoms, may also account for some of the variability.

Most estimates of lifetime prevalence of depression are based on retrospective reports and need to be interpreted with caution as they are likely to underestimate true lifetime prevalence.¹⁴¹ Retrospectively-reported lifetime prevalence of depression from community epidemiological surveys with adults aged 18-74 years in 28 countries¹³⁵ averaged 10.6% across countries (interquartile range of 6-14%). Prospective epidemiologic studies report much higher lifetime prevalence of major depression in the range of 30-40%.¹⁴¹

Course and outcome

The higher epidemiological estimates of lifetime prevalence than 12-month prevalence suggest that 33-50% of the people with a lifetime history of depression experience a depressive episode in a year. These estimates are broadly consistent with follow-up studies in clinical and community samples. However, this naturalistic course is diverse. Most depressive episodes remit within one year. The prevalence of persistent depression (i.e., an episode lasting more than 12 months) is estimated to be as low as 12% in people meeting criteria for a diagnosis of depression in community surveys; but it can be as high as 61% among those receiving treatment for depression in primary and secondary care settings (Table 2).¹⁴² The diversity of the naturalistic course in depression is also apparent in rates of recurrence after recovery. Among individuals who seek treatment, depression is often an intermittent recurrent disorder over the life course,¹⁴³ commonly with partial remission between episodes.¹⁴⁴ In primary or secondary care settings, follow-up studies of 5 years or more suggest that recurrence can be as high as 71-85%. However recurrence rates are much lower for people ascertained as having depression in community samples; between 27% and 45% report experiencing a recurrent episode over 20 years (Table 2).

Table 2. Persistence and recurrence of depressive disorders in community and clinical samples

Persistence					
Study	Setting	Sample	Indicator	Follow-up	Estimate
Finnish Health 2011 study ¹⁴⁵	Community-based	298 individuals with depression	Persistence: CIDI depression diagnosis at follow-up	11 years	21%
NEMESIS 1 ¹⁴⁶	Community-based	201 individuals with depression	Persistence: CIDI depression diagnosis at follow-up	7 years	29%
NEMESIS 2 ¹⁴⁷	Community-based	242 individuals with depression	% with 2 years of continuous symptoms based on CIDI and lifechart	6 years	12%
NESDA ^{142,148}	Mixed primary and secondary care	903 individuals with depression	% with 2 years of continuous symptoms based on CIDI and lifechart	6 years	34%
			Persistence: CIDI diagnosis at follow-up	2 years	42%
NESDO ¹⁴⁹	Mixed primary and secondary care	285 older (60+) individuals with depression	Persistence: CIDI diagnosis at follow-up	2 years	48%
NIMH-CDS ¹⁵⁰	Tertiary care	431 individuals with depression	% weeks with symptoms in 195,829 total follow-up weeks based on LIFE Psychiatric Rating Scale	12 years	59% of all weeks with depression symptoms; 15% of all weeks with (severe) depression symptoms
Recurrence					
Study	Setting	Sample	Indicator	Follow-up	Estimate
Lundby study ¹⁵¹	Community-based	344 individuals with remitted first-incident depression	SCID (DSM-IV) diagnosis at follow-up	40 years	40%
Baltimore ECA ¹⁵²	Community-based	92 individuals with remitted first-incident depression	DIS (DSM-III) diagnosis at follow-up	23 years	45%
NEMESIS 1 ¹⁵³	Community-based	687 individuals with remitted depression	CIDI (DSM-III) diagnosis at follow-up	20 years	42%

NEMESIS 2 ¹⁴⁷	Community-based	746 individuals with remitted depression	CIDI (DSM-IV) diagnosis at follow-up	20 years	27%
Depression relapse RCT ¹⁵⁴	Primary care	386 individuals with remitted depression	SCID (DSM-IV) diagnosis at follow-up	1 year	31%
Vantaa Depression Study ¹⁵⁵	Primary care	92 depressed participants who remitted of index disorder during follow-up	SCID (DSM-IV) diagnosis at follow-up	5 years	51%
Long-term INSTEL RCT ¹⁵⁶	Primary care	166 individuals with depression who remitted of index disorder during follow-up	CIDI (DSM-IV) diagnosis at follow-up	10 years	77%
NEMESIS ¹⁵⁷	Mixed primary and secondary care	375 individuals with depression who remitted of index disorder during follow-up	CIDI (DSM-IV) diagnosis at follow-up	2 years	27% (primary care) 34% (secondary care)
Vantaa Depression Study ¹⁵⁸	Secondary care	142 individuals with depression who remitted of index disorder during follow-up	SCAN & SCID (DSM-IV) diagnosis at follow-up	5 years	71%
In-patient study ¹⁵⁹	Tertiary care	57 individuals with depression who remitted of index disorder during follow-up	CID (DSM-III) diagnosis at follow-up	15 months	40%
NIMH-CDS ¹⁶⁰	Tertiary care	380 individuals with depression who remitted from index disorder during follow-up	SADS (DSM-III) diagnosis at follow-up	15 years	85%
Tertiary care study ¹⁶¹	Tertiary care	65 individuals with depression who remitted of index disorder during follow-up	SCID (DSM-IV) diagnosis at follow-up	3 years	59%


CIDI: Composite International Diagnostic Interview; DIS: Diagnostic Interview Schedule; SADS: Schedule for Affective Disorders and Schizophrenia; SCAN: Schedules for Clinical Assessment in Neuropsychiatry SCID: Structured Clinical Interview for DSM-IV; RCT: randomized controlled trial; Nemesis: The Netherlands Mental Health Survey and Incidence Study; NESDA: The Netherlands Study of Depression and Anxiety; NESDO: The Netherlands Study of Depression in Older Persons; NIMH-CDS: National Institute of Mental Health- Collaborative Depression Study.

Age of onset

Retrospective reports have been used to reconstruct the distribution of age-of-onset (AOO) – an alternative to the estimation of incidence.¹⁶² In the World Mental Health (WMH) surveys, median within-country depression AOO was 26 (interquartile range 17-37) years of age in high-income countries and 24 (17-35) years in low- and middle-income countries. There was also a meaningful secondary peak for onset late in life.¹⁶³ These AOO distributions are later than for a number of other common mental disorders, such as anxiety disorders, and many cases of depression are comorbid with these other temporally primary disorders.¹⁶⁴ There is considerable interest in the possibility that AOO might be relevant for identifying depression subtypes, although this line of investigation is still at an early stage of development.¹⁶⁵

There is an important implication of depression having a later AOO than many other common mental disorders. Lifetime prevalence (i.e., the proportion of the population who have experienced the disorder to date) is estimated directly from results of community epidemiological surveys. When a high proportion of first onsets occurs at ages later than those of respondents in the surveys, this estimate of lifetime *prevalence* will be lower than that of lifetime *morbidity risk* (i.e., the projected proportion of the population who will experience the disorder at some time in their life), which is estimated using actuarial methods with life tables.¹⁶⁶ Based on data from the WMH surveys, the average morbidity risk of depression at age 75 is projected to be 19.6% (i.e., it is estimated that almost one in five individuals around the world will have experienced depression by 75 years of age).¹³⁵ This is nearly twice as high as the proportion of WMH respondents with a lifetime history of depression at the time of survey. Also, as shown in Figure 3, the median AOO of major depression among the projected proportion of the population developing the disorder as of age 75 years—around the late 30s—is higher than the mean age-of-onset among people with a history of depression as of the time of survey. Two types of survey bias, early mortality of people with a history of depression and under-representation of the oldest old, likely lead these estimates to be conservative.

Figure 3. Age of depression onset among the projected proportion of the population (19.6%) developing the disorder as of 75 years of age



Results generated using data from 29 countries provided by the WHO World Mental Health Survey Consortium: www.hcp.med.harvard.edu/wmh. Morbid risk refers to the projected lifetime occurrence of major depression as of age 75 estimated using actuarial methods with life tables. “Onset” refers to lifetime first onset of a major depressive episode and does not take into account the occurrence of subthreshold symptoms.

Sub-threshold depressive syndromes

There has been a long-standing interest in expanding the definition of the depressive spectrum to characterize clinically significant manifestations that do not meet criteria for depression among people who might profit from early intervention.¹⁶⁷ Point prevalence of dysthymic disorder averages 1.5%.¹⁶⁸ But prevalence of subthreshold syndromes of depressive symptoms with shorter duration (typically two weeks) is as high as 17%.^{61,169} These syndromes, sometimes labelled as ‘minor depression’, might also overlap with the construct of adjustment disorder with depressed mood. Unlike depression, the prevalence of minor depression is high among children¹⁷⁰ and adolescents,¹⁷¹ and associated with substantial distress and impairment and with considerable medical and non-medical costs.¹⁷² These syndromes constitute a risk factor for subsequent onset of depression, and may be the sequelae of partial remission of an episode of major depression.¹⁷³

Comorbidities with other mental disorders

Comorbid anxiety and/or substance use disorders are found among most people diagnosed with depression, both in community epidemiological surveys¹⁷⁴ and in studies of primary care¹⁷⁵ or specialized care settings.¹⁷⁶ Numerous researchers have documented bivariate associations among hierarchy-free anxiety, mood, behaviour, and substance disorders that can be accounted

for by correlated latent predispositions to internalizing and externalizing disorders. The internalizing disorders can also be divided into secondary dimensions of fear (e.g., panic, phobia) and distress (e.g., major depressive episodes, generalized anxiety disorder, post-traumatic stress disorder) disorders. This structure is quite stable cross-nationally.¹⁷⁷

Longitudinal data have been used to investigate temporal progression across lifetime comorbid mental disorders and whether risk factors for individual disorders are more accurately conceptualized as risk factors for the latent dimensions underlying these disorders.¹⁷⁸ As one example, observed gender differences in depression prevalence became statistically non-significant when controls were included for latent internalizing and externalizing dimensions.¹⁷⁹

A cross-national analysis of this type, albeit based on retrospective AOO reports obtained in cross-sectional community epidemiological surveys, followed on from WMH surveys across 14 countries.¹⁶⁴ Almost all temporally primary lifetime anxiety, mood, disruptive behaviour, and substance disorders predicted the subsequent first onset of later disorders. Most time-lagged associations were explained by a model that assumed the existence of mediating latent internalizing and externalizing variables. Depression was no more important than several other internalizing disorders (generalized anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder) in defining these latent variables.

An ambitious population-based cohort study with similar logic used information about age of first treatment of common mental disorders in health registries for the 5.9 million residents of Denmark born in that country between 1990 and 2015.¹⁸⁰ As in the retrospective WMH study, all temporally primary mental disorders included in this Danish study were associated with elevated risk of subsequent onset of all temporally secondary mental disorders. Time-related decays were found in these associations as a function of the number of years since onset of the primary disorders. Early-onset mood disorders were associated with especially high absolute risks of subsequent neurotic disorders (anxiety disorders and depression) over the next five years among both men (30.6%) and women (38.4%).

Comorbidities with physical disorders

It is well established that depression is significantly associated with a wide variety of chronic physical disorders, including arthritis, asthma, cancer, cardiovascular disease, diabetes, obesity, hypertension, cognitive impairment, chronic respiratory disorders, a variety of chronic pain conditions, and dementia.¹⁸¹ These associations can reflect causal effects of physical disorders on depression, causal effects of depression on physical disorders, and effects of common antecedents, such as socioeconomic disadvantage or adverse lifestyle factors, which simultaneously affect both body and mind. There is also the often unrecognized problem of spurious association, when the same set of symptoms is double-counted to arrive at both a psychiatric and a physical diagnosis. In chronic obstructive pulmonary disease, for example, somatic symptoms such as fatigue, decreased appetite and weight loss may be simultaneously attributed to the physical and the psychiatric condition. This raises substantial risks of diagnostic confusion and potential for mismanagement in a situation where physical and psychiatric classifications fail to account adequately for each other, and the indications for treating depression need careful review.¹⁸² Equally important in clinical situations is the misattribution of depressive symptoms and signs to physical illness and consequent failure to recognise depression that is having a substantial impact on suffering and the course of the physical illness.

Physical disorders are influenced by depression in at least two ways. First, to the extent that it is a causal risk factor, depression leads to an increased prevalence of these physical disorders. Consistent with this possibility, meta-analyses of longitudinal studies show that depression is a consistent predictor of the subsequent first onset of coronary artery disease, stroke, diabetes, heart attacks, obesity, osteoporosis and certain types of cancer.¹⁸³ A number of biologically plausible mechanisms have been proposed to explain the prospective associations of depression with these disorders, such as hypothalamic-pituitary-adrenal hyperactivity, autonomic dysregulation, and impaired immune function.¹⁸⁴ In addition, a variety of unhealthy behaviours known to be linked to depression, such as elevated rates of smoking and drinking,¹⁸⁵ poor eating habits,¹⁸⁶ and unhealthy food intake, are simultaneous risk factors for physical disorders. Based on these observations, there is good reason to believe that depression might be a causal risk factor for at least some chronic physical disorders.

Second, even if depression is more a consequence than a cause of chronic physical disorders, as it appears to be for some disorders, comorbid depression is often associated with a worse course of the physical disorder.¹⁸⁷⁻¹⁹⁰ A number of mechanisms could be involved. One of the most consistently documented is the association of depression with non-adherence to treatment regimens.^{191,192} Differential population-based clustering of depression with co-morbid physical conditions based on patterns of underlying negative social determinants of health is also now being modelled in the syndemics literature. This is built on the idea that co-morbid conditions potentiate one another under certain social, economic, or cultural context.¹⁹³

Depression is a major source of morbidity and mortality in the elderly, with associated increases in public health burden, costs and use of services, and mortality, and reduced quality of life. In the case of dementia, depression may be a risk factor or a precursor; or else, dementia may be a risk factor or trigger for late-life depression; and the two conditions may be difficult to disentangle diagnostically among elderly people. In the Framingham Heart Study cohort¹⁹⁴ there was a 50% increased risk of dementia over a 17-year period among those with a diagnosis of depression at baseline compared with those without that diagnosis. Results were similar for those taking antidepressant medication. Hypotheses to explain this increased risk include chronic inflammatory and neurobiological changes (e.g., hippocampal damage due to glucocorticoid cascade),¹⁹⁵ the cholinergic impact of tricyclic antidepressants,¹⁹⁶ and lifestyle factors such as poor diet, smoking, and reduced physical activity or social engagement that are known to be associated with depression.¹⁹⁷ The co-occurrence of depression and diabetes appears to magnify the risk for dementia beyond that of either alone.¹⁹⁸ Depression often occurs at the early stages of the onset of dementia. This may be prodromal, with the depressive syndrome an early manifestation of an underlying neurodegenerative disease.¹⁹⁹ Alternatively, depressive symptoms may be a psychological response, a reaction to a person's growing awareness of the catastrophic consequences of his/her impending, irreversible impairment.

Global estimates of excess mortality indicate more than 2.2 million excess deaths in persons with depression, with particularly high rates of death among older individuals with cardiovascular disease.²⁰⁰ A meta-analysis containing data from more than 1.8 million individuals in 35 countries confirms the presence of a significant association between depression and excess all-cause mortality, although this association may have been overestimated because of publication bias and low study quality.¹⁹⁰

Suicidal behaviour

Suicide is ranked as the second leading cause of death among 15–29 year olds and as the 15th-most common cause of death at all ages worldwide.²⁰¹ A meta-review²⁰² reported an almost


twenty-fold risk of suicide for persons with depression with a standardized mortality ratio (SMR) of 19.7%. Depression is the most common psychiatric disorder reported in people who die by suicide: from available psychological autopsy studies²⁰³ it is estimated that depression is responsible for the largest proportion of the burden of disease attributed to suicide (as measured in DALYs: 46%; 95%CI 28% to 61%).²⁰⁴ That said, it appears that the relative contribution of depression to suicide is smaller in low- and middle-income countries^{205,206} where a mood disorder was identified in 25% of people who died by suicide. Suicide attempt is also far more common in people with depression.²⁰⁷ A meta-analysis of suicide attempts in individuals with depression found a lifetime prevalence of 31% (95%CI: 27-34%) and confirmed that suicide attempts were common in individuals with depression across the world.²⁰⁸

Meta-analytic evidence²⁰⁹ indicates that the risk of suicidal behaviour in persons with depression is significantly associated with previous suicide attempt, severe depression, anxiety, hopelessness, family history of psychiatric disorder, comorbid substance abuse disorder, personality disorder,²¹⁰ and sleep disorders, particularly nightmares and insomnia.²¹¹ Deaths from suicide among those with a current depressive episode occur mostly (75%) during the first episode, 19% in the second episode and 7% in persons with more than 2 depressive episodes.²¹²

The impact of depression on functioning

The burden associated with depression increases sharply in the second and third decades of life, and is mostly carried by the populations in middle-income countries (Figure 4). This high score for the number of disability-adjusted life years (DALYs) is partly attributable to the high estimated disability weight ranging from 0.145 (mild) to 0.396 (moderate) and 0.658 (severe), with the highest of these weights equivalent to those of the most severe physical conditions (e.g., 0.682 for AIDS not receiving antiretroviral therapy, 0.569 for terminal cancer).²¹³

Figure 4. The burden of depression across the life course according to country income



Updated from Kieling et al.²¹⁴ using Global Burden of Disease 2019 data. HIC: high-income countries; UMIC: upper-middle income countries; LMIC: low-middle income countries; LIC: low-income countries.

While there are a number of criticisms about the accuracy of disability weights²¹⁵⁻²¹⁷ it is doubtlessly true that depression is a highly burdensome condition and other studies have confirmed that the disability is experienced as one of the most severe of all health conditions. Community surveys examining the comparative effects of diverse diseases on various aspects of role functioning^{218,219} typically show that musculoskeletal disorders and depression are associated with the highest levels of disability among all commonly occurring disorders. The most compelling study of this sort was based on 15 national surveys carried out as part of the WMH Study.²²⁰ Disorder-specific self-reported role impairment scores were compared across people who experienced each of 10 chronic physical disorders and 10 mental disorders in the year before interview. Depression and bipolar disorder were the mental disorders most often rated “severely impairing” in all countries. None of the physical disorders considered, including cancer, diabetes and heart disease, had impairment levels as high as those for depression or bipolar disorder. Depression is also associated with the highest number of days out of role at the societal level of any physical or mental disorder. In the WMH surveys, for example, 62,971 respondents across 24 countries were assessed for a wide range of common disorders and for days out of role in the 30 days before interview.²²¹ Depression was associated with 5.1% of all days out of role, the fourth highest population attributable risk proportion of all the disorders considered (exceeded only by headache/migraine, other chronic pain conditions, and cardiovascular disorders) and by far the largest among the mental disorders.

The WHO World Health Surveys of nearly one-quarter of a million respondents across 60 countries examined the comparative decrements in perceived health associated with different chronic disorders.¹³⁶ A consistent pattern was found across countries and socio-demographic subgroups within countries: the association between depression and the decrement in perceived health was larger than for any of the four physical disorders considered (angina, arthritis, asthma, diabetes). A related study in the WMH surveys compared depression with 18 other disorders, physical (e.g., cancer, cardiovascular disorders, diabetes) and mental (e.g., bipolar disorder, panic disorder, post-traumatic stress disorder) in predicting a summary measure of perceived health.²²² Depression was one of the three disorders associated with the highest decrements in perceived health, the other two being severe insomnia and a group of neurological disorders that included epilepsy, Parkinson’s disease, and multiple sclerosis.

Depression affects a range of specific areas of functioning; this evidence is summarized below, with an emphasis on describing the effect of depression on life course outcomes (as opposed to the reverse pathway).

Education & employment: Early-onset mental disorders are associated with premature termination of education.²²³⁻²²⁵ Depression is significantly associated, at least in studies conducted in high-income countries, and after adjusting for comorbid conditions, with about 60% elevated odds of failure to complete secondary school. A number of prospective studies document the impact of depression on occupational difficulties. For example, an analysis of WMH data showed that a history of depression as of the age of completing schooling predicted current (at the time of interview) unemployment and work disability.²²⁶ These associations were significant only in high-income countries. This raises the possibility that the impairments associated with depression are influenced by contextual factors such as the complexity of work and the eligibility of depression for sickness-benefits or disability benefits.

Economic consequences: The personal earnings and household income of people with depression are substantially lower than those of people without depression.^{227,228} However, as with unemployment, depression could be a cause, a consequence, or both.²²⁹ Several prospective studies suggest that depression prior to completing education predicts substantially reduced income-earnings in adulthood after adjusting for level of educational attainment.^{230,231} Epidemiological surveys have estimated the workplace costs of depression on low work performance while on the job;²³² in the US, the annual salary-equivalent human capital value of these losses has been estimated in the range of \$30.1 billion²³³ to \$51.5 billion.²³⁴

Intimate relationships: While most of the literature on intimate relationships refers specifically to marriage, it is plausible that this evidence may generalize to other types of intimate relationships. Early-onset mental disorders predict low probability of ever marrying. For people who marry, these disorders may be positively associated with early (before age 18) marriage,²³⁵ which is known to be associated with a number of adverse life course outcomes. These associations are largely the same for men and women and across countries. Depression is one of the most important pre-marital mental disorders in these respects. A pre-marital history of mental disorders also appears to predict divorce,²³⁶ again with associations quite similar for husbands and wives across all countries and depression among the most important disorders in this regard.²³⁷ Marital dissatisfaction and discord are strongly related to depressive symptoms,^{238,239} with an average correlation between marital dissatisfaction and depressive symptoms of approximately $r = 0.4$ across studies and very similar patterns for men and women.²⁴⁰ Longitudinal studies show that this association is bidirectional,^{241,242} but with a stronger time-lagged association of marital discord predicting depressive symptoms than vice-versa.²⁴³ Fewer studies have considered the effects of clinical depression on marital functioning,^{244,245} but those consistently document significant adverse effects.

Intimate partner violence (IPV): IPV is partly a consequence of pre-existing mental disorders.²⁴⁶ The WMH surveys²⁴⁷ found that the association between premarital history of depression and subsequent intimate partner violence disappears after controls are introduced for disruptive behavioural disorders and substance use disorders, suggesting that depression might be a risk marker rather than a causal risk factor. However, a large sibling control study²⁴⁸ reported that men with depressive disorder had a higher risk of perpetrating IPV against women than their unaffected full siblings. The risk was further elevated when there was comorbidity with alcohol use disorders, drug use disorders, or personality disorder.

Parental functioning and offspring outcomes: Both maternal and paternal depression have an impact on the offspring, but the impact of maternal depression may be larger.²⁴⁹ The negative effects can include low birth weight, poor school performance, relatively high rates of physical health complications, and depression, anxiety, substance abuse and suicidal behaviour, with substantial, persistent, wide-ranging economic impacts.²⁵⁰ Effects on their offspring are sustained when parents experience persistent depression, live in poverty, or both.²⁵¹ These adverse effects may be mediated by the association of both maternal²⁵² and paternal²⁵³ depression with negative parenting behaviours. These associations are found throughout the age range of children, but are most pronounced for the parents of young children. Both laboratory and naturalistic studies of parent-infant micro-interactions have documented subtle ways in which depression in a parent leads to maladaptive interactions that impede infant affect regulation and later child development and increase risk of subsequent psychopathology.²⁵⁴

Experience of caregiving: For family members, the experience of caring for a depressed child or older adult is usually demanding and frequently an isolating experience. Most informal

mental health carers are women family members. They frequently have a double role caring for children and an older person living with depression. They may lose employment and contact with friends and outside activity, and even other members of the family. Family carers have heightened risk of becoming depressed or anxious themselves.²⁵⁵

THE ROOTS OF DEPRESSION

Three key observations have shaped our understanding of why some people become depressed. First, depression tends to run in families, often jointly with bipolar disorder, substance use, and anxiety disorders. Children of parents with depression or bipolar disorder, in particular, have an elevated risk of developing depression themselves even when they are not raised by their biological parents. But many children of affected parents do not manifest the syndrome, and most people with depression have unaffected parents. Second, onset of depression in adolescents and adults is in most cases preceded by childhood-onset disorders, such as attention-deficit/hyperactivity disorder (ADHD) and anxiety disorders. However, most children with ADHD or anxiety disorders will not end up developing depression as adults. Third, most early episodes of depression have an onset shortly after a stressful life event, in particular one involving loss, disappointment or humiliation, especially in people primed by early loss, neglect or trauma. Nevertheless, all people encounter stressful life events at some point in their lives and most do not develop depression in the aftermath. While these three observations point to genetic, developmental, and environmental origins of depression respectively, they also suggest that no single factor provides a complete explanation of why depression develops. Ultimately, it is the unique interplay of these factors, operating at different points of the life course, which constitutes the roots of depression in any individual.

Predisposing and protective factors

With systematic follow-up of large representative samples from childhood to adulthood, it has become apparent that the onset of a major depressive episode is not typically the first manifestation of psychopathology. In most cases, depression is preceded by childhood symptoms or disorders, including oppositional-defiant disorder, ADHD, and anxiety disorders.²⁵⁶ The prospective association between anxiety and depression is particularly strong and well established.²⁵⁷ The prospective association between ADHD and depression is more complex and may be particularly relevant for early-onset depression. Depression that manifests in childhood or early adolescence may be related to genetic liability to ADHD and other neurodevelopmental disorders²⁵⁸ as well as environmental risk factors. Childhood ADHD and anxiety disorders also both strongly predict bipolar disorder, which can start as adolescent-onset depression.²⁵⁹

Among the offspring of parents with depression, the risk of developing depression by early adulthood is 40%, a more than two-fold increase compared with offspring of parents without mood disorders.²⁶⁰ Analysis of an entire country's population, including individuals raised by their biological families and individuals raised by adoptive families, suggests that familial risk for depression is due to approximately equal contributions of genetic and environmental factors that are shared within families.²⁶¹ The genetic risk of depression is likely due to small effects of hundreds or thousands of common genetic variants, with overrepresentation of genes affecting brain development, inflammation, bioenergetics and neuronal signalling. The large number of common variants involved²⁶²⁻²⁶⁴ entails that every individual carries some risk variants for depression, and a polygenic score (indexing the individual's load of risk variants) predicts the genetic liability to depression better than any specific genetic variant.²⁶⁵ In

addition, the predictive power of molecular genetic information falls far short of estimates from family and twin analyses, indicating that the contribution of genetic variants to depression also depends on the environmental context.¹²

Much research has been done on early childhood adversities, suggesting that they are associated with an increased vulnerability to depression (as well as other psychopathology and somatic illnesses) in adulthood in the presence of stressful life events. Substantial evidence supports the idea that experiencing maltreatment during critical periods early in life increases a person's predisposition to a subsequent/later depressive episode.²⁶⁶ Moreover, convincing evidence indicates that experiencing maltreatment in childhood increases the likelihood of exhibiting an unfavourable course of illness, with higher rates of recurrence and persistence in adulthood.²⁶⁷ Maladaptive personality traits (which themselves have a variety of genetic and environmental roots) are also associated with increased vulnerability to depression. For example, the construct of neuroticism or negative affectivity has been shown to be associated with an increased probability of experiencing stressful life events and of subsequently responding to these events with depression.²⁶⁸ Cognitive models propose that individuals at risk for depression exhibit biases in information processing, privileging interpretations that are pessimistic and self-critical, leading to “depressogenic” cognitive styles.²⁶⁹ Variables related to an individual's interpersonal style might also represent risk factors for developing depression, possibly due to their contribution to stressful conflict and loss events.²⁷⁰ Indeed, the modal clinical presentation of people with personality disorders is a complaint of depression^{271,272} and significant proportions of people with depression have a comorbid personality disorder.²⁷³ Such comorbidity has adverse prognostic and therapeutic implications.

Lifestyle habits have also been consistently associated with depression. Meta-analytic evidence supports an association of low levels of physical activity²⁷⁴ and unhealthy dietary patterns with an increased risk of developing depression.²⁷⁵ Prior use of substances has been shown to increase the predisposition to depression; for example, adolescent cannabis consumption has been associated with increased risk of developing the disorder in early adulthood.²⁷⁶ A meta-analysis reported an association between tobacco smoking and increased risk of depression in cross-sectional studies, with the relationship maintained across several moderators.²⁷⁷ It is noteworthy, however, that the overall strength of associations is variable, and limited evidence is available to indicate the direction of causality between most lifestyle factors and depression, with a strong probability of bidirectional causation in most cases.

The importance of social determinants suggests that a perspective beyond the individual level is also required to deal with factors influencing depression. Population health science focuses on structural factors and on how they shape the health of individuals within and across populations.²⁷⁸ Many of the Sustainable Development Goals such as reducing gender and other inequities, and effective climate action align closely with factors which affect the risk of depression.²⁷⁹ There is now a large evidence base that intimate partner violence and sexual abuse, which are endemic globally, are major risk factors for depression, particularly in women,^{280,281} who are more likely to experience such violence, including coercive controlling behaviours.²⁸² Income inequality has been shown consistently as positively associated with the risk of depression (most of the available evidence coming from high-income countries).²⁸³ The relationship between poverty and depression is complex and likely to be characterized by both social causation (i.e., social and economic adversities increase the risk of depression) and social selection (i.e., people with depression drift into poverty) mechanisms. The experience of forced displacement due to conflict, climate change, and other causes is associated with high prevalence of depression, with numerous studies identifying one-third to half of refugees and

internally displaced populations meeting criteria for depression on self-report questionnaires.²⁸⁴ Following the evidence regarding the impact of natural and built environments on physical health, there are emerging data suggesting the relevance of biophysical factors such as air pollution, persistent organic and heavy metal pollutants,²⁸⁵ and ambient noise in terms of increasing the risk for developing depression.²⁸⁶

Conversely, some personal characteristics, interests, skills, and social support variables may constitute strengths that mitigate the impact of depression. Protective factors increase a person's resilience, i.e. the ability to maintain or regain mental health in the face of adversity or to bounce back from hardship and trauma.²⁸⁷⁻²⁸⁹ Factors such as history of secure attachment, cognitive abilities, self-regulation abilities, and positive peer/community support have been identified as contributing to resilience and enabling at-risk individuals to adapt or respond well to stressors. Resilience may be context- and time-specific, and may not be present across all life domains²⁸⁸: in other words, individuals might be resilient to one environmental hazard but not to others, and may exhibit resilience at one period in their lifetime but not at other points.²⁹⁰ From a systemic point of view, the capacity of the physical and social environments to facilitate the process of coping by the individual in a culturally meaningful way is also of utmost importance.²⁹¹ An adequate clinical assessment should therefore not only investigate mental phenomena potentially relevant to overcome negative circumstances, but also explore past situations in which the individual and his/her environment dealt with adversity, as previous successes might be relevant for current and future challenges.²⁹⁰

Precipitating and perpetuating factors

Precipitating factors occur shortly before the onset of depression, possibly interacting with predisposing factors to trigger the disorder. Many studies²⁹² adopt the overarching term “stressful life events” to encompass experiences such as bereavement, separation, life-threatening situations, medical illnesses, being subjected to violence, peer-victimization (e.g., bullying), loss of employment, and separation/divorce. There is substantial evidence corroborating the precipitating role of such proximal environmental influences in the development of depression. A large proportion of individuals, however, are apparently less vulnerable to these experiences. Childhood sensitisation through trauma or neglect may play a role in parsing vulnerability versus resilience. While acute life events might precipitate the onset of depression in vulnerable persons, research has also shown that individuals with depression have an increased propensity to experience acute stressors in comparison to those without a history of depression. This perpetuating pattern, designated stress generation,²⁹³ is particularly relevant for interpersonal events. Other factors contributing to the recurring and persistent nature of depression include substance use, behavioural patterns such as social withdrawal, and cognitive biases in attention, memory and interpretation. A ruminative response style (characterized by an over-analysis of problems) tends to intensify negative, self-focused thoughts and to hamper problem-solving, therefore perpetuating symptoms of depression.²⁹⁴ Identifying maintaining factors might be of special relevance, as they might be suitable to target to achieve sustained recovery.

Integrative models of pathogenic mechanisms

The search for discrete risk or protective factors associated with the onset and continuity of depression captures only a small proportion of the complexity of this condition. Multiple factors are likely to operate through a probabilistic chain that is conditioned by timing, dosage, and context, in which upstream distal factors (more precocious and less specific) influence more downstream proximal factors (affecting the individual closer to the onset of the condition and often more directly). The picture is further complicated by the evidence that no risk factor

appears to be either necessary or sufficient, that the same risk factor might confer increased risk for various mental disorders, and that many individuals exposed to risk factors do not develop depression.¹²

While theories emphasizing one aspect of causation have been applied with a modest degree of success (e.g., monoamine hypothesis, cognitive theory, interpersonal theory), a broadly applicable model of depression will need to incorporate genetic, developmental, and environmental factors and allow for heterogeneity of causation across individuals. Most conceptualizations that fulfil these requirements are variants of the “diathesis-stress” model (alternatively referred to as vulnerability-stress model). The diathesis-stress model posits that, following an acute stressor, a person who carries a diathesis (or vulnerability) that renders him/her sensitive to the stressor will develop depression. The vulnerability may have both biological (e.g., genetic, endocrine, inflammation, brain connectivity) and psychological (e.g., temperament, personality, beliefs) features.²⁹⁵ Each person may carry a number of vulnerabilities that may add on to an overall diathesis, or may make a person sensitive to different types of stressors. There is probably a complementary relationship between the degree of vulnerability and the severity of the stressor: a person with a high degree of vulnerability may develop depression even with a mild stressor, and a person with a low degree of vulnerability may only become depressed if encountering a stressor of extraordinary severity. With the accrual of studies on the joint effects of genetic and environmental factors in the causation of depression, the general stress-diathesis model can now be considered proven beyond reasonable doubt.^{12,296}

More developmentally informed models, referred to as “transactional,” also account for the fact that vulnerability can change over time due to both biological events (e.g. menarche, childbirth) and changes in the external environment.²⁹⁷ For example, exposure to adverse environments earlier in life or even *in utero* may not be sufficient to cause depression, but may create a vulnerability that will render the individual more likely to develop depression following a further stressful experience. Furthermore, the same characteristic may make an individual sensitive to both negative effects of adverse experiences and beneficial effects of positive experiences. This more inclusive conceptualization of personal vulnerability and potential has been described as the “differential susceptibility” model.²⁹⁸

The diathesis-stress and differential susceptibility models raise questions about the nature of individual vulnerability. To distinguish cause and effect, it is useful to consider individually stable and changeable aspects of vulnerability separately. Genetic variation provides an unbiased source of information about vulnerability, because genetic sequence is believed to remain unchanged from conception and throughout the life of an individual. Therefore, specifications of the diathesis-stress model that involve genetic measurement allow for stronger conclusions about causality. These genetic models include gene-environment correlation and gene-environment interaction.²⁹²

Gene-environment correlation occurs when a genetic variant makes an individual more likely to be exposed to a particular aspect of the environment. Some recently identified gene-environment correlations challenge the assumption that genes and environment are separate primary causal factors. Individuals with a high loading of depression-related genetic variants report more stressful life events, even life events that are typically thought to be relatively independent of the individual.²⁹⁹ For example, polygenic scores for depression, lower intelligence, and greater body weight predict whether an individual will be bullied.³⁰⁰ These findings stimulate a reconceptualization of the diathesis-stress model to incorporate the


interdependence of stressor and vulnerability.³⁰¹ In turn, gene-environment interaction occurs when a genetic variant makes an individual more sensitive to the impact of an environmental exposure. Incorporation of gene-environment interactions improves the prediction of depression over the polygenic risk score approach.³⁰² Stressful life events are more likely to lead to depression in individuals who have a higher load of genetic risk variants.³⁰³ It is also possible to measure genetic factors that render individuals more sensitive to both negative and positive environmental exposures, in the form of a polygenic score. This “polygenic sensitivity score” predicts greater negative and positive responses to adverse and beneficial exposures respectively, supporting the differential-sensitivity model.³⁰⁴

Some of the most powerful environmental factors are far removed in time from the actual onset of depression. For example, childhood maltreatment and bullying are associated with increased vulnerability to depression lasting for the individual’s lifetime. This raises the question of how non-genetic vulnerability factors remain active over long time periods. Psychological and personality development theories might account for this phenomenon. Equally, epigenetic modifications provide a suitable mechanism for such very long-term memory. Exposure to adverse environments early in life may lead to modifications of the genome, such as DNA methylation, that will continue to affect the expression of genes for prolonged periods of time without altering the genetic sequence. While specific epigenetic modifications have been associated with experimental exposures in animal models, finding a reproducible epigenetic signature of adversity in humans has been challenging.³⁰⁵ Exposure to adversity in childhood has also been found to increase the level of systemic inflammation.³⁰⁶ The long-term increase of inflammatory activity may well play a role in the pathogenesis of depression, as symptoms of depression overlap with those of inflammatory disease.

The present models of depression are being challenged by factors that do not easily fit into the gene-environment dichotomy. One such factor is the gut microbiome, the ensemble of bacteria living in the human digestive tract, which is individually variable and is affected by human genetic makeup, diet and other aspects of the environment. The fact that the microbiome is itself genetic in nature opens a host of possibilities, including complex interactions between human and bacterial genomes. Gut bacteria can produce neuroactive substances, including gamma-aminobutyric acid (GABA) and serotonin, which can affect the brain of the human host. Intriguingly, the presence of these bacteria has been linked to depression in their human hosts.³⁰⁷ Animal models have illustrated that a depressive phenotype can be transferred to a non-depressed animal by microbiome transplants from a depressed donor, and that depressed animals can have the phenotype removed by transplant from a non-depressed donor.³⁰⁸

The neural pathways of depression

The hundreds of genetic variants associated with depression, each of very low effect, are most concentrated among genes that are expressed in the prefrontal cortex and the anterior cingulate.²⁶³ These same brain areas show accelerated breakdown of monoamine neurotransmitters,³⁰⁹ increased neuro-inflammation,³¹⁰ reduced grey matter,³¹¹ and heightened reactivity to mood-relevant stimuli³¹² in individuals with depression. This convergence of evidence leaves little doubt that, while genetics and the environment are the primary movers, the final pathways of depression pathology occur in multiple but mutually interactive areas of the human brain (Figure 5).

Figure 5. Neural underpinnings of depression

Over the last 30 years, brain imaging has leveraged a conceptual shift in depression research. The dominant psychological and neurochemical theories of the past have been reframed to accommodate complementary genetic, developmental, molecular, and brain circuit models. The best replicated of early findings — frontal hypometabolism and hippocampal atrophy^{313,314} — remain foundational to current models of depression, although they are not pathognomonic. A conspicuous contradiction is that many individuals do not show these core changes, or demonstrate opposite patterns (e.g., frontal hypermetabolism). Increasing recognition of these individual differences, likely masked previously by the focus of earlier studies on group effects, assists the understanding of clinical heterogeneity in depression.^{315,316}

Other limbic (amygdala, insula, cingulate) and subcortical (basal ganglia, thalamus, periaqueductal grey, dorsal raphe, lateral habenula) abnormalities have also been reported, especially with the introduction of resting and task-based functional MRI (fMRI) and functional connectivity analyses. These findings are similarly variable. Differences among subgroups of people with depression, as well as variations in the degree of illness severity and duration, and the heterogeneous expression of clinical symptoms among those tested may contribute to the observed variance,^{317,318} though there is so far no consensus on the bases for these results.

The investigation of neural mechanisms sub-serving depression pathogenesis and progression continues based on the assumption that this is unlikely to be a disease of a single gene, brain region or neurotransmitter system. Depression is now modelled as a neural systems disorder.

A depressive episode is viewed as the net effect of failed network regulation in the context of emotional, cognitive or somatic stress.^{315,319} Employing this contemporary interconnected view, studies extend beyond properties of individual brain regions to examine instead integrated pathways and distributed neural networks. Technological and analytic advances³¹⁹⁻³²² including routine use of “big data” make it possible to acquire multiple neuroimaging data in the same individual in a single session. There is also increasing public availability of large multimodal imaging datasets.^{322,323} Translational studies using cell-specific animal models of depression-relevant behaviours further inform the interpretation of multimodal imaging data in people at all stages of risk and illness.³²⁴⁻³²⁶ Such studies have revealed subtle abnormalities of individual region and pathway structure and function.

Definitive precipitants or mediators of such “systems dysfunction” are not yet characterized. However, several factors appear to be strong contributors. In addition to acute and chronic life stressors, these include genetic vulnerability, affective temperament, developmental insults, and early childhood trauma.³²⁷⁻³²⁹ Depression network models have also evaluated mediators and moderators of resilience. Such studies draw upon animal models of acute and chronic stress exposure.^{330,331} Converging findings across species again point to the crucial role of cortico-limbic circuitry in the experience of depression, with different regional abnormalities emerging at different ages and developmental stages. A prominent observation is the involvement of distinct prefrontal cortical subregions and their connections to numerous subcortical structures, including the cingulate, hypothalamus, amygdala, hippocampus, nucleus accumbens, dorsal raphe and other brain stem nuclei.³²⁴⁻³²⁶ Links of these cortico-limbic circuits to physiological functions common to both chronic stress exposure and depression have emerged, including disruption of circadian functions, affective states, drives, motivation, intention and action. All these disturbances logically contribute to symptoms of low energy, apathy, anhedonia, negative mood, and changes in appetite, sleep and libido. These circuit aberrations can also result in anxiety, rumination, negative cognition and maladaptive habits. In the animal stress models, structural alterations (i.e., atrophy and morphological changes in neurons and glia) and functional adaptations (i.e., changes in blood flow, metabolism and gene expression) are observed, paralleling abnormalities seen in imaging and post-mortem studies of people with major depression. Chronic stress has additional time-dependent influences on systemic physiology. Immune, neuroendocrine, autonomic, metabolic and molecular mediators have further influence on cortico-limbic function in a bidirectional manner. This cascade of reactions will likely have impacts on cellular structure and function, neural network dynamics, and peripheral organ function, with differential effects in resilient and susceptible individuals.

Understanding brain plasticity and adaptive mechanisms, including their time course and trajectory, can be critical to the effective timing and delivery of various interventions. These observations might have important implications for treatment and prognosis; for example, different treatments appear to modulate distinct network nodes and their local and distant connections, and response may depend on targeting specific biological abnormalities.³³² Furthermore, the cascade of chemical and molecular adaptations that occur with depression and stress exposure might have a range of consequences, including irreversible structural and molecular damage that may well underlie treatment resistance phenomena.³²⁴ Imaging studies are now designed to explicitly develop biomarkers of treatment-specific subtypes that can guide optimal treatment selection for individual subjects as well as avoid treatment classes unlikely to be helpful.^{333,334} Further, treatments are now being tested to target chemical as well as imaging biotypes.³³⁵⁻³³⁸

THE PUBLIC UNDERSTANDING OF DEPRESSION

Due to sheer ignorance about mental illness, I often found myself left behind. Low levels of self-esteem and the overall guilt, shame, burden and stigma of having depression... aggravated the state of my mental health. In my studies... I would miss classes and not attend fieldwork. Unfortunately, due to a lack of awareness, this was construed as a personal failing. I was told to my face that- “depression was nothing but an excuse”, to “cheer up”, and informed that: “Medicine was not the solution to depression.”

- Richa Sharma, 25, Najafgarh, India

I thought people would only understand me if they lived what I was living, I felt that nobody could understand me. Only those going through what I was going through.

- João Veit Costa, 19, Porto Alegre, Brazil

Stigma & discrimination

Negative attitudes towards people living with depression, and stigma and discrimination, are associated across several world regions with negative outcomes: low help-seeking, poor treatment adherence and poor treatment outcomes, low quality of life, and risk of suicidal thoughts and behaviour.³³⁹⁻³⁴¹ The negative attitudes include blaming the person for the illness and expectations that someone with depression cannot perform familial and occupational roles nor cope with either hardships or the daily routine of life.^{342,343} Stigma may be encountered as beliefs about the attitudes of others (perceived stigma), or as a person’s own thoughts and beliefs about their own depression (personal or self-stigma). Both may be more marked among certain groups including people with less education and those who are more psychologically distressed.³⁴⁴ The accompanying prejudices include unwillingness to work with persons with depression or to have someone with depression marry into the family, and easily result in discrimination. Those living with depression report fear of disclosing depression in the workplace.³⁴⁵

Longitudinal data on public attitudes toward depression are available for some high-income countries; disappointingly, no reduction in public stigma has been reported over recent times. For example, in one US sample,³⁴⁶ in 1996 compared with 2006: 46% and 47% of the public respectively were unwilling to work closely with someone with depression; and 33% and 32% of the public respectively thought persons with depression were violent toward others. Those members of the public endorsing neurobiological models of depression were three times more likely than others to report that persons with depression were violent toward others.³⁴⁶ In the UK, there were no changes from 1998 to 2008 in attitudes such as people with depression are a “danger to others,” “they are to blame for their own illness,” and they will never fully recover.³⁴³ Repeated cross-sectional surveys of the Australian general population³⁴⁷ between 1995 and 2011 noted a meaningful increase (from 39% to 74%) in the proportion of respondents correctly recognising depression from a vignette; however, even though the dominant causes for depression were cited as stress-related, 40% of respondents continued to endorse weakness of character. Although long-term longitudinal studies are lacking from low- and middle-income countries, cross-sectional studies in Brazil, China, and Ethiopia also demonstrate high-levels of public stigma toward depression. Studies in São Paulo, Brazil, show a public perception of depression as associated with dangerousness.³⁴⁸ In Wuhan, China, public stigma against depression was greatest among men, older adults, and persons self-identifying as coming from well-functioning families.³⁴⁹ In Arba Minch, Ethiopia, stigma against depression was associated with lack of formal education.³⁵⁰

Conversely, attitudes may be less negative in cultural contexts where the symptoms of depression are attributed predominantly to problems of the heart, or to loss of the soul or other spiritual beliefs, rather than to a brain dysfunction.^{101,351} Youth, compared with older people, tend to report less negative attitudes towards depression³⁵²; though they also appear unwilling to disclose a diagnosis of depression to their peers. The causes of depression they most commonly report are stress, thinking patterns, and lack of willpower.³⁵²


Depression literacy

Knowledge about strategies to attain and maintain good mental health and about depression and its treatments is referred to as depression literacy.³⁵³ It is potentially an important determinant of help-seeking across age groups as well as relevant for public decision-makers. A meta-analysis (though only 15% of the studies were from low and middle income countries) reported a growing acceptance of treatments for depression over recent decades.³⁵⁴ However, attitudes toward treatment seeking vary across countries; while 64% of persons with depression in high-income countries perceived the need for “treatment” as operationalized in the World Mental Health surveys, only 35% in other countries did so.³⁵⁵ Lower levels of mental health literacy have been associated with a belief that one should use self-control to relieve depression rather than seek help.³⁵⁶ Depression can be poorly recognized among elderly people because of a view that cognitive decline is “part of ageing.” Young people and their parents may recognize depression although not seek help.

INTERVENTIONS TO REDUCE THE BURDEN OF DEPRESSION

In contrast to the reduction in the global burden of other medical conditions such as cardiovascular disease, largely driven by effective prevention strategies, there has been no reduction in the burden of depression over the past three decades (Figure 6). This contrast is apparent despite continuing efforts to address stigma and depression literacy, the robust state of the science of preventing and treating depression, and the evidence from population health science on the substantial effects possible from small changes in upstream macrosocial factors.

Figure 6. Global burden of ischemic heart disease and depressive disorders over time



Based on data from the *Global Burden of Disease up to 2019*. DALY: Disability-adjusted life-years.

Decreasing stigma and improving depression literacy

Strategies to decrease stigma and improve depression literacy are now seen by many as integral to national and international approaches to reducing the burden of depression. Evidence on how best to achieve these aims and the range of options is growing.

Advocacy

Advocacy to increase awareness of depression (and of mental ill-health more generally), decrease stigma and discrimination, and increase access to care has been evaluated in various contexts. Awareness campaigns have been mounted in many countries over the past two decades. An early review³⁵⁷ found modest improvements in knowledge and awareness of depression in the short term, and improved attitudes towards persons with mental illness. However the promotion of the “Decade of the Brain” in the U.S., which aimed to promote treatability of depression and other conditions, evidently did not reduce stigma. Attributing depression to biological causes may have the unintended consequence of increasing stigma. A meta-analysis of etiological attribution for mental illness, including depression, found that neurobiological explanations promote stigma: manifest as more desire for social distance, more expectations of dangerousness, and lower expectations of treatment outcomes.³⁵⁸ Stigma specific to depression seems to be lowest when a combination of life stress, chemical imbalances and genetic abnormalities is endorsed rather than a single biological cause.³⁵⁹ However, cultural context is also relevant, and biological and sociological explanatory models appear to contribute differentially to stigma based on cultural values.³⁶⁰

While sustained population-wide improvements in attitudes toward depression have not been demonstrated, social marketing seems to be effective in reducing the stigma of mental illness.³⁶¹ Certain initiatives such as mass media campaigns demonstrate positive attitudinal changes at least in the short-term.³⁶² Overall, the evidence suggests that mass media campaigns have small to moderate positive effects on community attitudes in their early aftermath. There is limited information available on long term follow-up, and mixed evidence on whether the campaigns result in increased use of care.³⁶³

Targeted interventions have also been evaluated. For people with mental illness, some group-level interventions show promise, while for students, social contact-based interventions usually achieve short-term attitudinal improvement.^{361,362} Other strategies include Mental Health First Aid training for the general public and for specific groups such as police and health workers. This program has been introduced in several countries and subpopulations, but so far has not consistently produced stigma-reduction sustained beyond six months after the training.³⁶⁴ There have been a few evaluations of stigma-reduction programs for primary care workers in low- and middle-income countries. These have also demonstrated up to now only short-term improvements in attitudes.^{365,366} Initiatives designed to change attitudes toward depression among health professional students in low- and middle-income countries have had mixed results.³⁶⁷

Social contact

Social contact appears to be the most effective type of intervention to improve knowledge about and attitudes towards mental illness in the short term, though the evidence for depression specifically and for longer-term benefits is weak.^{362,368,369} Investigation of workplace stigma-reduction initiatives is limited, and few of these specifically target depression.³⁴⁵

Interventions for depression literacy and stigma reduction in young people

Because the onset of depression frequently occurs early in life, mental health awareness and literacy are important for young people. A recent systematic review concluded that fewer than half of adolescents could recognize depression, with lower recognition rates in low- and middle-income countries (China, India, Jordan, Nigeria).³⁵² There was a preference overall for informal sources of help.³⁵² The impulse to handle problems on their own represents a significant barrier to treatment in this age group.³⁷⁰ The chance of moving through pathways to appropriate treatment is also influenced by the way complaints to a primary care practitioner are framed³⁷¹ — as well as providers’ reluctance to discuss the topic with adolescents³⁷² — two more reasons that interventions to improve mental health literacy are crucial.

In a rare study of the awareness in adults of childhood and adolescent depression, most parents in a U.S. national survey correctly identified a vignette of childhood depression as something more than daily troubles, labelled it a mental illness,³⁷³ and recognized the necessity of intervention. Other work suggests, however, that parents’ responses to adolescent depression are compromised by their own stigma towards and lack of knowledge about depression.³⁷⁴

Universal school-based programs have been undertaken either with this focus,³⁷⁵ or as depression and suicide prevention programs with depression and suicide literacy as a core component.³⁷⁶⁻³⁸⁰ Once more, however, there are conflicting results on changes in help seeking recommendations and intentions.^{376,381,382} One specific depression awareness and literacy training program reveals other significant outcomes. The Youth Aware of Mental Health (YAM) intervention grew out of the WPA Global Child Mental Health Program in collaboration with the WHO and the International Association of Child and Adolescent Psychiatry and Allied Professions. This was further developed in the context of the Saving and Empowering Young Lives in Europe (SEYLE) program, which was associated with a reduction in suicide attempts up to 12 months following intervention. The five-hour intervention included an awareness raising booklet covering six topics (awareness of mental health, self-help advice, stress and crisis, depression and suicidal thoughts, helping a troubled friend, and getting advice – who to contact) and lessons addressing these topics. Although not specifically assessed, there were numerous indications (such as students carrying the booklets 12 months later) that the students were directly empowered by these booklets and the brief role play sessions based on these: to take action for self or to support a peer finding help. YAM was compared to gatekeeper training in a randomized trial and found to be more effective.³⁸³

Treatment preferences

These have remained relatively stable across age groups over recent decades. Multiple systematic reviews describe a consistent preference among both the general public and people diagnosed with depression for counselling and other psychotherapy interventions over antidepressants.³⁸⁴⁻³⁸⁶ Elderly people with depression in Europe are among the few populations with an equal preference for medication, psychotherapy, and talking to friends and family as treatment options.³⁸⁷ The preference for psychotherapy is marked among adolescents, young adults, women, and minority ethnic groups,^{385,386,388} as well as those with prior experience with psychological treatments and more severe symptoms of depression.^{386,389} Explanations for the preference include the assumption that psychotherapy is better than antidepressant medication at resolving the causes of depression.³⁹⁰ Negative attitudes towards antidepressant use are linked with views that depression is a sign of emotional weakness or reflects one’s inability to deal with personal problems, or fears that it signals greater severity of depression symptoms.³⁸⁸ In some contexts, medication is considered irrelevant as depression is not seen as a medical condition, and self-help preferred.³⁹¹ Another study records a perception that many people are

misdiagnosed with depression and given antidepressants unnecessarily.³⁹² This echoes some academic critiques that current psychiatric practice is medicalizing sadness in the name of treating depression, leading ultimately to a loss of sadness and grief as ordinary, acceptable emotional reactions.^{60,393}

Importance of depression literacy for health workers

Depression remains stigmatized in the medical community.³⁹⁴ It is receiving increasing attention in some countries in campaigns addressing physician burnout and wellbeing: a combination of strategies (anonymous screening, outreach, education, peer support, and emergency mental health care access) may be effective in reducing depression and high rates of suicide among physicians and nurses.³⁹⁵ Teaching physicians to recognize depression in themselves and their colleagues and to find solutions that work for them can also be expected to repay as benefits to their patients.³⁹⁶


Health workers across the world, including those in low- and middle-income countries, acknowledge stigma toward people with depression.^{339,397} This is associated with low rates of depression recognition^{398,399} or poor quality of care. Physicians with stigmatizing attitudes often fail to offer appropriate physical health care to a person with documented depression, a practice known as diagnostic-overshadowing.³⁹⁷ Stigma may contribute to a bias, first, toward presentation of somatic complaints by patients and, second, toward health workers' treating the somatic concerns without exploring associated mental health problems such as depression.⁴⁰⁰ This overlaps with earlier constructs of masked depression.⁴⁰¹

Prevention

The approach to prevention is two-fold: population health science^{278,279,402,403} provides the basis for mobilising and measuring changes in the health status of populations, through policies and other interventions that influence the structural determinants of health (or macrosocial factors) such as income inequality and gender inequity; prevention science⁴⁰⁴ considers the interaction of risk, protective and other factors for individuals across the life course. This two-fold approach is grounded in an ecological understanding of the interactions of individuals with their proximal contexts (e.g., schools, family) and more distal contexts (e.g., social attitudes, economic policies) in a dynamic fashion over the life course.

We describe depression prevention through universal (offered to an entire population rather than specific groups), selective (targeted to individuals or groups at higher-than-average risk for depression) and indicated interventions (targeted to individuals showing signs of subthreshold depression) within the multi-level ecological framework: with the levels broadly categorized as structural, settings-based, and individual (Figure 7). To be effective, interventions need to be adapted with local experts and communities for selected settings at the appropriate ecological level. The prevention of the recurrence of an episode of depression is subsequently covered when considering interventions for remission and recovery from episodes of depression and the principles of care.

Figure 7. Opportunities for the prevention of depression across the lifecycle



Whole-of-society preventive interventions (conceptually these are *universal interventions*) address structural determinants of depression. Interventions shown in the second and third rows represent the more immediate or proximal ecological levels of settings and individuals. These interventions can (i) be categorised as *universal*, *selective* or *indicated* depending on the focus of the work (e.g. all children in a school vs children with learning or emotional difficulties; noting that whole school programs may include a mix of these intervention types); and (ii) focus on risk and protective factors at different points across the lifecycle, within the various social contexts.

Proximal interventions for the prevention of depression

Randomised controlled trials for preventing depression have examined interventions that use adapted versions of psychological treatments for depression delivered in a range of settings and population groups – schools, general medical care, pregnancy-related settings,⁴⁰⁵ and, increasingly, digital settings.⁴⁰⁶⁻⁴⁰⁹ They include universal, selective and indicated interventions. A meta-analysis of 156 trials reported small effects (pooled SMD of 0.16 [0.07–0.26]),⁴¹⁰ with smaller effects as expected for the trials of interventions designed as universal prevention programs. For cognitive behavioural therapy (CBT)-based preventive eHealth interventions, a pooled mean difference of 0.25 for short-term outcomes has been reported; however, no effect was detected on long-term incidence rates.⁴¹¹ All in all, based on these findings, the efficacy of specific psychological and educational interventions may be considered as relatively small, but meaningful.

A recent meta-analysis⁴¹² of RCTs included participants from high risk groups, of all ages, but without a diagnosis of depression at baseline. Each of the included studies assigned participants to a preventive psychological intervention or a care-as-usual or comparable control group, and ascertained incident cases of depression at follow-up with a diagnostic interview. The analysis reported an incidence risk ratio of 0.81 one year after the preventive intervention. Given the average control event rate of 28%, 19 people had to participate in the intervention to prevent one depressive episode compared to people in the control condition.

Such interventions, even if requiring modest health system investments, provide savings that often accrue elsewhere in the health system or wider economy. There are, however, economic challenges to implementation: savings from effective prevention may not accrue for many years, nor benefit the healthcare sector, creating resource disincentives to take action.^{413,414} We now examine the evidence on prevention across specific life course stages.

The perinatal period: A recent US Preventive Services Taskforce review⁴¹⁵ reports convincing evidence that pregnant or postpartum women who are at increased risk for depression — based on sub-threshold symptoms, history of depression, and/or socio-economic and demographic factors including recent intimate partner violence or other negative life events — would benefit from counselling (CBT or interpersonal psychotherapy [IPT] adapted for this purpose). The Taskforce also reviews evidence on non-psychological interventions. It concludes, consistent with an earlier systematic review on exercise,⁴¹⁶ that while the evidence base on exercise and social interventions to prevent antenatal depression in mothers is growing, it remains insufficient to support implementation and points to a prominent area of research need.

There is also a growing evidence base on the depression prevention effects of parental interventions in the perinatal period. These are designed to promote healthy parenting and family bonding, and include^{417,418} social programs addressing depressive symptoms; substance use counselling and treatment; screening for risks to the development of a child; attention to the behavioural needs of children with chronic medical disorders; and parent education programs. For many of these strategies, there is strong evidence of cost-effectiveness.⁴¹⁹ While this evidence comes mainly from high-income countries, a peer-delivered psychological intervention (The Thinking Healthy Programme) in India and Pakistan has been shown to have a moderate effect on remission from perinatal depression as well as low-cost to deliver and cost-saving through reduced health service use and productivity losses.^{420,421} A key delivery strategy during the perinatal period addresses perinatal health care concurrently with risk factors for depression, such as intimate partner violence, and preventive interventions.

Collaborative care (described in detail later) enables obstetricians, nurses, primary health care practitioners, social workers and mental health practitioners to provide integrated care in a single setting.⁴⁰³ An enduring and cost-saving preventive effect on postnatal depression was achieved in one study of a universal intervention⁴²² that trained health visitors (community health professionals) in identifying depression and psychological intervention methods.⁴²³

Several strategies devised to support the mental health of parents⁴⁰³ are successful and relevant in preventing adverse mental health outcomes in their offspring (see also below). However, the focus on pregnancy may not be early enough to prevent intergenerational transmission of depression. There is emerging evidence that poor mental health in the preconception period can be associated with poor mother infant bonding⁴²⁴ and with infant reactivity, a marker of future mental health problems.⁴²⁵ This raises the possibility of predicting perinatal depression from adolescence and before conception and investing in the future through promotion of education for girls, and addressing gender equity through societal interventions such as preventing child marriage, delaying marriage beyond adolescence and other measures.^{426,427}

Children and adolescents: Most depression prevention trials have been conducted with children and adolescents.⁴¹⁰ The focus is warranted given the substantial emergence of mental disorders in the first decades of life and the potential for shaping current and future generations.⁴²⁷ Nine out of 10 reviews of these trials report significant reductions in depressive symptoms,⁴²⁸⁻⁴³⁶ generally with small effect sizes. Four reviews analysed the incidence of depressive disorders as an outcome, and all reported reductions in incidence.⁴³⁰⁻⁴³² Subgroup results from a meta-analysis⁴¹² of psychological intervention trials indicate an incidence risk reduction of 0.71 (95% CI: 0.51–0.99) among high-risk children and adolescents without depression at baseline one year after the intervention. Given the average control event rate of 25%, 14 individuals had to participate in the intervention to prevent one additional episode of depressive disorder compared with the control group outcome.

Educational institutions, from schools to universities, offer unique opportunities for preventive interventions. Bullying at school (and in other settings) is an important target for interventions to avert a strong lifetime risk for depression.⁴³⁶ A large meta-analysis focused solely on school-based CBT detected small effects for depression prevention in the short- and medium-terms, with a small long-term benefit.⁴³¹ Another meta-analysis of school-based depression prevention programmes highlighted 81 RCTs with positive but small effect sizes.⁴³⁴ The SEHER trial from India is one of the few examples of a school-based intervention in a low-resource setting. It reported benefits from a lay counsellor-coordinated intervention targeting the social environment (school climate), with large and incremental effects (with time) in reducing bullying and depression symptom severity.⁴³⁷ A systematic review of 68 prevention programs for college, graduate and professional students in 15 countries⁴³⁸ reported moderate reductions in symptoms, regardless of delivery format or prevention level.

While economic evaluations suggest that depression prevention strategies in children and adolescents are cost-effective,⁴³⁹ many actions are initiated outside the healthcare sector (e.g. in schools). The costs of doing so might be a disincentive, even though interventions such as social and emotional learning programmes and anti-bullying initiatives offer strong economic pay-offs over quite long periods.⁴⁴⁰⁻⁴⁴² Many lifestyle risk factors and risk pathways for depression and non-communicable diseases are shared from childhood and adolescence onwards. This makes common preventive approaches attractive for targeting these factors. There are compelling reasons to target depression specifically in such shared approaches. Not only is depression an important negative health outcome in its own right, and its avoidance an

immediate incentive for young people and their families, but it is also likely to mediate the effects of many risk factors on other diseases.

Adults: Employment is demonstrated to reduce the risk of depression,⁴⁴³ possibly by providing a greater sense of autonomy, improved socioeconomic status, and avenues for personal development.⁴⁴⁴ Workplace interventions that increase employee control and promote physical activity appear to be associated with mental health benefits;⁴⁴⁵ those using CBT-based techniques typically report small benefits.⁴⁴⁶ A systematic review and meta-analysis reports small to medium effects for indicated preventive interventions in the workplace, targeting persons with sub-threshold depressive symptoms with either CBT-based (six studies) or other psychosocial interventions (two studies).⁴⁴⁷ There is also moderately strong evidence that CBT is cost-saving in workplace settings.⁴⁴⁸

Many trials of prevention through psychological interventions in group or individual format have been conducted in other settings, covering both selective and indicated prevention approaches. A meta-analysis of 32 RCTs (6,214 participants) of psychological interventions of various types among adults found that the chance of developing a depressive disorder was 21% lower than in the control groups.⁴⁴⁹ The authors concluded that prevention of depression seems feasible and psychological intervention may be an effective way to delay or prevent the onset of depressive disorders. Small reductions in depressive symptoms after psychological and educational interventions have been reported for primary care patients.⁴⁵⁰

The evidence base is growing for preventive interventions targeting the lifestyle factors of smoking and physical activity. Quitting cigarette smoking is associated with improved anxiety and depression.⁴⁵¹ There is meta-analytic evidence that exercise may have antidepressant effects^{452,453} and preventive benefits.^{454,455} A meta-analysis of prospective cohort studies reported a protective effect of physical activity against the emergence of depression across age groups and across geographical regions.²⁷⁴ There is strong evidence that exercise during pregnancy can reduce the risk of postpartum depression.⁴⁵⁶ The potential of diet as a modifiable variable to include in depression prevention programs has been examined with no clear findings to date.⁴⁵⁷

Prevention of depression needs to take into account sexual and intimate partner violence and abuse given their association.²⁸¹ Many health practitioners in primary and secondary care do not routinely enquire about intimate partner violence in routine health care consultations, nor do they all know how to respond safely to disclosures.⁴⁵⁸⁻⁴⁶⁰ When practitioners are trained to ask sensitively and safely about abuse and have clear referral pathways, clinical encounters can be opportunities for identification and referral for help, contributing to prevention of depression. This is demonstrated in a cluster trial in primary care⁴⁶¹ and suggested by a pilot study in secondary mental health care.⁴⁵⁹ Training for competencies in gender-based violence assessment and treatment in health care settings has been developed by the World Psychiatric Association.⁴⁶²

Older adults: Preventing late-life depression is likely to reduce the risk of suicide, dementia and age-related disability. The potential to prevent depression in the context of a chronic medical condition is illustrated by studies of depression and the use of antidepressant medicines after stroke. Meta-analytic findings indicate that antidepressant prophylaxis following acute stroke is likely to reduce the incidence of depression and improve motor and neurological function.⁴⁶³ Prevention trials have explored Vitamin D insufficiency and inflammation, using supplementation⁴⁶⁴ and low dose aspirin⁴⁶⁵ respectively, without any evidence of efficacy.

Loneliness is associated with the development of depressive symptoms, especially later in life.⁴⁶⁶ Simple signposting services—assessment of needs to help identify opportunities for participation in local social activities, based in primary care or community facilities—are both effective⁴⁶⁷ and cost-effective⁴⁴² in reducing social isolation and loneliness. Other strategies such as those addressing maladaptive social cognition exhibit promising results.⁴⁶⁸ The changes in lifestyle imposed by the physical distancing policies in many countries as a response to the COVID-19 pandemic represent a disproportionate challenge to older adults. They exacerbate the increase in rates of social isolation and loneliness that have concerned communities and governments in several parts of the world in recent years. In this context, the use of technology⁴⁶⁹ (ranging from traditional telephone calls to internet-delivered interventions) to promote social support and a sense of belonging may be a significant help, as well as broader befriending and community inclusion initiatives in the longer term.^{468,470}

Only one randomized controlled trial of indicated prevention specifically focused on older adults has been conducted in a low- or middle-income country.^{71,471} The DIL intervention (“Depression In later Life” and also signifying the Konkani word for “heart”) was delivered by lay counsellors to older persons at primary care clinics in Goa, India. It was grounded in problem solving therapy and also included brief behavioural treatment for insomnia, education in better self-management for common medical disorders like diabetes, and assistance in navigating medical and social services. Over one year, the intervention led to a significant reduction in incident episodes of depression compared to enhanced care as usual (4.4% versus 14.4%). The DIL intervention appeared to build resilience in the form of active coping, behavioural activation, and persistence, especially for dealing with health-related problems and their attendant threat to independence and degrading the quality of life.

Tackling structural determinants of health across the life cycle

While much of the empirical evidence on prevention has focused on proximal determinants described above, attention is also needed to address more distal structural factors of significance, which influence the inequitable distribution of proximal determinants, in particular poverty, income inequality, gender inequity, historic marginalization and displacement. This is consistent with a shift from cultural competency to “structural competency,” which emphasizes the need for social and health services and planners to be knowledgeable about the context and resources of their communities and service users, and actively draw upon resources to mitigate social and structural determinants of mental illness.²⁸³ Promoting structural competency is likely to provide dividends not only for prevention, but also for the treatment and care of individuals with depression.

Addressing structural factors through policy-based interventions that reach all parts of the population has the greatest potential impact on preventing depression.^{1,403,472-474} This approach, grounded in population health science, is equivalent to the use of public policy to change population patterns of diet, exercise and tobacco use in prevention of cardiovascular disease. These interventions lie figuratively at the base of the health impact pyramid devised by Frieden⁴⁷⁵ to describe the impact of different types of public health interventions; and tend to be the most effective, rapid, equitable, cost-effective and sustainable forms of prevention.⁴⁷⁶ How many people in a country live in conditions conducive to healthy development and to health and productivity across the life span, which is a fundamental human right,^{279,403} depends critically on public policy and planning.

Most countries have witnessed a dramatic increase in income inequality in the past three decades. On top of this, the COVID-19 pandemic has destabilised economies worldwide and the climate emergency and environmental degradation continue apace, fuelling this and other inequities. A recent systematic review demonstrates a greater risk of depression in populations with higher income inequality relative to populations with lower inequality.^{283,477} It proposes an ecological framework, with mechanisms operating at the national level (the neo-material hypothesis), neighbourhood level (the social capital and the social comparison hypotheses) and individual level (psychological stress and social defeat hypotheses) to explain this association. The authors conclude that policy makers should actively promote actions to support the fair distribution of income, such as progressive taxation policies and a universal basic income. As one example, in Malawi's scaled-up *Social Cash Transfer Program*,⁴⁷⁸ a program aimed at reducing poverty, hunger and improving school attendance, that reached 330,000 impoverished households, depressive symptomatology in youth was reduced by 15 percentage points. The reduction in young women was partially explained by increased social support, reiterating the importance of giving attention to peer support strategies and evidence of the synergistic impact of diverse sectors, through increased school attendance. Indeed, policies that reduce gender inequities and systematic disadvantages experienced by women, income inequities such as through universal health coverage and expanding opportunities for educational attainment, and racial or ethnic inequities linked in part to racism and discrimination can be potentially powerful preventive strategies.

The gender disparity in depressive disorders — as women are nearly twice as likely as men to report the experience of depression — may relate to inequalities beyond the level of health policies.⁴⁷⁹ It is likely that inequality may impact on depression through several different mechanisms — one such pathway being lack of access to financial resources, making it difficult for women to leave relationships where there is intimate partner violence.⁴⁷⁹⁻⁴⁸¹


Evidence exists to take pre-emptive action to halt the potentially damaging effects of poverty, income inequality, violence and other social inequities on the mental health of populations.²⁸³ A number of evidence-based strategies across the life course at individual and community levels can be used as well to mitigate the risks of depression arising from the more proximal adversities and risk factors noted above. There is, nonetheless, a need to learn more about the mechanisms of change and strengthen the evidence base through refined interventions and evaluation of broad public health programs and policies. Health professionals should ally themselves with other stakeholders in government, civil society and communities more generally to champion such policies, and the need for greater investments in proven interventions for the prevention of depression.²⁸³ A whole-of-society approach to the prevention of depression is justified, linked to measures such as those implemented to curtail alcohol consumption and overlapping with successful actions by many countries to reduce the prevalence of coronary heart disease and several forms of cancer.⁴⁸²

Staged approaches to early intervention, treatment and care

Staging models as used across healthcare⁴⁸³ offer a pragmatic guide to managing the heterogeneity of depression. They identify where an individual lies along a continuum of risk for illness progression (of the depressive illness or its underlying pathophysiology) and extension (additional complications beyond the syndrome of depression)^{484,485} (Figure 8) and aid in reviewing the person's needs for intervention, including early intervention. They acknowledge the transdiagnostic nature of psychopathology, assuming that illnesses begin with distressing symptoms and emerging functional impairment, at first, at least, below a clinically

significant threshold. Illness states may not progress from one stage to the other, and may change in the opposite direction as well, especially from stage 4 to 3. This may occur in the natural course of the condition or as a result of clinical or non-clinical interventions, so that people frequently reach partial or full remission.⁴⁸⁶ However, staging provides a model for responding to the state people are in and for seeking to reduce the risks of progression to a more advanced stage.

Figure 8. A clinical staging framework for depression



*Also described as “subsyndromal” or “subthreshold”; includes transdiagnostic presentations that could benefit from interventions.

The extent and rate of progression from one stage to the next — and whether this occurs — will differ between people. For example, most people with sub-clinical symptoms do not progress and frequently recover. Others show rapid progression to severe depression and do not come to clinical attention for the first time until they are very unwell and suicidal: especially when mental health literacy and help seeking are poor or weak, or access to care is difficult. Some of these people do not respond to first-line treatments and the situation calls for a staged care approach to allocating more intensive treatments. Ideally, this is best managed by a multidisciplinary collaborative care team (described below), particularly when comorbidity or complications are present.

Staged approaches to intervention for depression include: universal and selective preventive interventions (stage 0) and indicated prevention of depression (stage 1); interventions early in the course of a depressive disorder, from its first episode (stage 2), comprising the delivery of evidence-based first-line interventions for acute episodes of clinical-threshold depression; and the provision of second line or more complex interventions for people who do not respond to the first-line interventions or who present with or graduate to recurrent or persistent depression (stages 3 and 4).⁴⁸⁷

Intervening early in the course of the disorder

Clinical staging provides a framework for planning and recommending interventions from the earliest point that a need for care emerges in the course of a depressive illness (indicated prevention). The illness presentation is highly variable at the point a person's distress first comes to professional attention — whether this be in an educational, welfare or workplace context, or in a primary care or other clinical setting. The need, mode and most appropriate setting for intervening in the first stages of illness can vary according to the level of distress and disability, the availability of resources, as well as the help-seeking behaviour of the affected person. For example, indicated prevention can be offered as self-help, or as online or school-based interventions. It can also be offered in clinical settings (as in primary care or linked frontline community-based mental health programs).

The first episodes of depression may provide the next critical opportunity for early intervention. Recalling that deaths from suicide among those with a current depressive episode occur most often (75%) during the first episode underscores the urgent need to identify and treat adequately the very first major depressive episode. In addition, the risk of recurrence after the first two episodes is substantially less than after the third and subsequent episodes, indicating an early potential for recovery on which interventions should capitalise.⁴⁸⁸ Consistent with this, structural brain changes are minimal during the first episode of depression, but become more evident with recurrence.^{489,490} This has led to suggestions that depression can be itself neurotoxic, and that recurrence is associated with an active process of neuroprogression⁴⁹¹: that is, the experience of depression causes brain changes that make depression more likely in the future.⁴⁹² Early episode depression is less likely to be complicated overall (despite the risk of suicide) than depression later in the course of the illness. People with first or early episodes of uncomplicated depression can usually be cared for, at least initially, in primary care settings. The net benefit of early intervention, given that some episodes are self-limited without treatment, is an urgent priority for research investment.

Episodes of depression early in life affect critical developmental processes and life domains, particularly during adolescence and early adulthood, posing a major threat to lives and future potential. This includes developmental tasks, creating a stable identity, completing education, commencing work, establishing intimate relationships, and starting a family. Successful navigation of these tasks establishes a trajectory through adulthood, while failure to do so compounds over many decades, and even trans-generationally. Enhanced primary care for youth mental health – where young people can refer themselves, or be referred by family, educators, or primary care doctors – represents an important innovation to reach young people very early in the course of emerging mental ill-health.⁴⁹³ Innovative models of integrated youth health care, known as 'headspace' centres in Australia, have spread to a number of countries.⁴⁹⁴ Care is holistic and integrative, and alongside treatment for depression, intervention is provided for physical health, substance use, education, employment, and other developmental and social needs.

Risk-factors such as sexual trauma and bullying are common to a wide range of mental health problems,^{495,496} and should be addressed as part of early preventive efforts. The trans-diagnostic perspective⁴⁹⁷ recognises that emerging mental ill-health is fluid, made up of a range of clinical presentations which ebb and flow prior to distillation into more stable subsequent phenotypes later in the course of the illness. Early interventions (especially psychosocial interventions, but also including judicious use of medications such as selective serotonin reuptake inhibitors) may thus have beneficial effects across a range of syndromes.⁴⁹⁷

Interventions for remission and recovery from depressive episodes

When I'm depressed, I feel dead inside, like a shell of a person going through the motions... I can't stop crying, even when positive things are going on around me.

- Annika Sweetland, 44, United States

Sometimes the simplest things are the ones that make me feel alive... When I go to bed thinking about the breakfast I'm going to prepare the next day, I know I'm not depressed anymore.


- Nacho Guevara, 47, Costa Rica

Here we consider the treatment of depressive episodes that meet clinical severity threshold criteria (other than episodes experienced as part of bipolar disorder). A number of the principles of care apply to all forms of depression, and to mental ill-health in general. However, there are important variations in the care for people with bipolar disorder that we do not address here.

The WHO's mhGAP guidelines⁴⁹⁸ based on a review of the effectiveness of first-line treatments for depression and the feasibility of their delivery in routine care settings have recommended either of two treatments for any individual: antidepressant medication (in particular SSRIs) or brief, structured psychological treatments based on CBT or IPT (including variants of these treatments such as behavioural activation, problem-solving therapies, mindfulness, acceptance and commitment therapy). A significant proportion of people will remit even with no treatment ("spontaneous remission"), and there are no aggregate differences in effects or in effect modifications between the two primary monotherapies for an acute episode of depression. Our current state of knowledge therefore precludes precision medicine approaches to predict who will respond to 'watchful waiting' or to a specific first-line treatment so that we can confidently allocate individuals to any of these specific interventions (i.e. the 'optimum' intervention for an individual). Clinicians may recommend, as throughout health care, a period of watchful waiting for those with a mild condition, for further assessment and monitoring, relationship building and shared decision-making. Other initiatives used in this period may include brief interventions such as psychoeducation and lifestyle interventions, particularly exercise, that may also promote remission. These interventions may be employed also as adjuncts to the two primary monotherapies. Insomnia is increasingly considered as a comorbid condition rather than an accompanying symptom of depression, and treatments targeted at insomnia may improve⁴⁹⁹ and prevent depression.⁵⁰⁰

Non-responders to antidepressant medication may show additional benefit from switching to or augmentation with other medication. Alternatively, combined treatment (psychotherapy plus medication) works better than either alone. Non-responders to these second line treatments may benefit from neuro-modulation therapies such as electroconvulsive therapy (ECT) and brain stimulation. Effective treatment leads to improvements in a range of outcomes, beyond depression alone, including improved physical well-being, function and reduced suicidal behaviour, all of which are often prioritized by patients. Thus, depression treatment works very well because of the enormous variety of treatments, but it is often necessary to go through a sometimes protracted process of trial and error to find the right treatment for the right person. This is especially true for people receiving treatment for the first time, who have no past experience about what worked for them on a previous occasion. Figure 9 depicts the steps in the management of an episode of depression. We now briefly review the evidence in support of these treatment options.

Figure 9. Clinical interventions for depression



Effectiveness of self-help and social interventions on depression outcomes

Guided self-help (internet-based or not), which encompasses interventions based on effective psychological therapies, but designed to be entirely or mostly self-delivered, is as effective as individual, group or telephone psychotherapies, with moderate effect sizes (Cohen's d range 0.51-0.69) compared with care as usual.⁵⁰¹ Unguided self-help can also have smaller but significant effects⁵⁰²; moreover, it has an advantage that it does not require contact with a helping person. However, individuals with depression seem to benefit more when there is at least a modicum of human interaction, especially in more severe depression.⁵⁰³ There is less consistent evidence in support of lifestyle interventions, with higher quality studies generally showing small effects, as for exercise⁴⁵³ or quitting smoking, or null effects as for omega-3 fatty acids and Vitamin D. While the evidence base on the effectiveness of social interventions, ranging from structural interventions such as housing and income support to social support interventions such as peer support, is less well studied, there are indications that these are also potentially important strategies for persons who are experiencing such adversities.⁵⁰⁴

Effectiveness of first-line treatments on depression outcomes

Some 750 trials with over 30,000 participants provide evidence for various psychotherapies for the acute treatment of major depression,⁵⁰⁵ and more than 500 trials involving over 110,000 participants provide support for the efficacy of antidepressants.⁵⁰⁶ Efficacy is comparable in magnitude to therapy for common medical disorders.⁵⁰⁷ When measured against the common comparator, pill placebo, CBT had an SMD of 0.20 (0.01 to 0.38)⁵⁰⁸ and antidepressants an SMD of 0.30 (0.26 to 0.34).⁵⁰⁶ Given the average placebo response rate of 40%,⁵⁰⁹ the SMD of 0.3 or 0.2 would translate into NNTs of approximately 9 and 13, respectively.⁵¹⁰⁻⁵¹²

We now have a relatively clear understanding of possible differences in efficacy among active antidepressants,⁵⁰⁶ optimal dosing of new generation antidepressants^{513,514} and delivery formats for psychotherapies.⁵⁰¹ Among adults, direct comparisons of antidepressants reported that several specific antidepressants were more effective than other antidepressants (range of ORs for response 1.19–1.96), whereas others were in a least efficacious group (0.51–0.84),⁵⁰⁶ There have been no discernible differences detected so far among different psychotherapies.⁵⁰⁵ On average, pharmacotherapies and psychotherapies are similarly efficacious.⁵¹⁵ There is no evidence that personal treatment preferences, particularly in people with no prior treatment exposure, moderate symptomatic outcomes.⁵¹⁶

In children and adolescents, CBT and IPT may be seen as first-line treatments, with medicine added if these therapies are not successful.⁵¹⁷ A recent systematic review⁵¹⁸ suggests antidepressant medicine—specifically fluoxetine—alone or in combination with CBT is the most efficacious treatment in moderate-to-severe depressive disorder. However, the quality of the evidence is low. This is set in the context of the evidence of smaller effects in children and adolescents, than in adults and older adults, of both antidepressants and psychotherapy compared with placebo.⁵¹⁹ Treatment choices need to take this into consideration, together with the risk of suicidality with or without treatment (even as that remains to be elucidated).

Limitations of first-line treatments

The use of antidepressants is associated with a number of unwanted effects. While a number of specific side effects are commonly reported with use of SSRIs, for example, nausea, dry mouth, headache, diarrhoea, tremor, dizziness, anxiety, nervousness, agitation, insomnia, constipation,⁵²⁰ and sexual side effects, none of these except for increased risk of osteoporosis⁵²¹ are associated with enduring impacts.⁵²² A recent umbrella review of systematic

reviews examined 120 putative associations of antidepressant medication and adverse outcomes and observed that while there were some associations, none of them remained after sensitivity analyses adjusting for confounding by indication and the authors concluded with no absolute contraindication to antidepressants.⁵²³

Of concern is the so-called discontinuation syndrome or withdrawal syndrome^{524,525} upon abrupt or gradual discontinuation of SSRIs and SNRIs. Withdrawal symptoms have been reported to occur typically within a few days and persist for a few weeks; but many variations are possible including later onset and longer duration.⁵²⁶ One review reports incidence rates ranging from 27% to 86% (weighted average of 56%) based on individual reports in surveys⁵²⁴ and another at 31% based on RCTs employing a withdrawal symptom scale.⁵²⁷ While gradual and hyperbolic tapering may mitigate the symptoms,⁵²⁸ there is a paucity of adequate research to guide their management.⁵²⁹ The question of withdrawal may be related to increases in prolonged prescription in some countries.^{530,531}

Second and third-line treatments

Partial or non-response to depression treatment is common in clinical practice. Close to half the people treated for major depression fail to achieve symptomatic remission during initial acute or short-term treatment. The expression “treatment-resistant depression” is commonly used in the literature to describe situations of failure to achieve a reduction in depressive symptoms, frequently defined as occurring after at least two courses of antidepressants.⁵³² This concept has been criticized for a number of reasons, including its inconsistent definition and sometimes limited consideration of psychosocial approaches to intervention. More recently, the notion of “difficult-to-treat depression” has been proposed to encompass the acute phase of treatment as well as sustained response and remission. It provides a more positive framing, aiming to address overall functioning and quality of life as well as depressive symptoms to enhance engagement of the patient and consideration of the whole range of interventions.⁵³³

Before concluding that a given treatment approach is not effective, it is important to consider the possible reasons for failure to respond, including: treatment adherence; diagnostic accuracy; co-occurring conditions, whether psychiatric or medical; and factors in the psychosocial context that complicate treatment or necessitate adaptation of clinical care to meet a person’s needs.⁶⁷ There may be need for additional resources, social interventions or other support for adequate and personalized clinical care in the face of stressors or life events such as bereavement. People of different backgrounds may vary in their understanding of, and beliefs about, depression, and what constitutes acceptable, needed or appropriate care. Family member or carer support for engagement in treatment is a vital dimension of this social context.

In short-term trials of depression monotherapy, participants receive one medication or one psychotherapy for 8-16 weeks. Only a limited number of clinical trials is available to guide practice when people fail to respond to the initial treatment. Recent systematic reviews of pharmacotherapy studies identified seven trials for dose escalation,⁵³⁴ four for switching of antidepressants,⁵³⁵ 48 for various augmentation agents,⁵³⁶ or 25 studies for augmentation of pharmacotherapy with psychotherapies.⁵³⁶ Reviews have found no evidence to support dose escalation but some evidence for the other strategies. In the Sequence Treatment Alternatives and Relieve Depression (STAR*D) study — a study designed to test treatments to achieve remission — by switching ineffective treatments after 8 weeks the remission rate reached 67% over one year among participants who remained in the study. Even if remission was reached after several trials, it was associated with better prognosis than for treatment as usual.⁵³⁷ It is notable that some characteristics of depression linked to poor outcome of first line

antidepressant treatment may also predict good response to augmentation strategies. For example, profound loss of interest and reduced activity were associated with non-response to SSRI antidepressants, but good response to augmentation with aripiprazole.⁵³⁸ In addition, some psychotherapies have been developed specifically for persistent depressive disorder.⁵³⁹

The efficacy of the choice among these strategies is not the only consideration, however; tolerability and safety outcomes are also essential. An example of a current comparative effectiveness trial for the pharmacotherapy of treatment-resistant depression is the US-based multisite trial, OPTIMUM, being carried out both in the specialty mental health sector and in primary care. OPTIMUM provides a stepped-care algorithm that specifies augmentation and switching strategies, such as aripiprazole, bupropion and lithium, on a platform of measurement-based care.⁵⁴⁰ Combination of the first-line treatments is another promising strategy. Higher response rates can be achieved with combined treatment with medication and psychotherapy. The response rate of combined treatment compared with placebo is about twice as large as medication alone compared with placebo. While these differences underscore the advantages of combined treatment, it is not possible to conclude from evidence now available whether this is an additive effect of the two treatments or simply the result of personalized allocation of the optimum treatment.⁵¹⁵

Depression with psychotic features is a severe form of the condition (discussed earlier) and one of the few depression subtypes for which specific pharmacotherapy is indicated. A systematic review of 12 RCTs (929 participants) reports no evidence of efficacy for monotherapy with an antidepressant or an antipsychotic, but superior efficacy of their combination over either monotherapy alone or placebo.⁵⁴¹

Finally, a number of additional options are now available for treatment-resistant/refractory/difficult to treat or persistent depression. Neuromodulation therapies such as ECT or rTMS have been established as successful in the short term (with relatively large SMDs). The long-term stability of their efficacy is yet to be established.⁵⁴² Drugs that focus on the glutamatergic system (ketamine, esketamine, rapastinel), the GABAergic system (brexanolone, SAGE-217), the opioidergic system (buprenorphine, samidorphan), and the inflammatory system (minocycline) have been developed and trialled, with promising results for some.⁵⁴³⁻⁵⁴⁵ However, the initial results for many novel treatments have not been replicated.⁵⁴⁶ Novel psychological treatments based on the ‘third wave’ of cognitive behavioural interventions⁵⁴⁷ include mindfulness-based CBT, acceptance and commitment therapy, and meta-cognitive therapy. A growing number of studies also show that transdiagnostic psychological interventions aimed at people with depression or anxiety or both are also effective in the treatment of depression.⁵⁴⁸ Other psychological treatments derive from a mechanistic understanding of psychopathology based on experimental findings such as interpretation bias modification.⁵⁴⁹

Preventing relapse and recurrence

Achieving remission and recovering from an acute episode is insufficient given the high risk of relapse and recurrence.⁵⁵⁰ Inter-episode wellness intervals tend to become progressively shorter, and the risk of treatment resistance increases with each succeeding episode. Thus, getting well is not enough, it is staying well that really counts. A growing evidence base provides an expanding set of treatment options for preventing relapse and recurrence. It is well demonstrated that once participants have recovered with antidepressant treatment, continued pharmacotherapy reduces the risk of relapse or recurrence by half, resulting in NNTs of approximately 4 to prevent a relapse within a year among people at high risk of relapse (for

example, those who have experienced multiple episodes).⁵⁵¹ These trials keep the dosage for continuation treatment at the level of the initially successful acute treatment.


A recent network meta-analysis of 81 trials found that initiating the treatment of a depressive episode with psychotherapy, alone or added to pharmacotherapy, may increase substantially the chances of getting well and staying well for up to a year by 12-16 percentage points compared with initiating the treatment with drugs only.⁵⁵² Accumulating evidence from 30 trials also supports efficacy of mindfulness-based CBT, preventive CBT, and IPT in relapse prevention.⁵⁵³ The results of a recent systematic review and meta-analysis indicate reduced risk of relapse and recurrence in patients remitted from a depressive episode when psychotherapy is sequentially integrated with antidepressant medication.⁵⁵⁴

For people recovering from psychotic depression, continuing the antipsychotic medication over several months at least is needed in order to prevent relapse and recurrence.⁵⁵⁵ There is evidence that continuation ECT may also be effective in sustaining remission in people with refractory depression.⁵⁵⁶

Other impacts of first-line treatments

People with depression typically come into treatment with several problems and concerns.⁵⁵⁷ The impact of treatments on other outcomes, in particular functional outcomes, is at least as important as on the mental health symptoms. Figure 10 shows that the psychological treatment of depression has considerable effects on quality of life, social functioning and social support: less evidence is available on the effects of antidepressant treatments on this range of outcomes. The question of whether the treatment of depression *per se* has a significant effect on suicidality does not have a definitive answer, largely due to low power of trials to detect rare outcomes, though there are real-world studies which suggest an association (discussed later).⁵⁵⁸

Figure 10. The effects of psychological treatment for depression on relevant outcomes



Psychotherapies include: acceptance and commitment; acceptance and commitment therapy with extensive email support; behavioural activation; body, mind, spirit psychotherapy; cognitive-behavioural therapy (CBT); coping with depression dialectical behaviour therapy skills training; guided self-help; interpersonal counselling; interpersonal psychotherapy; life review; mindfulness-based cognitive therapy and coping with depression; problem solving therapy; problem-solving treatment; psychodynamic psychotherapy; religious CBT, non-religious therapist; mindfulness based cognitive therapy; supportive psychotherapy.

Depression treatments have been tested in people diagnosed with depression comorbid with various somatic conditions. The studies show consistent improvements in depression status in all these groups. The treatment effect on somatic outcomes, however, has generally not been significant (Table 3). An exception to this is the positive effect of antidepressant treatment on glycaemic control in those with diabetes;⁵⁶⁵ for which there is also strong evidence of cost-effectiveness. Other meta-analyses and large randomized trials found insufficient evidence for effects on survival or cardiac events. This could indicate that the strong epidemiological association between depression and somatic health is not directly causal, or that depression treatment does not target directly the pathology underlying the pathway from depression to somatic condition; or that it takes trials of longer duration and with larger samples to observe the impact of depression treatment on somatic outcomes.

The transgenerational effects of depression treatment on families and on future generations are fields of growing interest. Emerging evidence demonstrates that the effective treatment of persistent postnatal depressive symptoms in mothers is associated with improved child outcomes at 2 years of age.⁵⁶⁶

Table 3. The effects of depression treatment on general medical disorders

Study	Studies/sample	Intervention vs. Control	Results on depression symptoms	Results on somatic outcome(s)
Meta-analytic evidence				
Pizzi 2011 ⁵⁶⁷	4 RCTs in 734 patients with myocardial infarction and depression	SSRI treatment vs. placebo or no intervention	Reduction (SMD: -0.34 [-0.06 to -0.63])	No reduction of CHD readmissions (0.74 [0.44 to 1.23])
Cristea 2019 ⁵⁶⁸	7 RCTs in patients with diabetes and depression or depressive symptoms	Psychotherapy vs. TAU	Not presented	No difference in glycaemic control (change in HbA1C) (Hedges' g: -0.01 [-0.30 to 0.29])
Baumeister 2012 ⁵⁶⁵	4 RCTs in 441 patients with diabetes and depression	Psychological intervention vs. TAU	Reduction (SMD: -0.42 [-0.70 to -0.14])	No significant effect on HbA1c (pooled ES not shown)
Baumeister 2012 ⁵⁶⁵	5 RCTs in 238 patients with diabetes and depression	Antidepressant treatment vs. placebo	Reduction (SMD: -0.61 [-0.94 to -0.27])	Reduction in HbA1c (SMD: -0.4% [-0.6% to -0.1%])
Sharpe 2014 ⁵⁶⁹ Walker 2014 ⁵⁷⁰ Mulick 2018 ⁵⁷¹	2 RCTs in 642 patients with cancer and depression	Multicomponent collaborative care for People with Cancer (DCPC) vs. TAU	Reduction in mixed cancer (SMD: -0.78 [-0.90 to -0.66]) Reduction in lung cancer (SMD: -0.38 [-0.58 to -0.18])	No difference in survival (HR: 0.92 [0.72 to 1.18])
Legg 2019 ⁵⁷²	2 RCTs in 2,829 patients with stroke and with(out) depression 3 RCTs in 3,245 patients for mortality outcome	SSRI vs. placebo	Reduction (SMD: -0.11 [-0.19 to -0.04])	No difference in disability score (SMD: -0.01 [-0.09 to 0.06]) No difference in mortality (HR: 0.99 [0.79 to 1.25])
Selection of individual randomized treatment studies (sample size>200)				
ENRICH ⁵⁷³	2,481 patients with MI and major/minor	CBT-based psychosocial intervention with SSRI	Reduction in HamD after 6 months: -10.1 in IntG,	No difference in event-free 4-year survival (75.9% vs. 75.8%)

MIND-IT ⁵⁷⁴	depression and/or low support 331 patients with MI and depression	treatment when indicated vs. TAU SSRI treatment vs. TAU	-8.4 in TAU No difference in BDI after 18 months: 11.0 in IntG 10.2 in TAU	No difference in cardiac events after 18 months: 14% in IntG 13% in TAU
SADHEART ⁵⁷⁵	369 patients with MI and depression	SSRI treatment vs. placebo	HamD change after 16 weeks: -8.4 in IntG -7.6 in placebo	No difference in cardiac safety measures (including change in LVEF)
Katon 2010 ⁵⁷⁶	214 patients with poorly controlled diabetes and/or MI plus depressive symptoms (PHQ9≥10)	Collaborative care vs. TAU	Reduction in 12-month SCL-20 score (SMD -0.41 [-0.56 to -0.26])	No difference in 12-month HbA1c: -0.56% (-0.85 to -0.27%) Reduction in 12-month LDL cholesterol: -9.1 (-17.5 to -0.8) No difference in 12-month blood pressure: -0.4 (-6.9 to 0.1)
PROSPECT ^{577,578}	396 older patients with depression, 60-94 years	Algorithm-based care vs. TAU	% Reduction in HamD score after 4 months: 41% in intervention 24% in TAU RR=3.9 (1.8 to 8.5)	No reduction in 8-yr mortality in IntG vs. TAU (HR 0.76 [0.57 to 1.00])
Naik et al. 2019 ⁵⁷⁹	225 patients with uncontrolled diabetes and depression (PHQ9≥10)	Telephone intervention with collaborative goal-setting and behavioural activation vs. enhanced usual care	Reduction: PHQ-9 after 12 months (SMD: 2.14 [0.18 to 4.10])	No reduction in HbA1c after 12 months (mean difference: -0.06% [-0.61% to 0.50%])

RCT: Randomized controlled trial; TAU: Treatment as usual; SMD: Standardized mean difference; MI: myocardial infarction; depression: major depressive disorder; CHD: coronary heart disease; SSRI: selective serotonin reuptake inhibitor; SMD: standardized mean difference; TAU: treatment as usual; IntG: intervention group; DCPC: depression care for cancer patients; HamD: Hamilton Depression Scale; BDI: Beck Depression Inventory; LVEF: left ventricular ejection fraction; PHQ: Patient Health Questionnaire HbA1c: haemoglobin A1c.

Translation to clinical practice

RCTs and their meta-analyses are considered the gold standard for assessing the effects of treatments. Bias is a significant problem, however, as for RCTs in all fields. The failure to publish negative trial results, as demonstrated for drug trials⁵⁸⁰ and psychotherapy trials,⁵⁸¹ leads to overestimating effect sizes in meta-analyses. These problems are diminishing, thanks to concerted efforts across a number of countries to regulate trial registration and reporting.⁵⁸² Belief in the superiority of an intervention, or researcher allegiance,⁵⁸³ has been associated with stronger observed effects of therapies, particularly in psychotherapy research.⁵⁸⁴ The risk of bias was rated as low in only 18% of trials in a meta-analysis of 500 drug trials in depression⁵⁰⁶ and in only 23% studies in a meta-analysis of almost 300 psychotherapy trials.⁵⁸⁵

The generalizability of trial evidence to practice is also compromised by the fact that over 90% of trials are conducted in countries covering 10% of the world's population. Furthermore, most trials recruit participants attending mental health facilities. These participants do not represent people experiencing depression in the population⁵⁸⁶: they are more likely to have had prior treatments and to have complicated or persistent episodes of depression and high levels of personality disorder comorbidity⁵⁸⁷ that may dampen the effects of the active treatment. They are also more likely to have high awareness of their depressive condition and to be accessing other therapies (including informal support) that enhance the effects of the control arm. It has been estimated that only 12 to 34% of people in routine outpatient care are eligible for participation in a pharmacotherapy trial: others are ineligible because of comorbidities or failing to meet the minimum severity threshold.⁵⁸⁸ Although this problem is smaller in psychotherapy research,^{589,590} and the efficacy of psychotherapies appears of similar magnitude between high- and low-/middle-income countries when they are tested in randomised trials,⁵⁸⁵ generalizability of research to practice needs attention in this area too. Evidence on cost-effectiveness (for *any* therapy) does not readily transfer from one country to another because of differences in health and other systems, in the availability and relative salaries of care professionals, and in funding arrangements that alter incentives to deliver treatment and the associated unit costs. It is especially dangerous to assume that economics evidence from a high-income country will be relevant in low- or middle-income countries.

An important and desirable aspect of randomised trials is the need for participants to be blind to, or unaware of, the condition to which they are assigned. This is impossible for trials of psychotherapy. Although it is possible in drug trials, participants often discern from noticeable side effects when they receive active drug rather than placebo.⁵⁹¹ The use of waiting list control groups as often the case in psychotherapy research may lead to an overestimation of the effects of treatment.^{592,593} The nature of care as usual or treatment as usual depends heavily on the health care system of the country and the study setting, ranging from (almost) no care to specialised mental health care by well-trained professionals.⁵⁹⁴ This contributes to extensive heterogeneity between trials.⁵⁹⁵ The choice of non-specific treatment, such as non-specific counselling, as a control condition is also a problem for a depression trial. These therapies can result in good outcomes, comparable for example to those recorded for CBT.⁵⁹⁶ Ultimately, the choice of a control condition depends on the research question that is to be answered.


Finally, we must recognize the challenge of reconciling the relatively modest effect sizes of the two first-line treatments for depression with the experience of clinical practice. There is an outstanding need for practice research on how best to apply, combine or sequence one or more of the approaches to first-line treatment in primary health care.⁵⁹⁷ The most obvious reason for the dissonance is that many people recover without treatment. Trials with a control group seek

to discern the treatment effects over and above spontaneous recovery, while in routine care the latter cannot be distinguished. Additionally, trial participants usually receive regular assessments and close attention, including many hours of clinical contact, and promise of alternate treatment at study completion. The short-term benefit from these personal contacts and conditions can diminish group treatment differences. Further, in short-term trials of depression monotherapy, participants receive only one medication or one psychotherapy for 8-16 weeks. In clinical practice, however, if an individual does not respond or responds partially, changes to the treatment plan are often made earlier. For example, in the Strategic Use of New generation antidepressants study, switching or augmenting medications as early as 3 weeks was associated with an NNT of 10 in achieving remission by 9 weeks in comparison with standard length acute phase treatment.⁵⁹⁸ Personalizing the second line treatment choice through machine learning identified a small group of individuals (around 8%) who would fare better if continued unchanged on their initial treatment.⁵⁹⁹ As for some other clinical conditions, particular forms of treatment are more effective for some people than for others.

Principles of care

Care is provided across the world in various settings and with very different resources available to assess and plan and intervene. Whether the person needing care is met in their own home, a community setting, a primary care clinic, or a hospital or institutional setting, the principles of care are the same. She or he will ideally be offered the same standards of care or support as a person with a physical illness or injury, especially as the presentations of somatic and mental illnesses are often intertwined. This should include the opportunity to access and receive timely care at the onset of illness, still a major obstacle around the world. Data from the WMHS covering 15 countries indicate that, among community-dwelling adults meeting diagnostic criteria for depression, less than half had any contact with a general medical or specialist provider, and only 10% received effective care.⁶⁰⁰ There was a consistent discrepancy between HICs and LMICs, with coverage estimates in the former on average double those in the latter: though even in HIC, less than a fifth of adults meeting criteria received effective care (Figure 11).

Figure 11. Contact with services and effective coverage for depression care for community dwelling adults in 15 countries⁶⁰⁰



Results generated using data from 15 countries provided by the WHO World Mental Health Survey Consortium: www.hcp.med.harvard.edu/wmh. Contact with services among representative samples of community dwelling adults defined as any contact with specialist mental health or general medical health provider for a mental health condition; adequate pharmacotherapy, as taking an antidepressant with adequate medication control and adherence; adequate psychotherapy, as complying with at least eight sessions from an adequate provider or still being in treatment after two visits; and adequate combination of pharmacotherapy and psychotherapy as adequate pharmacotherapy and/or psychotherapy for mild and moderate depression, and a combination of both adequate pharmacotherapy and psychotherapy for severe depression. All HICs vs LMICs comparisons $p < 0.001$. HICs: high-income countries; LMICs: low- and middle-income countries.

In most countries and contexts, it is primary care and community health workers who provide the bulk of care for and have the most extensive contact with people living with depression and their families. The use of hybrid models of digital and in-person care is accelerating to become a feature of care in many parts of the world, blending with the use of guided self-help and tailored social interventions to support quality and rights-based care.

The United Nations Convention on the Rights of People with Disabilities (CRPD) establishes the rights of people with depression and other mental disorders to social inclusion and to choice of health care of the same quality as that offered to people with all health conditions, as close as possible to their homes and respecting their personhood and rights.¹ People needing treatment for depression face risks when stigma and discrimination surrounding mental disorders and their treatment prompt fear and exclusion. There is widespread agreement that coercive practices are over-used in depression care when it is delivered in institutional and also in some community settings. The WPA in common with WHO advocates for a pragmatic approach to implementing viable alternatives to coercion,⁶⁰¹ one of which is adopting a community-based collaborative care approach that includes shared or supported decision-making.

Diagnosis and formulation

Establishing the presence or absence of the disorder is an essential step in clinical care. Initial screening for depression can be reliably achieved with a brief validated measure such as the PHQ-9 or a diagnostic interview.⁶⁰² However a more detailed clinical assessment is required to inform whether treatment is recommended, and then which types of interventions are likely to be most acceptable and effective. Formulation aids in reaching the ultimate goal of shared or supported decision-making through identifying the person’s values or preferences as well as the factors informing a clinician’s personalised treatment recommendations (Panel 2).⁶⁰³

Panel 2. Factors relevant for clinical assessment and decision-making (“formulation”)

- Age, gender, language, culture, family, history of violence or abuse, and living arrangements
- Severity of the clinical picture (e.g., syndromal vs. subsyndromal, global score on a rating scale)
- Staging of the disorder (including course features, such as first episode, persistence, relapse/recurrence)
- Current life stressors and presence/absence of support
- Suicide risk assessment
- Concomitant substance abuse, physical health
- History of manic/hypomanic episodes
- Presence of psychotic features
- Antecedent variables (e.g., family history, developmental history, early environmental exposures, previous psychiatric diagnoses)*
- Other concomitant variables (e.g., personality traits/cognitive schemas, religious and spiritual beliefs, psychiatric comorbidities, social functioning, neurocognition, maladaptive cognitive schemas, dimensions of psychological well-being)*

*Assessments recommended in specific circumstances, for example persistent or treatment resistant depression.

Formulation assists in choosing which medication, psychosocial or lifestyle approaches to treatment and care a person might need or expect, as well as identifying individuals at risk of suicide.⁶⁰⁴ It can also mould expectations of therapy; for example, evidence suggests a history of childhood trauma and personality disorders might predict poorer response to initial interventions.⁶⁰⁵ Formulation typically assembles five domains of information and understanding that are based on awareness of the factors shown in Panel 2 and critical in clinical decision-making: *presenting problems*, identifying what the clinician and the person with depression see as difficulties, or foci needing treatment; *predisposing factors* referring to potential biopsychosocial vulnerabilities; *precipitating factors* referring to salient circumstances preceding the onset or exacerbation of the presenting episode; *perpetuating factors*, which are situations or dynamics that serve to maintain or worsen the condition; and *protective/positive factors*, strengths or supports that may mitigate the impact of depression on a person’s life. Formulation allows more informed discussion between the person and clinician about choices in treatment, care and life circumstances and prepares the way for personalised interventions concordant with the person’s values and expectations.

Clinicians need to understand the meaning of a person’s presentation with depression in the context of their developmental and previous history and current circumstances. It is fundamental first of all to know about developmental history, attachment styles and personality development, as well as prodromal and major depressive episodes – age of onset, number of such episodes, their severity, duration, functional consequences, effects on cognition, and duration of inter-episode intervals – or burden of residual inter-episode symptoms and dysfunction as the case may be. Family history of depression (and what treatments have helped), medical history, social support, religious and spiritual affiliations and beliefs, life circumstances and life events and previous treatment history provide further vital context for understanding the current need for treatment, and the types and duration of treatment likely to be helpful. Delineation of co-occurring psychiatric disorders and of somatic illnesses is necessary for treatment planning.

Collaborative care

Collaborative care is the best-evaluated approach for translating evidence from randomized trials and realizing the goals of staged approaches in practice.⁶⁰⁶ Collaborative care integrates team-based health, social and support services. It offers a ready platform for reaching underserved populations, for engaging in task-sharing of mental health care with non-specialist providers, for mitigating the barriers posed by stigma, in that people receive care at home or where they want to receive it, for promoting engagement with family caregivers, for the implementation of measurement-based care, and for allowing the use of algorithms of care that better match intensity of services with the level of needs. Moreover, it is amenable to both treatment and prevention of depression.


The aim of collaborative care is to consider the outcomes that matter most to people with depression and their caregivers. Critical to this goal is the use of shared decision making, giving primacy to the individual’s perspective, as discussed later. Functional recovery is often as important as symptomatic recovery, and is a significant factor in predicting longer term prognosis.⁶⁰⁷ Vocational recovery can be achieved with support from practitioners with educational and employment expertise.⁶⁰⁸ Relationships in families and friendship groups are often disrupted and social support endangered when most needed. Collaborative care is usually family-centred as well as person-centred – recognizing that family caregivers are often demoralized, need information about depression and its treatment, and play a vital role in providing advice about their family member’s background and condition, in forming part of a safety net to prevent suicide, and in encouraging treatment adherence. Recovery support includes specific attention to maintaining or retrieving positive social connections. Once people have recovered, the next challenge is to sustain the recovery, the support for which is typically neglected in crisis oriented acute service models. Self-help aided by technology and engaging a wider community of helpers including spiritual providers, may be highly relevant for some individuals.

Team configurations vary across and within countries. In well-resourced settings they generally include mental health specialists, primary care clinicians, and social workers, and ideally vocational and educational support workers, concerned with care management and working with broader systems (Figure 12). The mental health specialists may be co-located in primary care or in mental health facilities; the critical requirement is coordination between these sectors. Collaborative care may be enabled or enhanced in scarce-resource settings with the engagement of lay counsellors or community health workers.⁶⁰⁹ Task sharing with lay community workers aims to confront the scarcity of specialised health and mental health workers and improve access to care and deliver brief psychosocial interventions.

Achieving and sustaining good quality of care and a rights-based approach in a collaborative care system is ideally integrated in the monitoring of standards and quality of care in the local health services, using the principles of quality improvement and considering outcomes that matter most to people with depression and their caregivers. Measurement-based care (MBC) may be used to assist clinicians to dynamically assess outcomes and initiate modifications in treatment plans accordingly. MBC includes standardized assessment of depressive symptoms, medication side effects, and adherence. It typically uses a multi-step decision tree (algorithm) in treatment planning to match level or intensity of care with the needs of individuals and assist with consistent follow-up. MBC shows promise of resulting in higher remission and recovery rates than does care as usual.^{537,610}

Collaborative care also allows the integration of specific care for people at risk of suicidal behaviour and those with comorbid medical conditions. For people with comorbid conditions such as diabetes or heart disease, systematic reviews indicate that collaborative care can not only improve depressive symptoms,⁶¹¹ but also has beneficial impact on self-management of chronic disease.⁶¹² The COINCIDE trial, for example, tested the effectiveness and cost-effectiveness of collaborative care offered to people with depression and diabetes or cardiovascular disease by wellbeing practitioners and practice nurses. Care included behavioural activation, cognitive restructuring, graded exposure, lifestyle advice, management of drug treatment, and prevention of relapse. The intervention improved depression outcomes and increased self-management. Effect sizes were modest, but the intervention was delivered in the context of routine practice in areas of high deprivation.⁶¹³ Both clinical and cost effectiveness persisted at two years.⁶¹⁴ The recent INDEPENDENT trial replicated these findings in a low-resource setting (India).⁶¹⁵ The cost-effectiveness of collaborative care for depression in the UK⁶¹⁶ and in India has been demonstrated in recent years. Within public primary-care facilities in Goa, the engagement of lay health workers in the care of people with common mental disorders was not only cost-effective but also cost-saving.⁶¹⁷

Figure 12. The collaborative care team



* Note on terminology: these terms are used interchangeably at different points in the report. We are aware of the strong preferences of people for either of these or alternate terms and use them respectfully.

Personalized care

There are two distinct perspectives to personalized care for depression: one seeks to place the person at the centre of clinical decisions, prioritising outcomes that matter to the person and enabling the individual to make a fully informed decision about treatment. Such an approach explicitly addresses co-morbidities and social determinants. Importantly, outcomes that matter to individuals are not necessarily present in currently available instruments used to capture the construct of depression. Domains such as mental pain and overall functioning, for instance, despite being highly ranked by people with depression, informal caregivers, and healthcare professionals, are not covered by most depression rating scales used in clinical trials.⁶¹⁸ This perspective is synonymous with the concept of ‘person-centred’ care and central to collaborative care described above.

The second perspective of personalized care is aligned with precision medicine, and aims at identifying characteristics of an individual associated with the outcome of different treatment options in order to offer a good match between the individual and the treatment received.^{190,603,619} While most treatments of depression have comparable effects at the group level with no or only small group differences, individuals with specific genetic, biological, psychosocial, and/or environmental characteristics, including moderators and prognostic factors might respond better to one treatment than to another. For example, preliminary research indicates that pharmacotherapy is probably more effective than psychotherapy in individuals with dysthymia and persistent depression,⁶²⁰ and combined treatments are more effective than either treatment alone in older adults.⁵¹⁵ It has long been expected that the efficacy of pharmacological treatments could be improved with increasing knowledge of genotyping,⁶²¹ as about 50% of response to antidepressants can be attributed to genetic factors.⁶²² Applying a precision treatment algorithm to data from a trial comparing antidepressant medication vs CBT yielded an additional benefit on remission of ‘matching’ individuals to either treatment based on only five clinically sensible indices (personality disorder, marital status, employment status, number of prior medications trials, and number of precipitants).⁶²³ Despite the promise of these preliminary studies, the current state of knowledge about moderators and prognostic factors is of limited significance in guiding individualized care.⁶²⁴

Machine learning techniques using big datasets offer a promising approach to developing personalized treatments of depression and prediction models for treatment outcomes.⁵⁹⁹ Another promising area of research is the identification of neuroimaging patterns or biomarkers to predict illness vulnerability, discriminate depression subtypes, or guide treatment selection in individuals. Beyond treatment selection at initiation of treatment, such indicators are also needed to identify people likely to develop treatment resistance or those at risk for relapse. Recent studies implementing this general approach have identified several putative treatment selection brain biotypes with potential utility for choosing between psychotherapy and medication and for stimulation-based treatments such as transcranial magnetic stimulation and deep brain stimulation.^{333,336} In parallel, others continue to search for biological or behavioural surrogates of such brain-based biotypes, with equivalent specificity but with more potential widespread availability.^{516,625}

Digital strategies

The enhancement of treatment and care by leveraging digital technologies is a significant new frontier in health care. Digital strategies may extend the reach of other clinical interventions to underserved populations, or increase the period, intensity or quality of care for those already served. Internet CBT (iCBT) was one of the earliest attempts to take advantage of the emerging

digital technologies in depression care. It is now well-established that iCBT, when supported by human guidance, is as effective as face-to-face CBT and is superior to various control conditions.⁵⁰¹ There is also evidence of cost-effectiveness in primary care settings,⁶²⁶ although a recent review concluded that face-to-face CBT had a higher probability of being cost-effective.⁶²⁷ Unguided iCBT can also have smaller but significant effects.⁵⁰² Computer-based iCBT is rapidly being superseded by smartphone app-based iCBT and novel app-based approaches are emerging such as cognitive-emotional training.⁶²⁸ None of the thousands of apps so far available, however, has yet obtained regulatory approval. A recent individual participant network meta-analysis was able to distinguish potentially helpful (e.g., behavioural activation), less helpful, or potentially harmful (e.g., relaxation) iCBT components. The study also showed a decrease in dropout rates when human encouragement to proceed with iCBT was combined with automated encouragement.⁶²⁹

Digital technologies also offer new possibilities for the way we screen, diagnose, assess, and monitor people with depression and the way we train mental healthcare personnel and monitor their care delivery. Computerised adaptive testing enables more efficient, flexible and precise administration of individual-reported outcome measures.⁶³⁰ Digital technologies for workforce training⁶³¹ and monitoring of care include natural language processing of the services as they are delivered, and automatic feedback on adherence to quality indicators or indicators of individual improvement. Care delivery including collaborative care can be extended in various ways by the use of tele-medicine. This has been demonstrated in diverse contexts during the COVID-19 pandemic wherein digital technology has become the standard delivery platform for mental health care. Shared decision making (SDM) may be facilitated for individuals who prefer automatic, interactive display of information specific to their own characteristics and needs⁶³² on interactive web pages or smartphone apps.⁶³³ Several trials are examining the feasibility and effects of such personalised interactive decision aids.⁶³⁴ There is special interest in support for decisions regarding use of antidepressants in pregnancy.⁶³⁵

Technology offers the possibility that response to treatments will be monitored more closely through smart devices, so that timely and efficient adjustments in interventions can be implemented. Digital phenotyping, the “moment-by-moment quantification of the individual-level human phenotype in situ using data from personal digital devices”⁶³⁶ takes advantage of unprecedented types and amounts of data including movement, pulse rate, blood pressure, and sleep, meals and other lifestyle patterns, in addition to repeated self-report and neurocognitive tests.⁶³⁷ Such phenotyping may lead to support for differential diagnosis⁶³⁸ and prediction of relapses or recurrences.⁶³⁹ Systems have been developed that integrate digitally-assisted diagnostics, prognostics, decision-making, therapeutics and outcome assessments into an electronic health record (EHR) system, for example the Learning Healthcare System (LHS), to create a continual cycle of care improvement.⁶⁴⁰ This interactive tool can empower both the individuals with depression and their health care providers in personalised and evidence-based decision making.

However, several barriers limit the coverage and impact of digital innovations. First, the perspectives of individuals are of paramount importance for all digital strategies. Experience shows that their uptake and sustained use by the intended users is low.⁶⁴¹ In one large pragmatic trial of unguided iCBT, the median number of completed sessions for two widely used programs was one out of eight and one out of six.⁶⁴² While the dropout rate from routine treatment, mainly through antidepressant pharmacotherapy, may also be high (e.g., in one claims database analysis we found that 28% never returned after the initial prescription and

55% dropped out within 3 months),⁶⁴³ the rate of dropouts is greater for digital therapies than face-to-face routine treatments.⁵⁰¹

Second, installing, updating and troubleshooting digital devices is not straightforward or easy for some individuals and professionals alike. While half the psychiatric outpatients surveyed reported a positive view of mental health apps, only one in four had ever downloaded an app and only one in ten was currently using an app.⁶⁴⁴ Relying on digital interventions may widen inequalities in access to care due to the “digital divide.” We may need “digital navigators” as members of the collaborative care team to help support both the patients and the clinicians in engaging with the digital world.⁶⁴⁵ Third, we need innovative ways to assess and control the quality of the thousands of mental health apps already in the market, entering the market and being continually updated. The UK NHS has launched an Apps Library homepage listing evaluated applications. Fourth, the whole system must be accountable for privacy and ethical concerns.^{646,647}

Care in specific contexts and populations

Preventing suicide in the context of caring for people with depression: While people living with depression have a much higher risk of suicidal behaviour than others in the population (see Epidemiology and Burden, “Suicidal behaviour”), most do not die by suicide or attempt suicide. Hence it is important for clinicians to aim to identify and intervene with those at higher risk. Interventions that are currently used for suicide prevention include counselling with patients and family care givers to reduce access to lethal means for suicide, together with the use of suicide-specific interventions (e.g., safety planning), and attention to contextual factors such as family discord and the need for social support. These and similar elements of re-engineering practice have been associated with reductions in suicide of up to 29% in clinical populations in the UK,⁶⁴⁸ and with even more dramatic reductions associated with changes in the Henry Ford Health System in the U.S.⁶⁴⁹ Using anti-depressants has a modest effect in reducing suicides⁶⁵⁰ in adult and older populations with depression. Ecological studies in Europe⁶⁵¹ do indicate suicide rates have fallen in countries where there has been greater increase in the use of antidepressants; however, ecological studies even if consistent are no proof of causation. There is strong evidence that the use of lithium has added benefits for its unique anti-suicidal effects (although this effect may be specific to individuals with bipolar depression).⁶⁵² There is a body of early evidence for use of ketamine intravenously for rapid reduction of suicidal ideation;^{653,654} however, the longer-term impacts are still unknown.⁶⁵⁵ Some depressed suicidal individuals may require admission to hospital, but there is weak evidence to support suicide watch and the close monitoring prescribed by most guidelines.⁶⁵⁶ Such workforce intensive protocols are potentially intrusive and unwelcome, and may be unwarranted given their questionable efficacy.⁶⁵⁷

Despite evidence gaps of these kinds there are very few cost-effectiveness studies on improving or optimising services to prevent suicide in people with depression, in hospital or community settings. One example is better training for primary care physicians to identify individuals at risk of suicide linked to moderate to severe depression in England. This was evaluated and found to be highly cost-effective.^{658,659}

Nonetheless meta-analyses show that clinical judgments about suicide risk predict subsequent suicidal behaviours only weakly.⁶⁶⁰ Based on this evidence, numerous attempts have been made to develop suicide prediction tools using patient self-report scales, neuropsychological tests, medical records, or some combination of these as predictors of suicidal behaviours. This

literature has been reviewed extensively.⁶⁶¹⁻⁶⁶³ Composite prediction strength for most such models is in the range considered either acceptable (AUC=0.7-0.8) or excellent (AUC=0.8-0.9).⁶⁶⁴ However, given the rarity of suicidal behaviours, positive predictive value (PPV; prevalence of subsequent suicidal behaviour among patients predicted to be at high risk) is low even among the patients predicted to be at high risk and a substantial proportion of the patients who go on to engage in suicidal behaviours are predicted not to be at high risk. This has led many critics to argue that suicide prediction tools have no clinical value.⁶⁶⁵ This negative evaluation has to be tempered, though, by two considerations.⁶⁶⁶⁻⁶⁶⁸ First, no existing suicide prediction study has ever applied the full range of significant predictors found in the literature to a large heterogeneous sample of patients and used best-practices statistical methods to develop a stable prediction model. Second, even though PPV in such an optimal model would still be relatively low, the net benefit would likely be positive given that several suicide prevention interventions are cost-effective even at low PPV.^{669,670}

Maternal depression: The general principles of treating depression in mothers are the same as those for adults more generally: with an additional concern relating to the potential risk of adverse outcomes from in utero exposure to psychotropic medications. Given that the effects of foetal exposure to SSRIs remain unclear, and given the suggested caution in their use during pregnancy,⁶⁷¹ an individualised collaborative risk-benefit analysis is a sensible option. This considers the consequences of untreated depression as well as the effects of antidepressants on both mother and infant. A national case series of suicides reveals that perinatal deaths of women from suicide are associated with depression that has not been actively treated with medication.⁶⁷² Although there are fewer studies on breastfeeding exposure, most SSRIs have been found to pass only minimally into breast milk.⁶⁷³ Of course, psychological treatments do not carry any of these risks and can be offered as first-line treatments of maternal depression (other than in severe depression, for example with psychosis, when pharmacotherapy is indicated).

A recent systematic review reports effective psychosocial interventions for depression in women experiencing IPV in low and middle income countries.⁶⁷⁴ Strong evidence supports the effectiveness of psychosocial interventions for perinatal depression delivered by non-specialist providers including those delivered by peers in these contexts.⁶⁷⁵

Remission of depression in a mother has positive effects on her school aged and adolescent children^{564,676} for at least a year afterwards:⁶⁷⁷ including the children of mothers treated with medication^{676,678} or psychotherapy,⁶⁷⁹⁻⁶⁸² and varying with the severity of maternal depression.⁶⁸³ Comorbid problems such as intimate partner violence (IPV) need to be addressed for immediate safety for the family and to reduce deleterious effects on children.⁶⁸⁴

Children and adolescents: Several general principles are key to successfully engaging young people in care. These include providing psychoeducation at a developmentally appropriate level and implementing person- and family-centred, shared decision-making initiatives. Practitioners must also contend with the definition of outcomes and the development and use of multidimensional and multi-informant measures.⁶⁸⁵ These encourage the essential integration of multiple perspectives.⁶⁸⁶ There is a growing evidence-base for providing collaborative care for depression, working not only in team-based and measurement-guided, but also in youth-driven, family-centred approaches.⁶⁸⁷ In one randomized controlled trial that compared collaborative care with enhanced usual care, youth in the intervention group reported higher rates of clinical response (68% vs. 39%) and remission (50% vs. 21%), as well as satisfaction with care⁶⁸⁸ — this model also seems to be cost-effective.⁶⁸⁹ A meta-analysis⁶⁹⁰ of

routine specialist mental health care suggests that between 33% and 40% of young people experiencing severe and complex depression showed measurable improvement. Several factors contributed to these results, including active supports in care delivery; involvement of parents and active outreach; and efforts to increase engagement with the young people, fostering a more open and empowering relationship between them and the practitioners. There is good evidence for the effectiveness of psychological therapies for depression in adolescents,⁶⁹¹ and emerging evidence for the use of modular, trans-diagnostic psychological treatments (compared with ‘disorder’ specific treatments).⁶⁹² Beyond clinical approaches, attention has been directed to more rigorous assessment of a variety of self-delivered and community approaches.⁶⁹³ Children and adolescents spend an important proportion of their times in school settings in which assessment and interventions can take place. A recent example demonstrated the effectiveness of a brief, lay counsellor delivered, problem solving treatment for adolescents with common mental health problems in India.⁶⁹⁴

Older adults: The hallmark of major depressive disorder in older adults is co-occurrence with medical disorders, high rates of mild cognitive impairment, association with social determinants of well-being (e.g., bereavement, social role transitions, social isolation and loneliness, and depletion of social and economic resources), exposure to polypharmacy, and risk for suicide. Collaborative care involves the delivery of evidence-informed, late-life depression treatment and suicide prevention through coordinated medical, mental health and social services, offered within primary care. This is preferred by many to specialty mental health, because of less stigma and greater access, trust, and affordability. Pioneering studies, such as IMPACT⁶⁹⁵ and PROSPECT,⁵⁷⁷ have identified core “ingredients” of collaborative care: (1) virtual or actual co-location of mental health expertise within primary care settings (e.g., through telepsychiatry or placement of mental health specialists, such as social workers or psychiatric nurses, within clinics); (2) multidisciplinary teams; (3) measurement-based care to monitor treatment adherence, efficacy and tolerability; (4) engagement of family care-givers to respond to both person-focused and family-centred needs; and (5) evidence-informed provision of acute and continuation treatment modalities both to achieve remission and to maintain recovery and wellness. Collaborative care models also increasingly use community health workers and lay counsellors to facilitate outreach and task sharing in low-resource settings, in the service of both treatment and prevention of depression.⁴⁷¹

Forced migrants, refugees, and other populations affected by humanitarian crises: More than 235 million people are living in settings of humanitarian crises.⁶⁹⁶ The Inter-Agency Standing Committee, which includes UN institutions and a range of humanitarian response organizations, recommends that mental health services in humanitarian settings follow a tiered approach with promotion of basic services and security available to all individuals, followed by bolstering of community and family supports for those in particular risk groups or with moderate psychosocial distress.⁶⁹⁷ The WHO mental health Gap Action Programme-Humanitarian Intervention Guide⁴⁹⁸ recommends ruling out normal reactions to major loss, bereavement, and displacement when considering a diagnosis of depression, as well as consideration of other possible diagnoses such as prolonged grief disorder. The guidelines highlight the role of psychoeducation, stress management, and strengthening social support, in addition to referring to evidence-supported psychosocial interventions and prescription of antidepressant medication.

Most evidence on psychosocial interventions focuses on treatments which have been adapted from specialist-delivered interventions in high-resource settings, e.g., Trauma-Focused Cognitive Behavioural Therapy (TF-CBT). New psychological interventions have been

developed specifically intended for delivery by non-specialists to populations affected by humanitarian crises, e.g., Problem Management Plus (PM+).⁶⁹⁸ Self-help plus (SH+) is also a new intervention developed for administration to large groups in humanitarian settings; SH+ requires limited involvement of facilitators and is built around audio recordings for guided learning of basic psychological skills for persons with mild to moderate psychosocial distress.⁶⁹⁹ An umbrella review identifies moderate evidence for the benefit of these interventions for adults (but not to date for children) with depression in humanitarian settings, though weak strength of association for any specific treatment, such as CBT or IPT.^{418,700}

RECOMMENDATIONS

This Commission has synthesized a large body of science, spanning disciplines ranging from neuroscience to global health, to generate an understanding of the nature of depression, its impact on people and communities, how it might be prevented and the pathways to recovery. By design, this is, for the most part, a narrative review scripted by a team of scholars and practitioners who were purposively chosen to reflect their individual and complementary leadership of this range of disciplines. That said, we believe that the science points to a number of specific key messages and actionable recommendation.

We present recommendations for action by four primary stakeholders: the general community and, in particular, persons with the lived experience of depression; practitioners who are in a position to prevent and treat depression; researchers who lead scientific endeavours to reduce the burden of depression; and decision-makers who design policies and finance their implementation (Panel 3).

Panel 3. Recommendations of the Lancet WPA Commission on Depression

Reducing the burden of depression requires united action by diverse stakeholders.

The general community, including people with lived experience of depression

1. *Seek help early. This increases the chances of preventing or recovering from an episode of illness.*
2. *Talk with family and friends if possible, taking confidence from the knowledge that depression is a common human condition experienced across the ages and across cultures.*
3. *Remain hopeful because most persons with depression will recover with the right support and treatment.*
4. *Ensure that treatment is informed by evidence-based practice, focused on your priorities, with decisions made collaboratively, and engaging where possible and appropriate with your family, friends, community, and peer supporters.*
5. *Find partners or groups to sustain you in educating yourself about the illness, practicing self-care to get well and stay well, sharing your experience and supporting others as a peer support worker or advocate; and look for opportunities to speak up as an expert or organise for the need for care, against discrimination, and for social changes that support mental health and reduce the risks of depression.*

Health care practitioners

1. *Learn about depression: about the variations in its origins, presentation and course, and about the lived experience of depression.*
2. *Pro-actively recognise and assess the risks of depression, the onset of the illness early in its course and at any stage in life, and its consequences.*
3. *Personalize your management approach to prevention, treatment and recovery in view of each person's needs, challenges and strengths, keeping in mind their socio-cultural context, family and developmental history and life circumstances, their own priorities, and the available resources.*

4. *Practice collaborative care and implement quality assurance and rights-based approaches, working with the person with depression to achieve optimal outcomes.*
5. *Prioritise the therapeutic alliance, continuity of care and the rights of people to receive care with dignity and choice, the needs of families where appropriate, and the obligation to reduce stigma associated with depression.*

Researchers and research funders

1. *Understand the aetiology and nature of the condition across the life course and evolve (urgently) a multidisciplinary and collaborative approach to reducing the burden of depression.*
2. *Engage people with lived experience of depression and their families, as well as practitioners and policymakers, in the conception, design, and implementation of research.*
3. *Identify under-used and novel prevention targets from social determinants to individual vulnerabilities, and engage with partners in evaluating program implementation and policy changes.*
4. *Design and test therapies addressing early intervention and novel mechanisms of disease.*
5. *Prioritise the development of precision medicine approaches to optimize prevention, care, and recovery.*

Decision makers

1. *Respond to the experience of people with depression and to the science, recognising that depression 1) has profound effects on people's health, social relationships, and economic and educational opportunities, and 2) affects people everywhere but is more likely to affect those living in poverty and adversity from historic or contemporary losses, injustices, and inequities.*
2. *Secure investment across society in prevention and health promotion, targeting determinants of health across the life course, in particular during childhood and emerging adulthood, and across the whole of society and the environment to tackle economic and social inequities.*
3. *Secure investment in depression care, including intervening early in the course of the disorder and sustaining care as needed, because existing treatments work, can reduce human suffering, and make economic sense from a societal perspective.*
4. *Support the sustainable implementation of rights-based depression care, including legal and collaborative care frameworks integrated across the health and social welfare systems, co-designed with people with lived experience of depression and their families.*
5. *Invest in research, including basic and practice and implementation science.*

The community/persons living with depression

The important thing in the process of recovery is to have small funs and to continue to have them. Small things you can enjoy in your everyday life: get in touch with the nature, get in touch with people, find your favourite music, find your favourite movies.

- Keigo Kobayashi, 41, Kyoto, Japan

Perhaps the central question that dominates the public understanding of depression is the boundary between depression as a health condition, as opposed to an extension of social suffering and the expected range of human responses to stress and loss. The evidence we present compellingly demonstrates that while the boundaries between these normative human emotional states and depression are not always clear, and that the experience of depression itself can take diverse forms, these two experiences are distinct in many ways, for example in their duration, impact on daily functioning, and long-term health consequences. Moreover, historical and cross-cultural evidence demonstrates that the condition has been described since ancient times and in diverse civilizations, and, although the experience of depression can take many forms, the core illness experience is very similar across cultures. Above all, depression can affect anyone, and is never the person's "fault" or a sign of psychological "weakness."

While depression can affect a person at any point in their lives, it is most likely to have its onset in young adulthood. While many persons will experience just one episode, others will have repeated episodes and a few may experience persistent distress for long periods.

Just as you would for other health concerns, you should find help for depression — and do so early, because the longer the illness lingers, the longer you suffer needlessly and the chances of recovery are diminished. There is a wide range of interventions which can promote recovery, from self-help (interventions based on psychological therapies designed to be learned independently by the person or used with only modest levels of guidance) and lifestyle changes to psychological therapies provided by legitimate workforces (including those engaged in task-sharing) in different settings, antidepressant medication, and more specialized therapies for those who continue to experience the illness despite trying these options. Most people who seek and find healthcare will recover with the aid of interventions recommended in primary care or community settings, through appropriately trained and supported community-based providers and primary care practitioners. There are a variety of evidence-based interventions that can provide relief to the great majority of people with depression, but no one intervention is right for everyone and multiple trials of different interventions may be needed to find what works for you. Therefore, keep in mind that recovery is a journey: if you do not strike gold on the first trial, persisting with alternatives will incrementally but continuously increase your chances of recovery.⁷⁰¹ Mental health professionals often work with primary care providers to support this work. They also provide direct care to a significant proportion of people who do not receive interventions in primary care or do not recover with those interventions. A relatively small number of people may need brief periods of care in hospital and other treatments.

Your role in the recovery process is central, using information from reliable sources and seeking help early to find what helps you the most. It is crucial that you are an active partner in decision-making, ensuring that your priorities and needs are being addressed. Your needs and priorities may range from relief for specific distressing symptoms (such as not being able to sleep or being tormented by ruminations) to social concerns (such as unemployment) or care for health conditions (such as diabetes). Addressing your ideas, concerns and expectations in a holistic manner is the hallmark of good quality primary care which is why this is the ideal first setting for you to seek help. And, if you and a healthcare provider decide together that medication or psychotherapy is likely to be helpful, always remember to engage with this agreed treatment for they are most effective when taken in the right dose (for e.g. the number of sessions of therapy), the right way (for e.g. practicing skills taught in sessions at home) and the right duration (for e.g. often up to a year for antidepressant medication). Upon recovery, remember that it is just as important to remain well through incorporating the skills you have learned in every-day life, engaging your family and friends and other community resources to support you through difficult times, and being sensitive to the signals which indicate you may be relapsing so that you can act quickly and reverse the slide.

When you recover, you may want to think about how your journey can help others who are also living with depression, the vast majority in silence, unable to get the appropriate support and care because of the lack of skilled providers or adequately resourced services, or because they are embarrassed to do so for the reasons we highlight earlier. Your lived experience makes you an ‘expert’ in understanding this condition and the pathways to recovery, and you may wish to play a role in sharing this expertise in your community, becoming involved with civil society groups as a peer support worker or advocate, and mobilizing your community to demand that policy makers invest in depression prevention and care (in particular, the

scientifically proven interventions which work). Your voice is crucial to effect policy change, to ensure that others in your community are able to access the care science has shown works.

Health Care Practitioners

A wide range of practitioners can provide treatments for depression, from community health workers delivering brief psychological therapies, to family doctors offering advice, support and/or antidepressant medication, to coaches guiding people engaged with internet-delivered psychotherapy, to mental health specialists offering the full range of interventions. The messages we have distilled apply to varying degrees to these diverse providers, but are most germane to non-specialist practitioners.

It is imperative that you give depression the same attention as you would to other common conditions, such as diabetes and hypertension, by learning all you need to know about depression, in particular about its diverse origins, presentations and course. Depression rarely occurs by itself; it occurs in a developmental, social, environmental and economic context, it is very often a companion to chronic medical conditions (such as diabetes) whose outcomes it worsens, and may co-occur with other mental health conditions too (such as harmful drinking). Depression can also profoundly affect the health of others in the family, most notably the child of a depressed parent. Depression can be brought to remission in the great majority of cases with evidence based and persistent treatment, but may require many trials of different treatments until a regimen is found that works; and upon recovery, it is important to bear in mind that depression may be recurrent in some people.

Although the varying presentations of depression often mean that its ‘hallmark’ features, such as sadness or loss of interest, may not be obvious in many people, it is important to detect depression and offer help as early as possible. Pro-active detection strategies can be used: asking a few questions about mood and ability to engage with and find pleasure in daily life would suffice. Do not overlook adolescents and young people whose clinical presentation may be changeable and mixed, and who may be more reticent to share their inner experiences. The admission of such symptoms should trigger a fuller inquiry to assess the range of other symptoms, their severity and duration. Simple screening tools like the PHQ-9 may be useful for this purpose. Bereavement is one particular life event which requires thoughtful inquiry to distinguish the normative response associated with grief from depression. Also, gender-based vulnerabilities which render women more likely to experience sexual abuse or intimate partner violence or abuse need to be addressed simultaneously with treating depression.

The diversity of depression histories and presentations means that you need to personalize your management approach in view of the individual’s problems and strengths, keeping in mind their background, life circumstances, families, co-occurring medical conditions and priorities. While there are, as yet, no definitive individual characteristics which can guide practitioners on which intervention to use, offering a choice of the primary evidence-based treatments is the aspiration with the goal of meeting individual preferences. This range of strategies which call for a person-centred approach to depression care is more difficult for a provider working in isolation, and a collaborative care delivery model is the most effective one to integrate the diversity of depression into routine care. The collaborative care ‘team’ always includes the primary care practitioner and the person with depression, but also extends to the community health worker (who typically plays a range of roles, from supporting adherence to providing brief psychological treatments) and a mental health specialist (who typically provides guidance, consultation and referral for patients with severe and refractory conditions). For many people, engaging with their family members is also an important element. Family

members can support the recovery process, especially when recognised and included by the care team, but also experience relief from their own distress through a better understanding of the illness. Coordination with social welfare services, such as those which support women who are experiencing domestic violence, and with spiritual providers in certain contexts, enhances the chances of recovery. If you work in isolation, try to identify others who could work with you to build a team.

We emphasize the importance of collaborative care, the most cost-effective way to extend the effective coverage of known interventions to the wider population as a component of universal health care. The essence of this delivery model is empowering primary care to provide integrated care for multiple morbidities, often by sharing care with community workers, and addressing social determinants of health. Mental health specialists need to actively engage with the scaling up of collaborative care by supporting primary care practices in their geographic area, and offering guidance, consultation and clinical care for people with refractory or complex depression presentations.

Diagnosis-driven and evidence-informed treatment (on the one hand) and individual person-centred case formulation (on the other) are complementary and synergistic rather than antithetical. Persons living with depression benefit from shared or supported decision-making with clinicians that is informed both by the best available scientific evidence and by an empathic understanding of the specific risk and protective factors relevant for a given individual.⁷⁰² Available treatment guidelines need to be leavened by an understanding of individual-specific risk and protective factors and by an individual's preferences and expectations. We strongly recommend instituting quality assurance strategies, at the very least by keeping track of individual and aggregate metrics, such as the numbers and proportions of people with depression who are detected, initiated on evidence-based treatments, and have completed the treatment and recovered.

Remain persistent and hopeful in pursuing multiple sequential treatments when one has failed, and provide encouragement and support to people with depression to do the same. Finally, it is implicit that all practitioners must respect and champion the rights of individuals with depression to receive good quality care with dignity, on par with any other medical condition, and take responsibility for ensuring that the treatment setting is free from stigma towards people experiencing depression. In doing that, consider how your own attitudes towards people living with depression align with contemporary values in depression care. At the heart of this commitment is the therapeutic alliance and the principles of shared and supported decision making which emphasize that the patient's will and preferences are at the centre of treatment plans.

Researchers and research funders

An urgent priority for the depression research community is to evolve a multidimensional approach, incorporating the interplay of genetics, brain biology and experiences/stressors across the lifespan. The complex and heterogeneous nature of the condition poses particular challenges for researchers as the phenotype varies considerably, does not show distinct boundaries, and is the result of diverse pathways and leads to diverse outcomes. Such an effort will need “collaboration across disciplines and settings to form a community of mental health scientists inclusive of any discipline that uses evidence in a rigorous and transparent way to inform understanding of mental health”⁷⁰³ and should involve a common set of research methods and metrics applied in diverse populations, in the spirit of data-sharing and capacity building. This, in turn, requires large scale consortiums and a parallel shift in the mind-set of

traditional research funding mechanisms which typically pit researchers into competition with one another and where the efficiency of substantive, consortium style, long-term funding, is diluted by multiple smaller grants.

There is a pressing need to enhance the effectiveness and impact of known interventions for the prevention and care of depression, and to evaluate the costs and effectiveness of their widespread implementation in diverse settings and across populations. Precision medicine approaches need to be applied for assessing differential response to first-line treatments and evaluating the combination and sequential allocation of diverse treatment approaches to enhance overall response rates.^{554,597} Moreover there is a range of approaches beyond these biomedical treatments ranging from exercise, meditation and yoga⁷⁰⁴ to community support that await further investigation for their utility as preventive, ameliorative and adjunctive measures. Social and economic policies need to be evaluated for their anticipated or unanticipated effects on risk factors and depression prevalence.⁴¹³

Translation of discoveries in the domains of prevention and therapeutics into practice face formidable barriers limiting both the demand for care and access to quality care, and the implementation of practice and policy changes. While these barriers are experienced universally, far greater challenges are encountered in the least resourced communities and countries, and evidence does not necessarily generalise from one context to another. Elaborating these barriers and designing and evaluating innovative strategies to address them is essential if we are to achieve higher levels of effective coverage of evidence based interventions. The flourishing of ‘frugal innovations’ in global mental health, such as the use of task-sharing of brief psychological therapies, is one example of delivery science which can address some of these barriers.

Finally, we strongly recommend the engagement of persons with lived experience of depression and their families in all aspects of research: from defining the research priorities and questions, to advising on the methods, interpreting the findings and communicating the results to the community and decision-makers. In view of the magnitude of challenges that result from mental health stigma and discrimination, a concerted effort is needed for methodologically strong research that will provide robust evidence to support decisions on investment in interventions to reduce stigma.

Decision/Policy makers

There is arguably no other health condition which is as common, as burdensome, as universal and as treatable as depression which has attracted such little policy attention and so few resources. Despite the science showing that depression causes profound, enduring suffering and premature mortality, is associated with poor physical health, social and economic disadvantage and enormous loss of productivity for the country, opportunities are lost for prevention of much of the burden and the vast majority of people affected by the condition suffer in silence. Much of the inaction stems from myths about the condition, such as that it is not a ‘real’ health condition distinguishable from everyday misery, or that it is a concern only of affluent persons or contexts, or that it requires very expensive treatment programs, or that prevention and treatments don’t work.

These myths also prevail amongst health care practitioners and the general community, restricting demand for interventions, and deflecting financial investments to build a robust, evidence-based, mental health care system and collaborations for prevention and care across education, health and other sectors. The singular focus on narrowly defined biomedical models

of care, based on binary diagnoses-driven algorithms and heavily reliant on mental health specialists, who are scarce in number or inequitably distributed within and between countries, is an additional structural barrier. There may be a perceived tension between the concept of ‘scaling up’ that requires a degree of standardization of ‘packages’ of care and the personal formulation approach which we advocate in this Commission; we think that these tensions can be navigated by distinguishing specific, evidence-based, guidelines which are standardized for implementation across all contexts from the approach in an individual clinical encounter, which needs to be tailored to the person, through a stepped collaborative care approach.

There is now sufficient evidence demonstrating the effectiveness of collaborative care models for delivering interventions across the diversity of depression presentations. Key members of the team are non-specialist providers, such as community health workers and peer support workers, who can deliver a significant proportion of front-line care. Utilizing such locally recruited, widely available and low-cost human resources not only addresses the formidable barrier of lack of skilled providers and constrained budgets, but also helps reduce stigma and cultural barriers, and aligns with person-centred integrated care. It is also consistent with the staged approach to depression care, enabling many persons with depression to quickly receive low-intensity interventions, freeing up and supporting scarce specialised services to address the relatively less common, complicated and refractory presentations. Of course, explicit in the concept of collaborative care is the seamless integration and mutual support of such front-line provision with primary and specialist care, and with social welfare services. Throughout this continuum of care, it is important to ensure that only evidence-based interventions are scaled up and those which have historically been neglected, such as psychological therapies, given particular attention. Some high-income countries have introduced programs providing improved access to psychological therapies⁷⁰⁵ for persons with depression and anxiety symptoms detected in primary care, showing that this is feasible but needs further evaluation in terms of cost-effectiveness.

Challenges in scaling up this delivery model are the building of a community-based mental health workforce, because the orthodox models of training (typically expert-led workshops) and quality assurance (similarly, expert-led supervision) are not sustainable; and enabling seamless coordination of care across the platforms of delivery. Digital platforms offer a unique, and a very timely opportunity in the context of physical distancing policies, to build a mental health capable workforce and enable coordinated care. Digitally delivered training and delivery models, such as tele-psychiatry, will enable much larger numbers of providers to be trained and greatly increase the reach of experts; their relevance has greatly increased as a result of the pandemic. Still, many barriers remain, including formal recognition by payers and decision-makers that such collaborative and digitally enabled delivery formats represent good value for money, in both the short- and longer-term. Another threat is the risk of push-back from sceptics who claim such models of care represent low-quality; there is no evidence that this is the case, as long as such models are adequately resourced to ensure that each worker has access to training and referral at a more expert level, and that quality improvement strategies are implemented. There are welcome signals that these approaches are being adopted; for example, mental health specialists in several countries are now reimbursed for their work in primary care settings, including remote consultation on clinical management under specified circumstances.

Prevention has been historically the most neglected aspect of depression. This is in part because most interventions are outside the health sector, targeting determinants in the salient environments of pregnancy and early childhood extending to emerging adulthood, including support for parenting, promoting school climate and building social and emotional





competencies, and from there to adult and later life, promoting economic equity, shared life chances and social connectedness. Measures to reduce violence in the family and bullying at school, workplace mental health promotion, and addressing loneliness, particularly in older adults, are key preventive interventions. Targeting key lifestyle determinants such as diet, physical activity, smoking and other substance misuse has resonances in prevention of other non-communicable disorders.

Thus, whole-of-government actions are required, well beyond the traditional health sector, to successfully realize the population-wide coverage of these interventions, with a particular emphasis on addressing existing disparities, for example by increasing allocations for poor and historically disadvantaged and dispossessed populations including indigenous societies around the world. Tackling the climate emergency and the continuing threats of pandemics and other global and regional emergencies that exacerbate existing inequities and threats to health are vital parts of global and national efforts to prevent depression. But whole-of-government approaches challenge the silo-budgeting conventions of public bureaucracies (especially those that are performance-managed) and require strong commitment to *long-term* cross-sectoral, solutions. Preventive efforts outside the state sector (e.g., in workplaces) may also be hard to incentivise. Even when preventive strategies or treatments appear cost-effective, there may therefore be economic and other structural barriers to implementation. Thus, budgetary allocations for preventive strategies need to be ear-marked from the relevant ministries which are concerned with these diverse sectors. Investing in depression prevention and care represents excellent value for money, not least due to the contribution they can make to the attainment of several of the SDGs (Figure 13).

Figure 13. Depression and the Sustainable Development Goals

How depression relates to this SDG	The SDG	Actions to prevent or treat depression that contribute to achieving the SDG
<p>Being depressed impairs work performance and increases the risk of becoming unemployed, inadequately employed or inactive, and increases vulnerability to economic, social and environmental shocks and disasters. It is also associated with increased health care costs, often out-of-pocket in most countries with inadequate universal mental health coverage.</p>	 <p>1 NO POVERTY</p> <p>End poverty in all its forms everywhere.</p>	<p>Increasing people’s likelihood to find and hold a job, reducing disability associated with co-morbid medical conditions, less isolation and morbidity among family caregivers, decreasing health care costs, and increasing people’s resilience when exposed to shocks and disasters.</p>
<p>Poor nutrition is a risk factor for depression, and depression is associated with unhealthy eating habits and obesity. Depression in mothers is strongly associated with childhood undernutrition and stunting.</p>	 <p>2 ZERO HUNGER</p> <p>End hunger, achieve food security and improved nutrition and promote sustainable agriculture.</p>	<p>Enabling persons to take a more active hand in self-care, including provision and intake of adequate nutrition, and enabling parents to create a more nurturing environment for the healthy growth and development of children.</p>

How depression relates to this SDG	The SDG	Actions to prevent or treat depression that contribute to achieving the SDG
<p>Depression is, by itself, the single most burdensome mental health condition. It also increases the risk of a number of other health conditions, such as cardiovascular events, other mental health conditions such as substance use, and worsens their prognosis, contributing to premature mortality.</p>	 <p>3 GOOD HEALTH AND WELL-BEING</p> <p>Ensure healthy lives and promote well-being for all at all ages.</p>	<p>Promoting substantial improvement of health-related quality of life, with reduction in mortality risk from non-communicable diseases, including cancer-related deaths, and suicidal behaviour.</p>
<p>Maternal depression adversely affects offspring cognitive development and educational attainment; being depressed during childhood or adolescence has a negative impact on educational performance and outcome; depression reduces the access of adults to technical, vocational and tertiary education and reduces their chances for successful completion.</p>	 <p>4 QUALITY EDUCATION</p> <p>Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all.</p>	<p>Enhancing educational attainment across the life course, ultimately contributing to the protection of cognitive reserve and brain health.</p>
<p>Depression disproportionately affects women, in part due to gendered disadvantages faced by girls and women, including interpersonal violence, fuelling further gender inequalities in education, health and income.</p>	 <p>5 GENDER EQUALITY</p> <p>Achieve gender equality and empower all women and girls.</p>	<p>Improving the health of girls and women, including reduced self-harm, increasing agency and self-efficacy, and reducing exposure to interpersonal violence.</p>
<p>Depression is a major drag on productivity and economic growth.</p>	 <p>8 DECENT WORK AND ECONOMIC GROWTH</p> <p>Promote sustained, inclusive and sustainable economic growth, full and productive employment and decent work for all.</p>	<p>Improving productivity at work, contributing to greater economic performance of industry, and fostering equal opportunities of employment for those with depression. <i>The Economist</i> voted addressing the burden of depression as an economic best buy.</p>

How depression relates to this SDG	The SDG	Actions to prevent or treat depression that contribute to achieving the SDG
<p>Marginalised and disadvantaged communities are more vulnerable and income inequality is associated with higher risk of depression.</p>	 <p>10 REDUCED INEQUALITIES</p> <p>Reduce inequality within and among countries.</p>	<p>Reducing health inequalities (including premature mortality) and, ultimately, reducing income inequalities.</p>
<p>Person-centred urban spaces, for example with minimal noise/air pollution, green spaces, night lighting, pedestrian zones and bike lanes which encourage physical activity and attention to personal safety, reduce the risk of depression.</p>	 <p>11 SUSTAINABLE CITIES AND COMMUNITIES</p> <p>Make cities and human settlements inclusive, safe, resilient and sustainable.</p>	<p>Promoting a positive cycle between more inclusive, safe and sustainable settlements and a psychologically resilient, socially connected and healthy population.</p>
<p>Extreme climate events and associated disasters lead to an increased risk for depression.</p>	 <p>13 CLIMATE ACTION</p> <p>Take urgent action to combat climate change and its impacts.</p>	<p>Strengthening resilience and adaptive capacity to climate change, preventing depression's sequelae, including grief over catastrophic loss of livelihood and life.</p>
<p>Wars, civil conflicts and socially fractured societies lead to trauma and stressors associated with threats to personal safety, loss, bereavement and displacement which increase the risk for depression.</p>	 <p>16 PEACE, JUSTICE AND STRONG INSTITUTIONS</p> <p>Promote peaceful and inclusive societies for sustainable development, provide access to justice for all and build effective, accountable and inclusive institutions at all levels.</p>	<p>Enabling persons and communities affected to better address and cope with the diverse stressors and tolerate diversity, ultimately contributing to the rebuilding of shattered lives and communities.</p>

A final word for decision makers concerned with development assistance for health, such as the international aid departments of wealthier countries and foundations: the evidence we present clearly shows that depression is a health condition which hits the poorest people,

communities and countries the hardest. Much of the global unmet need for prevention and care is concentrated in these populations and this burden is expected to grow considerably following the COVID-19 pandemic, refugee crises and the climate emergency. Despite this, development assistance has almost entirely neglected mental health even though these countries need substantial external financial support to adequately resource their mental health care systems. It is time to change.

CONCLUSION

Depression is one of the leading causes of avoidable suffering and premature mortality in the world but has attracted little policy attention. Most countries are ill-equipped to deal with the burden of depression, not only because of the long-standing under-resourcing of mental health care systems and the massive paucity of skilled providers, but also because of the rigid silos that typically separate mental health expertise and mental health care from primary health care and community support sectors, and that separate health policy from other pertinent areas of public policy such as education, employment, migration and welfare benefits.

This Commission provides a message of hope, not only in the form of robust evidence on what can be done to prevent and treat depression, but also how such interventions can be delivered even in the least resourced contexts. This evidence offers us an historic opportunity for united action to transform mental health care systems globally. Investing in actions to reduce the burden of depression enables individuals to regain and maintain their well-being, hope for the future and the necessary cognitive capabilities to be effective in their work and personal lives. Collectively the impact will contribute to strengthening national economies and to the attainment of the Sustainable Development Goals. Paired with this, we urge decision-makers to consider seriously the call for a whole-of-society approach to the prevention of depression that can be expected to deliver benefits equivalent to those found in many countries from reducing the prevalence of coronary heart disease and several forms of cancer. We cannot think of a more important set of investments, now more than ever before.

.

Contributors

HH, VP, CK, and CB drafted and revised the whole report. MB, PC, TAF, RCK, MM, PM, CFR, and MMW led the drafting of specific sections of the report. All authors contributed text to sections of the report, and all reviewed and revised the paper for intellectual content. HH, VP, CK, CB, PC, TAF, RCK, MM, CFR, CD, BAK, HM, and BP also contributed specific non-text items.

Declaration of interest

HH reports her role as President of the World Psychiatric Association during the period of preparing and submitting the report for publication and support through Australian National Health and Medical Research Council (NHMRC) Practitioner Fellowship. VP reports being a co-founder of Librum, a mental health consulting firm, and has consulted with Johnson & Johnson, with no fees received related to the submitted work. His research on depression is supported by the NIMH and the Wellcome Trust. CK is a *Conselho Nacional de Desenvolvimento Científico e Tecnológico* (CNPq), Brazil, researcher and a UK Academy of Medical Sciences Newton Advanced Fellow. MB reports grants from NHMRC as Senior Principal Research Fellow, during the conduct of the study; personal fees from Servier, Lundbeck, Livanova, Grunbiotics, Otsuka, RANZCP, ANZJP, and Medisquire India, outside the submitted work; and three issued patents (Modulation of Physiological processes and agents useful for same, Modulation of diseases of the central nervous system and related disorders, and Xanthone-rich plant extracts or compounds therefrom for modulating diseases of the central nervous system and related disorders issued). CB reports travel support from Wellcome Trust and personal fees from the University of Melbourne and the World Psychiatric Association, during the conduct of the study. TAF reports grants and personal fees from Mitsubishi-Tanabe and personal fees from MSD and Shionogi, outside the submitted work; and patent 2018-177688 pending, as well as intellectual properties for Kokoro-app licensed to Tanabe-Mitsubishi. RCK was a consultant for Datastat, Inc., Holmusk, RallyPoint Networks, Inc., and Sage Pharmaceuticals. He has stock options in Mirah, PYM, and Roga Sciences. CR reports consultant fees from the Depression and Bipolar Support Alliance, Weill Cornell School of Medicine, UpToDate, The University of Maryland School of Public Health, Psychopharmacology Institute, and Merck, and an honorarium from the American Association for Geriatric Psychiatry, outside the submitted work; and royalties from the University of Pittsburgh and Oxford University Press. MMW in the last 3 years has received research funding from NIMH, Brain and Behavior Foundation, Templeton Foundation and the Sackler Foundation, and has received book royalties from Perseus Press, Oxford Press, and APA Publishing and royalties on the social adjustment scale from Multihealth Systems. DC is funded by the African Academy of Sciences, and is involved as the founder of Friendship Bench which supported by Boehringer Ingelheim. CD reports grants from National Institute for Health and Social Care (England), personal fees from World Organisation of Family Doctors, personal fees from iheed - Accredited Medical Education Online (Ireland), outside the submitted work; and as Chair of the Working Party for Mental Health of the World Organisation for Family Doctors, CD advocates for the central role of family doctors in the assessment and management of depression in primary care settings. LH reports funding from the South London and Maudsley NHS Foundation Trust/King's College London Biomedical Research Centre; the UKRI Collaborative Mental Health Network plus: Violence, Abuse and Mental Health: Opportunities for change (ES/S004424/1); NIHR HS&DR ESMI II: The Effectiveness and cost effectiveness of community perinatal Mental health services (17/49/38); and salary support from the South London NIHR Applied Research Collaboration. HM reports personal fees from Abbott Labs, outside the submitted work; and a patent US 2005/0033379A1 licensed to Abbott Labs. BP reports grants from Jansen Research, grants from Boehringer Ingelheim, outside the

submitted work. MT reports personal fees from Acadia Pharmaceuticals, Inc., personal fees from Allergan, personal fees from Alto Neuroscience Inc, personal fees from Axsome Therapeutics, personal fees from Engage Health Media, personal fees from GreenLight VitalSign6 Inc, personal fees from Janssen, personal fees from Merck Sharp & Dohme Corp, personal fees from Myriad Neuroscience, personal fees from Navitor Pharmaceutical Inc, personal fees from Otsuka, personal fees from Perception Neuroscience, personal fees from SAGE Therapeutics, personal fees from Signant Health, personal fees from Academy Health, personal fees from Akili Interactive, personal fees from Health Research Associates, personal fees from Jazz Pharmaceutical, personal fees from Lundbeck Research USA, personal fees from Perception Neuroscience Holdings, personal fees from Pharmerit International, outside the submitted work. All other authors declare no competing interests.

Acknowledgments

We thank the World Psychiatric Association (WPA) for endorsement and support. We gratefully acknowledge foundational funding from The University of Melbourne. Generous funding support was also provided by the American Foundation for Suicide Prevention.

Commission meetings were hosted by the Harvard Medical School in Boston, and by the Wellcome Trust in London. The Wellcome Trust provided additional in-kind support as well as travel support for participants from low- and middle-income countries. The Wellcome Trust and UNICEF worked together to support the participation of young people with lived experience as consultants in preparing the report including crafting the recommendations. We thank Kate Martin (Wellcome Trust) and Marcy Levy (UNICEF) for their collegial work and advice and Grace Gatera and Josiah Tualamali'i for their contribution. We thank Alex Riley for his contributions and advice from the perspective of lived experience during three meetings of the Commission. Sarah Kline, Charlene Sunkel and the Global Mental Health Peer Network, and Michaela Amering and the WPA Service User and Carer Advisory Group provided valuable advice and support in convening consultations on the report's recommendations.

We thank United for Mental Health, especially Sarah Kline and Melanie Archer, for advance assistance with preparing for dissemination of the report, and The American Psychological Association for advice and invaluable assistance with dissemination of the report. We thank Ellen Gay Detlefsen for providing a list of reliable websites on depression for the community, Ioana A. Cristea for assistance with Table 3, and Nancy A. Sampson, Irving Hwang, and Wai Tat Chiu for support with figures generated with data from the WHO World Mental Health Survey Consortium. We also wish to thank all the individuals from around the world who kindly provided testimonials.

REFERENCES

1. Patel V, Saxena S, Lund C, et al. The Lancet Commission on global mental health and sustainable development. *Lancet* 2018; **392**(10157): 1553-98.
2. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**(10159): 1789-858.
3. Murphy JM, Laird NM, Monson RR, Sobol AM, Leighton AH. A 40-year perspective on the prevalence of depression: the Stirling County Study. *Arch Gen Psychiatry* 2000; **57**(3): 209-15.
4. Kaiser BN, Haroz EE, Kohrt BA, Bolton PA, Bass JK, Hinton DE. "Thinking too much": A systematic review of a common idiom of distress. *Soc Sci Med* 2015; **147**: 170-83.
5. Goldberg D. The heterogeneity of "major depression". *World Psychiatry* 2011; **10**(3): 226-8.
6. Monroe SM, Anderson SF. Depression: The Shroud of Heterogeneity. *Current Directions in Psychological Science* 2015; **24**(3): 227–31.
7. Fried EI. Moving forward: how depression heterogeneity hinders progress in treatment and research. *Expert Rev Neurother* 2017; **17**(5): 423-5.
8. Stringaris A. Editorial: What is depression? *J Child Psychol Psychiatry* 2017; **58**(12): 1287-9.
9. Kendler KS. From Many to One to Many-the Search for Causes of Psychiatric Illness. *JAMA Psychiatry* 2019.
10. Malhi GS, Mann JJ. Depression. *Lancet* 2018; **392**(10161): 2299-312.
11. Lippard ETC, Nemeroff CB. The Devastating Clinical Consequences of Child Abuse and Neglect: Increased Disease Vulnerability and Poor Treatment Response in Mood Disorders. *Am J Psychiatry* 2020; **177**(1): 20-36.
12. Uher R, Zwickler A. Etiology in psychiatry: embracing the reality of poly-gene-environmental causation of mental illness. *World Psychiatry* 2017; **16**(2): 121-9.
13. Ruscio AM. Normal Versus Pathological Mood: Implications for Diagnosis. *Annu Rev Clin Psychol* 2019; **15**: 179-205.
14. Lovell AM, Read UM, Lang C. Genealogies and Anthropologies of Global Mental Health. *Cult Med Psychiatry* 2019; **43**(4): 519-47.
15. Cuijpers P, Stringaris A, Wolpert M. Treatment outcomes for depression: challenges and opportunities. *Lancet Psychiatry* 2020.
16. Patel V. Rethinking mental health care: bridging the credibility gap. *Intervention* 2014; **12**: 15-20.
17. Stieglitz J, Schniter E, von Rueden C, Kaplan H, Gurven M. Functional Disability and Social Conflict Increase Risk of Depression in Older Adulthood Among Bolivian Forager-Farmers. *J Gerontol B Psychol Sci Soc Sci* 2015; **70**(6): 948-56.
18. Stieglitz J, Trumble BC, Thompson ME, Blackwell AD, Kaplan H, Gurven M. Depression as sickness behavior? A test of the host defense hypothesis in a high pathogen population. *Brain Behav Immun* 2015; **49**: 130-9.
19. Shostak M. Nisa: The life and words of a! Kung woman: Harvard University Press; 2009(2009).
20. Archer J. Grief from an evolutionary perspective. Handbook of bereavement research: Consequences, coping, and care. Washington, DC: American Psychological Association; 2001(2001).

21. Winkelman M. Shamanic universals and evolutionary psychology. *Journal of Ritual Studies* 2002; **16**(2): 63-76.
22. Madhavi AHPS. DEPRESSION-AN AYURVEDIC OUTLOOK INTRODUCTION. *Journal of Ayurveda and holistic medicine* 2017; **5**: 12-23.
23. Berrios GE. Melancholia and depression during the 19th century: a conceptual history. *Br J Psychiatry* 1988; **153**: 298-304.
24. Lin K-M. Traditional Chinese Medical Beliefs and Their Relevance for Mental Illness and Psychiatry. I. In: Kleinman A, Lin T-Y, eds. *Normal and Abnormal Behavior in Chinese Culture*. Dordrecht: Springer Netherlands 1981: 95-111.
25. Agren H. The conceptual history of psychiatric terms in Traditional Chinese Medicine. *Explorations in the History of Science and Technology in China*. Shanghai 1982(1982).
26. Koontz R, Orr H. *Blood and Beauty: Organized Violence in the Art and Archaeology of Mesoamerica and Central America*. Cotsen Institute of Archaeology Press; 2009(2009).
27. Geck MS, Cristians S, Berger-González M, Casu L, Heinrich M, Leonti M. Traditional Herbal Medicine in Mesoamerica: Toward Its Evidence Base for Improving Universal Health Coverage. *Frontiers in Pharmacology* 2020; **11**(1160).
28. Buenaflor E. *Cleansing Rites of Curanderismo: Limpias Espirituales of Ancient Mesoamerican Shamans Inner Traditions/Bear*; 2018(2018).
29. Toohey P. Acedia in Late Classical Antiquity. *Illinois Classical Studies* 1990; **15**(2): 339-52.
30. Jackson SW. Acedia the sin and its relationship to sorrow and melancholia. In: Kleinman A, Good B, eds. *Culture and depression*. Berkeley: University of California Press; 1985: 43-62.
31. Toghyani M, Kajbaf MB, Ghamarani A. What Does Islamic Lifestyle Say about Depression Management? *Zahedan J Res Med Sci* 2018; **20**(7): e67766.
32. Durrany K. Arab psychiatry *Studies in the History of Medicine* 1980; **iv**: 214-24.
33. Haque A. Psychology from Islamic Perspective: Contributions of Early Muslim Scholars and Challenges to Contemporary Muslim Psychologists. *Journal of Religion and Health* 2004; **43**(4): 357-77.
34. Jacobson E. 'Life-Wind Illness' In Tibetan Medicine: Depression, Generalised Anxiety, And Panic Attack: Brill; 2007(2007).
35. Millard C. *Tibetan Medicine And The Classification And Treatment Of Mental Illness:: Brill*; 2007(2007).
36. Zhao J, Niu C, Wang J, et al. The depressive-like behaviors of chronic unpredictable mild stress-treated mice, ameliorated by Tibetan medicine Zuotai: involvement in the hypothalamic-pituitary-adrenal (HPA) axis pathway. *Neuropsychiatr Dis Treat* 2018; **14**: 129-41.
37. Aquinas T. *Thomas Aquinas Summa Theologia*. Londong: Blackfriars and Eyre & Spottiswoode 1964(1964).
38. Marsilio F. *Three Books on Life* [Florence, 1489] Tempe, AZ: Medieval and Renaissance Texts & Studies; 1989(1989).
39. Yuan T-F. Traditional Chinese Medicine in treatments to depression. *Neuroendocrinol Lett* 2009; **30**(1): 17-8.
40. Burton R. *The anatomy of melancholy*: Thomas Tegg; 1845(1845).
41. Kendler KS. The Origin of Our Modern Concept of Depression-The History of Melancholia From 1780-1880: A Review. *JAMA Psychiatry* 2020.
42. Esquirol E. *Des maladies mentales: considerees sous les rapports: medical, hygienique et medico-legal*. Tome Premier. Bruxelles: Librairie Medical et Scientific de J. B. Tircher; 1838(1838).

43. Kong J, Wilson G, Park J, Pereira K, Walpole C, Yeung A. Treating Depression With Tai Chi: State of the Art and Future Perspectives. *Frontiers in Psychiatry* 2019; **10**(237).
44. Horowitz AV. DSM - I and DSM - II. : The Encyclopedia of Clinical Psychology; 2015(2015).
45. Goldstein WN, Anthony RN. The diagnosis of depression and the DSMs. *Am J Psychother* 1988; **42**(2): 180-96.
46. Jaiswal YS, Williams LL. A glimpse of Ayurveda - The forgotten history and principles of Indian traditional medicine. *J Tradit Complement Med* 2016; **7**(1): 50-3.
47. Lee S, Kleinman A. Are somatoform disorders changing with time? The case of neurasthenia in China. *Psychosom Med* 2007; **69**(9): 846-9.
48. World Health Organization. International Classification of Diseases 11th Revision. 2019. <https://icd.who.int/en>.
49. International Advisory Group for the Revision of ICDM, Behavioural D. A conceptual framework for the revision of the ICD-10 classification of mental and behavioural disorders. *World Psychiatry* 2011; **10**(2): 86-92.
50. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington: American Psychiatric Association; 1980(1980).
51. McGlinchey JB, Zimmerman M, Young D, Chelminski I. Diagnosing major depressive disorder VIII: are some symptoms better than others? *J Nerv Ment Dis* 2006; **194**(10): 785-90.
52. Kessler RC, Zhao S, Blazer DG, Swartz M. Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey. *J Affect Disord* 1997; **45**(1-2): 19-30.
53. Kendler KS, Gardner CO, Jr. Boundaries of major depression: an evaluation of DSM-IV criteria. *Am J Psychiatry* 1998; **155**(2): 172-7.
54. Paykel ES, Hollyman JA, Freeling P, Sedgwick P. Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. *J Affect Disord* 1988; **14**(1): 83-95.
55. Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. *Arch Gen Psychiatry* 1989; **46**(11): 971-82; discussion 83.
56. Ruscio J, Ruscio AM. Informing the continuity controversy: a taxometric analysis of depression. *J Abnorm Psychol* 2000; **109**(3): 473-87.
57. Grove WM, Andreasen NC, Young M, et al. Isolation and characterization of a nuclear depressive syndrome. *Psychol Med* 1987; **17**(2): 471-84.
58. Melartin T, Leskela U, Rytasala H, Sokero P, Lestela-Mielonen P, Isometsa E. Comorbidity and stability of melancholic features in DSM-IV major depressive disorder. *Psychol Med* 2004; **34**(8): 1443-52.
59. Arieti S, Bemporad J. Severe and mild depression: the psychotherapeutic approach. New York: Basic Books; 1978(1978).
60. Horwitz AV, Wakefield JC. The loss of sadness: how psychiatry transformed normal sorrow into depressive disorder. Oxford: Oxford University Press; 2007(2007).
61. Rodriguez MR, Nuevo R, Chatterji S, Ayuso-Mateos JL. Definitions and factors associated with subthreshold depressive conditions: a systematic review. *BMC Psychiatry* 2012; **12**: 181.
62. Ayuso-Mateos JL, Nuevo R, Verdes E, Naidoo N, Chatterji S. From depressive symptoms to depressive disorders: the relevance of thresholds. *Br J Psychiatry* 2010; **196**(5): 365-71.
63. National Institute for Health and Care Excellence. Depression in adults: treatment and management. London: National Institute for Health and Care Excellence; 2017(2017).

64. Judd LL, Rapaport MH, Paulus MP, Brown JL. Subsyndromal symptomatic depression: a new mood disorder? *J Clin Psychiatry* 1994; **55 Suppl**: 18-28.
65. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960; **23**: 56-62.
66. Zimmerman M, Morgan TA, Stanton K. The severity of psychiatric disorders. *World Psychiatry* 2018; **17**(3): 258-75.
67. Maj M, Stein DJ, Parker G, et al. The clinical characterization of the adult patient with depression aimed at personalization of management. *World Psychiatry* 2020; **19**(3): 269-93.
68. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 2001; **16**(9): 606-13.
69. Levis B, Benedetti A, Thombs BD. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. *Bmj* 2019; **365**: 11476.
70. Kohrt BA, Luitel NP, Acharya P, Jordans MJ. Detection of depression in low resource settings: validation of the Patient Health Questionnaire (PHQ-9) and cultural concepts of distress in Nepal. *BMC Psychiatry* 2016; **16**: 58.
71. Reynolds CFR, Patel V. Screening for depression: the global mental health context. *World Psychiatry* 2017; **16**(3): 316-7.
72. Fried EI, Nesse RM. Depression sum-scores don't add up: why analyzing specific depression symptoms is essential. *BMC Med* 2015; **13**: 72.
73. Wakefield JC, Schmitz MF. Severity of complicated versus uncomplicated subthreshold depression: New evidence on the "Monotonicity Thesis" from the national comorbidity survey. *J Affect Disord* 2017; **212**: 101-9.
74. Boschloo L, Bekhuis E, Weitz ES, et al. The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis. *World Psychiatry* 2019; **18**(2): 183-91.
75. van Praag HM. The diagnosis of depression in disorder. *Aust N Z J Psychiatry* 1998; **32**(6): 767-72; discussion 73-7.
76. Helmchen H, Linden M. Subthreshold disorders in psychiatry: clinical reality, methodological artifact, and the double-threshold problem. *Compr Psychiatry* 2000; **41**(2 Suppl 1): 1-7.
77. Healy D. Dysphoria. Symptoms of depression. New York: Wiley; 1993: 23-42.
78. Haroz EE, Ritchey M, Bass JK, et al. How is depression experienced around the world? A systematic review of qualitative literature. *Soc Sci Med* 2017; **183**: 151-62.
79. Fried EI, Epskamp S, Nesse RM, Tuerlinckx F, Borsboom D. What are 'good' depression symptoms? Comparing the centrality of DSM and non-DSM symptoms of depression in a network analysis. *J Affect Disord* 2016; **189**: 314-20.
80. Ziebold C, Goldberg DP, Reed GM, et al. Dimensional analysis of depressive, anxious and somatic symptoms presented by primary care patients and their relationship with ICD-11 PHC proposed diagnoses. *Psychol Med* 2019; **49**(5): 764-71.
81. Farchione TJ, Fairholme CP, Ellard KK, et al. Unified protocol for transdiagnostic treatment of emotional disorders: a randomized controlled trial. *Behav Ther* 2012; **43**(3): 666-78.
82. Goldberg DP, Huxley P. Common mental disorders: A bio-social model. New York, NY, US: Tavistock/Routledge; 1992(1992).
83. Martin LA, Neighbors HW, Griffith DM. The experience of symptoms of depression in men vs women: analysis of the National Comorbidity Survey Replication. *JAMA Psychiatry* 2013; **70**(10): 1100-6.

84. Harald B, Gordon P. Meta-review of depressive subtyping models. *J Affect Disord* 2012; **139**(2): 126-40.
85. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013(2013).
86. Maj M, Pirozzi R, Di Caprio EL. Major depression with mood-congruent psychotic features: a distinct diagnostic entity or a more severe subtype of depression? *Acta Psychiatr Scand* 1990; **82**(6): 439-44.
87. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disord* 2018; **20**(2): 97-170.
88. Jones I, Chandra PS, Dazzan P, Howard LM. Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period. *Lancet* 2014; **384**(9956): 1789-99.
89. Weygandt W. Über die Mischzustände des manisch-depressiven Irreseins: JF Lehmann; 1899(1899).
90. Sato T, Bottlender R, Schroter A, Moller HJ. Frequency of manic symptoms during a depressive episode and unipolar 'depressive mixed state' as bipolar spectrum. *Acta Psychiatr Scand* 2003; **107**(4): 268-74.
91. Donohue MR, Whalen DJ, Gilbert KE, Hennefield L, Barch DM, Luby J. Preschool Depression: a Diagnostic Reality. *Current Psychiatry Reports* 2019; **21**(12): 128.
92. Ross E, Ali A, Toner B. Investigating issues surrounding depression in adolescent girls across Ontario: a participatory action research project. *Can J Commun Ment Health* 2003; **22**(1): 55-68.
93. McGorry PD, Hartmann JA, Spooner R, Nelson B. Beyond the "at risk mental state" concept: transitioning to transdiagnostic psychiatry. *World Psychiatry* 2018; **17**(2): 133-42.
94. Thapar A, Collishaw S, Pine DS, Thapar AK. Depression in adolescence. *Lancet* 2012; **379**(9820): 1056-67.
95. Lachal J, Speranza M, Schmitt A, et al. Depression in Adolescence: From Qualitative Research to Measurement. *Adolescent Psychiatry* 2012; **2**(4): 296-308.
96. Berk M, Dodd S, Callaly P, et al. History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. *J Affect Disord* 2007; **103**(1-3): 181-6.
97. Rodda J, Walker Z, Carter J. Depression in older adults. *BMJ* 2011; **343**: d5219.
98. Salk RH, Hyde JS, Abramson LY. Gender differences in depression in representative national samples: Meta-analyses of diagnoses and symptoms. *Psychol Bull* 2017; **143**(8): 783-822.
99. Girgus JS, Yang K. Gender and depression. *Curr Opin Psychol* 2015; **4**: 53-60.
100. Kammerer M, Marks MN, Pinard C, et al. Symptoms associated with the DSM IV diagnosis of depression in pregnancy and post partum. *Archives of women's mental health* 2009; **12**(3): 135-41.
101. Kleinman A, Good B. Culture and depression : studies in the anthropology and cross-cultural psychiatry of affect and disorder. Berkeley: University of California Press; 1985(1985).
102. Dowrick C. Depression: beyond the disease era. *London J Prim Care (Abingdon)* 2009; **2**(1): 24-7.
103. Kessler RC, Ustun TB. The WHO World Mental Health surveys: global perspectives on the epidemiology of mental disorders. New York: Cambridge University Press; 2008(2008).

104. Kirmayer LJ. Cultural variations in the clinical presentation of depression and anxiety: implications for diagnosis and treatment. *J Clin Psychiatry* 2001; **62 Suppl 13**: 22-8; discussion 9-30.
105. Keys HM, Kaiser BN, Kohrt BA, Khoury NM, Brewster AR. Idioms of distress, ethnopsychology, and the clinical encounter in Haiti's Central Plateau. *Soc Sci Med* 2012; **75**(3): 555-64.
106. Min SK, Suh S-y. The anger syndrome hwa-byung and its comorbidity. *Journal of Affective Disorders* 2010; **124**(1): 211-4.
107. Kwon H, Yoon KL, Joormann J, Kwon J-H. Cultural and gender differences in emotion regulation: Relation to depression. *Cognition and Emotion* 2013; **27**(5): 769-82.
108. Gan P, Xie Y, Duan W, Deng Q, Yu X. Rumination and Loneliness Independently Predict Six-Month Later Depression Symptoms among Chinese Elderly in Nursing Homes. *PLoS One* 2015; **10**(9): e0137176.
109. Erzen E, Çikrikci Ö. The effect of loneliness on depression: A meta-analysis. *International Journal of Social Psychiatry* 2018; **64**(5): 427-35.
110. Brown A, Scales U, Beaver W, Rickards B, Rowley K, O'Dea K. Exploring the expression of depression and distress in aboriginal men in central Australia: a qualitative study. *BMC Psychiatry* 2012; **12**(1): 97.
111. Nock MK, Borges G, Bromet EJ, et al. Cross-national prevalence and risk factors for suicidal ideation, plans and attempts. *British Journal of Psychiatry* 2008; **192**(2): 98-105.
112. Ventevogel P, Jordans M, Reis R, de Jong J. Madness or sadness? Local concepts of mental illness in four conflict-affected African communities. *Confl Health* 2013; **7**(1): 3.
113. Meyer SR, Robinson WC, Chhim S, Bass JK. Labor migration and mental health in Cambodia: a qualitative study. *J Nerv Ment Dis* 2014; **202**(3): 200-8.
114. Hinton DE, Reis R, de Jong J. The "Thinking a Lot" Idiom of Distress and PTSD: An Examination of Their Relationship among Traumatized Cambodian Refugees Using the "Thinking a Lot" Questionnaire. *Med Anthropol Q* 2015; **29**(3): 357-80.
115. Patel V, Simunyu E, Gwanzura F, Lewis G, Mann A. The Shona Symptom Questionnaire: the development of an indigenous measure of common mental disorders in Harare. *Acta Psychiatr Scand* 1997; **95**(6): 469-75.
116. Muhwezi WW, Okello ES, Neema S, Musisi S. Caregivers' experiences with major depression concealed by physical illness in patients recruited from central Ugandan Primary Health Care Centers. *Qual Health Res* 2008; **18**(8): 1096-114.
117. Kidia K, Machando D, Bere T, et al. 'I was thinking too much': experiences of HIV-positive adults with common mental disorders and poor adherence to antiretroviral therapy in Zimbabwe. *Trop Med Int Health* 2015; **20**(7): 903-13.
118. Patel V, Chowdhary N, Rahman A, Verdeli H. Improving access to psychological treatments: lessons from developing countries. *Behav Res Ther* 2011; **49**(9): 523-8.
119. Chibanda D, Mesu P, Kajawu L, Cowan F, Araya R, Abas MA. Problem-solving therapy for depression and common mental disorders in Zimbabwe: piloting a task-shifting primary mental health care intervention in a population with a high prevalence of people living with HIV. *BMC Public Health* 2011; **11**(1): 828.
120. Hinton DE, Patel A. Cultural Adaptations of Cognitive Behavioral Therapy. *Psychiatr Clin North Am* 2017; **40**(4): 701-14.
121. Singla DR, Kohrt BA, Murray LK, Anand A, Chorpita BF, Patel V. Psychological Treatments for the World: Lessons from Low- and Middle-Income Countries. *Annu Rev Clin Psychol* 2017; **13**: 149-81.
122. Kohrt BA, Jordans MJD, Tol WA, Luitel NP, Maharjan SM, Upadhaya N. Validation of cross-cultural child mental health and psychosocial research instruments: adapting the

- Depression Self-Rating Scale and Child PTSD Symptom Scale in Nepal. *BMC Psychiatry* 2011; **11**(1): 127.
123. Kaiser BN, Ticao C, Anoje C, Minto J, Boglosa J, Kohrt BA. Adapting culturally appropriate mental health screening tools for use among conflict-affected and other vulnerable adolescents in Nigeria. *Global Mental Health* 2019; **6**: e10.
 124. Gormez V, Kılınçaslan A, Oregul AC, et al. Psychometric properties of the Turkish version of the Revised Child Anxiety and Depression Scale – Child Version in a clinical sample. *Psychiatry and Clinical Psychopharmacology* 2017; **27**(1): 84-92.
 125. Stickley A, Koyanagi A, Kuposov R, et al. Loneliness and its association with psychological and somatic health problems among Czech, Russian and U.S. adolescents. *BMC Psychiatry* 2016; **16**(1): 128.
 126. Rose-Clarke K, Hassan E, Bk P, et al. A cross-cultural interpersonal model of adolescent depression: A qualitative study in rural Nepal. *Social Science & Medicine* 2021; **270**: 113623.
 127. Reed GM, First MB, Kogan CS, et al. Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. *World Psychiatry* 2019; **18**(1): 3-19.
 128. Shear MK, Reynolds CF, 3rd, Simon NM, et al. Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial. *JAMA Psychiatry* 2016; **73**(7): 685-94.
 129. Heeke C, Kampisiou C, Niemeyer H, Knaevelsrud C. A systematic review and meta-analysis of correlates of prolonged grief disorder in adults exposed to violent loss. *Eur J Psychotraumatol* 2019; **10**(1): 1583524.
 130. Goldstein RD, Petty CR, Morris SE, et al. Pre-loss personal factors and prolonged grief disorder in bereaved mothers. *Psychol Med* 2019; **49**(14): 2370-8.
 131. Stelzer EM, Höltge J, Zhou N, Maercker A, Killikelly C. Cross-cultural generalizability of the ICD-11 PGD symptom network: Identification of central symptoms and culturally specific items across German-speaking and Chinese bereaved. *Compr Psychiatry* 2020; **103**: 152211.
 132. Stelzer EM, Zhou N, Merzhvynska M, et al. Clinical Utility and Global Applicability of Prolonged Grief Disorder in the ICD-11 from the Perspective of Chinese and German-Speaking Health Care Professionals. *Psychopathology* 2020; **53**(1): 8-22.
 133. Killikelly C, Bauer S, Maercker A. The Assessment of Grief in Refugees and Post-conflict Survivors: A Narrative Review of Etic and Emic Research. *Front Psychol* 2018; **9**: 1957.
 134. Ferrari AJ, Somerville AJ, Baxter AJ, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. *Psychol Med* 2013; **43**(3): 471-81.
 135. Bromet EJ, Andrade LH, Bruffaerts R, Williams DR. Major depressive disorder. *Mental Disorders Around the World: Facts and Figures from the WHO World Mental Health Surveys*. New York: Cambridge University Press; 2018.
 136. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. *Lancet* 2007; **370**(9590): 851-8.
 137. Kessler RC, Karam EG, Lee S, Bunting B, Nierenberg AA. Bipolar spectrum disorder. *Mental Disorders Around the World: Facts and Figures from the WHO World Mental Health Surveys*. New York: Cambridge University Press; 2018.
 138. Saunders KE, Goodwin GM. The course of bipolar disorder. *Advances in psychiatric treatment* 2010; **16**(5): 318-28.
 139. World Health Organization. *Depression and Other Common Mental Disorders: Global Health Estimates*. Geneva: WHO, 2017.

140. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle: Institute for Health Metrics and Evaluation (IHME), 2020.
141. Moffitt TE, Caspi A, Taylor A, et al. How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment. *Psychol Med* 2010; **40**(6): 899-909.
142. Verduijn J, Verhoeven JE, Milaneschi Y, et al. Reconsidering the prognosis of major depressive disorder across diagnostic boundaries: full recovery is the exception rather than the rule. *BMC Med* 2017; **15**(1): 215.
143. Coryell W, Solomon D, Leon A, et al. Does major depressive disorder change with age? *Psychol Med* 2009; **39**(10): 1689-95.
144. Klein DN, Shankman SA, Rose S. Dysthymic disorder and double depression: prediction of 10-year course trajectories and outcomes. *J Psychiatr Res* 2008; **42**(5): 408-15.
145. Markkula N, Härkänen T, Nieminen T, et al. Prognosis of depressive disorders in the general population- results from the longitudinal Finnish Health 2011 Study. *J Affect Disord* 2016; **190**: 687-96.
146. Rhebergen D, Batelaan NM, de Graaf R, et al. The 7-year course of depression and anxiety in the general population. *Acta Psychiatr Scand* 2011; **123**(4): 297-306.
147. Ten Have M, de Graaf R, van Dorsselaer S, Tuithof M, Kleinjan M, Penninx B. Recurrence and chronicity of major depressive disorder and their risk indicators in a population cohort. *Acta Psychiatr Scand* 2018; **137**(6): 503-15.
148. Penninx BW, Nolen WA, Lamers F, et al. Two-year course of depressive and anxiety disorders: results from the Netherlands Study of Depression and Anxiety (NESDA). *J Affect Disord* 2011; **133**(1-2): 76-85.
149. Comijs HC, Nieuwesteeg J, Kok R, et al. The two-year course of late-life depression; results from the Netherlands study of depression in older persons. *BMC Psychiatry* 2015; **15**: 20.
150. Judd LL, Akiskal HS, Maser JD, et al. A Prospective 12-Year Study of Subsyndromal and Syndromal Depressive Symptoms in Unipolar Major Depressive Disorders. *Archives of General Psychiatry* 1998; **55**(8): 694-700.
151. Mattisson C, Bogren M, Horstmann V, Munk-Jorgensen P, Nettelbladt P. The long-term course of depressive disorders in the Lundby Study. *Psychol Med* 2007; **37**(6): 883-91.
152. Eaton WW, Shao H, Nestadt G, Lee HB, Bienvenu OJ, Zandi P. Population-based study of first onset and chronicity in major depressive disorder. *Archives of general psychiatry* 2008; **65**(5): 513-20.
153. Hardeveld F, Spijker J, De Graaf R, Nolen WA, Beekman AT. Recurrence of major depressive disorder and its predictors in the general population: results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). *Psychol Med* 2013; **43**(1): 39-48.
154. Gopinath S, Katon WJ, Russo JE, Ludman EJ. Clinical factors associated with relapse in primary care patients with chronic or recurrent depression. *J Affect Disord* 2007; **101**(1-3): 57-63.
155. Riihimäki KA, Vuorilehto MS, Melartin TK, Isometsä ET. Five-year outcome of major depressive disorder in primary health care. *Psychol Med* 2014; **44**(7): 1369-79.
156. Conradi HJ, Bos EH, Kamphuis JH, de Jonge P. The ten-year course of depression in primary care and long-term effects of psychoeducation, psychiatric consultation and cognitive behavioral therapy. *J Affect Disord* 2017; **217**: 174-82.
157. Hardeveld F, Spijker J, De Graaf R, et al. Recurrence of major depressive disorder across different treatment settings: results from the NESDA study. *J Affect Disord* 2013; **147**(1-3): 225-31.

158. Holma KM, Holma IA, Melartin TK, Rytsala HJ, Isometsa ET. Long-term outcome of major depressive disorder in psychiatric patients is variable. *J Clin Psychiatry* 2008; **69**(2): 196-205.
159. Ramana R, Paykel ES, Cooper Z, Hayhurst H, Saxty M, Surtees PG. Remission and relapse in major depression: a two-year prospective follow-up study. *Psychol Med* 1995; **25**(6): 1161-70.
160. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. *Am J Psychiatry* 1999; **156**(7): 1000-6.
161. Paterniti S, Sterner I, Caldwell C, Bissertebe J-C. Childhood neglect predicts the course of major depression in a tertiary care sample: a follow-up study. *BMC Psychiatry* 2017; **17**(1): 113.
162. Boshuizen HC, Greenland S. Average age at first occurrence as an alternative occurrence parameter in epidemiology. *Int J Epidemiol* 1997; **26**(4): 867-72.
163. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. *Annu Rev Public Health* 2013; **34**: 119-38.
164. Kessler RC, Ormel J, Petukhova M, et al. Development of lifetime comorbidity in the World Health Organization world mental health surveys. *Arch Gen Psychiatry* 2011; **68**(1): 90-100.
165. Yalin A, Young AH. The age of onset of unipolar depression. Age of onset of mental disorders: Etiopathogenetic and treatment implications. New York: Springer; 2018.
166. Kessler RC, Angermeyer M, Anthony JC, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. *World Psychiatry* 2007; **6**(3): 168-76.
167. Angst J, Merikangas K. The depressive spectrum: diagnostic classification and course. *J Affect Disord* 1997; **45**(1-2): 31-9; discussion 9-40.
168. Charlson FJ, Ferrari AJ, Flaxman AD, Whiteford HA. The epidemiological modelling of dysthymia: application for the Global Burden of Disease Study 2010. *J Affect Disord* 2013; **151**(1): 111-20.
169. Vandeleur CL, Fassassi S, Castelao E, et al. Prevalence and correlates of DSM-5 major depressive and related disorders in the community. *Psychiatry Res* 2017; **250**: 50-8.
170. Wesselhoeft R, Sorensen MJ, Heiervang ER, Bilenberg N. Subthreshold depression in children and adolescents - a systematic review. *J Affect Disord* 2013; **151**(1): 7-22.
171. Carrellas NW, Biederman J, Uchida M. How prevalent and morbid are subthreshold manifestations of major depression in adolescents? A literature review. *J Affect Disord* 2017; **210**: 166-73.
172. Cuijpers P, Smit F, Oostenbrink J, de Graaf R, Ten Have M, Beekman A. Economic costs of minor depression: a population-based study. *Acta Psychiatr Scand* 2007; **115**(3): 229-36.
173. Cuijpers P, Smit F. Subthreshold depression as a risk indicator for major depressive disorder: a systematic review of prospective studies. *Acta Psychiatr Scand* 2004; **109**(5): 325-31.
174. Wanders RB, van Loo HM, Vermunt JK, et al. Casting wider nets for anxiety and depression: disability-driven cross-diagnostic subtypes in a large cohort. *Psychol Med* 2016; **46**(16): 3371-82.
175. Kotiaho S, Korniloff K, Vanhala M, et al. Psychiatric diagnosis in primary care patients with increased depressive symptoms. *Nord J Psychiatry* 2019; **73**(3): 195-9.
176. Lamers F, van Oppen P, Comijs HC, et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). *J Clin Psychiatry* 2011; **72**(3): 341-8.

177. de Jonge P, Wardenaar KJ, Lim CCW, et al. The cross-national structure of mental disorders: results from the World Mental Health Surveys. *Psychol Med* 2018; **48**(12): 2073-84.
178. Benazzi F. Various forms of depression. *Dialogues Clin Neurosci* 2006; **8**(2): 151-61.
179. Kramer MD, Krueger RF, Hicks BM. The role of internalizing and externalizing liability factors in accounting for gender differences in the prevalence of common psychopathological syndromes. *Psychol Med* 2008; **38**(1): 51-61.
180. Plana-Ripoll O, Pedersen CB, Holtz Y, et al. Exploring Comorbidity Within Mental Disorders Among a Danish National Population. *JAMA Psychiatry* 2019.
181. Gold SM, Köhler-Forsberg O, Moss-Morris R, et al. Comorbid depression in medical diseases. *Nature Reviews Disease Primers* 2020; **6**(1): 69.
182. Dowrick C, Katona C, Peveler R, Lloyd H. Somatic symptoms and depression: diagnostic confusion and clinical neglect. *Br J Gen Pract* 2005; **55**(520): 829-30.
183. Penninx BW, Milaneschi Y, Lamers F, Vogelzangs N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. *BMC Med* 2013; **11**: 129.
184. Cohen S, Rodriguez MS. Pathways linking affective disturbances and physical disorders. *Health Psychol* 1995; **14**(5): 374-80.
185. Davis L, Uezato A, Newell JM, Frazier E. Major depression and comorbid substance use disorders. *Curr Opin Psychiatry* 2008; **21**(1): 14-8.
186. Paans NPG, Bot M, Brouwer IA, et al. The association between depression and eating styles in four European countries: The MoodFOOD prevention study. *J Psychosom Res* 2018; **108**: 85-92.
187. Gillen R, Tennen H, McKee TE, Gernert-Dott P, Affleck G. Depressive symptoms and history of depression predict rehabilitation efficiency in stroke patients. *Arch Phys Med Rehabil* 2001; **82**(12): 1645-9.
188. Mancuso CA, Rincon M, McCulloch CE, Charlson ME. Self-efficacy, depressive symptoms, and patients' expectations predict outcomes in asthma. *Med Care* 2001; **39**(12): 1326-38.
189. Peyrot M, Rubin RR. Levels and risks of depression and anxiety symptomatology among diabetic adults. *Diabetes Care* 1997; **20**(4): 585-90.
190. Cuijpers P, Vogelzangs N, Twisk J, Kleiboer A, Li J, Penninx BW. Comprehensive meta-analysis of excess mortality in depression in the general community versus patients with specific illnesses. *Am J Psychiatry* 2014; **171**(4): 453-62.
191. Cluley S, Cochrane GM. Psychological disorder in asthma is associated with poor control and poor adherence to inhaled steroids. *Respir Med* 2001; **95**(1): 37-9.
192. Ziegelstein RC, Fauerbach JA, Stevens SS, Romanelli J, Richter DP, Bush DE. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. *Arch Intern Med* 2000; **160**(12): 1818-23.
193. Mendenhall E, Kohrt BA, Norris SA, Ndeti D, Prabhakaran D. Non-communicable disease syndemics: poverty, depression, and diabetes among low-income populations. *Lancet* 2017; **389**(10072): 951-63.
194. Saczynski JS, Beiser A, Seshadri S, Auerbach S, Wolf PA, Au R. Depressive symptoms and risk of dementia: the Framingham Heart Study. *Neurology* 2010; **75**(1): 35-41.
195. Canet G, Chevallier N, Zussy C, Desrumaux C, Givalois L. Central Role of Glucocorticoid Receptors in Alzheimer's Disease and Depression. *Frontiers in neuroscience* 2018; **12**: 739.
196. Muliya KP, Varghese M. The complex relationship between depression and dementia. *Annals of Indian Academy of Neurology* 2010; **13**(Suppl 2): S69-73.

197. Saczynski JS, Pfeifer LA, Masaki K, et al. The effect of social engagement on incident dementia: the Honolulu-Asia Aging Study. *Am J Epidemiol* 2006; **163**(5): 433-40.
198. Katon W, Pedersen HS, Ribe AR, et al. Effect of depression and diabetes mellitus on the risk for dementia: a national population-based cohort study. *JAMA Psychiatry* 2015; **72**(6): 612-9.
199. Brommelhoff JA, Gatz M, Johansson B, McArdle JJ, Fratiglioni L, Pedersen NL. Depression as a risk factor or prodromal feature for dementia? Findings in a population-based sample of Swedish twins. *Psychology and aging* 2009; **24**(2): 373-84.
200. Charlson FJ, Baxter AJ, Dua T, Degenhardt L, Whiteford HA, Vos T. Excess Mortality from Mental, Neurological, and Substance Use Disorders in the Global Burden of Disease Study 2010. In: Patel V, Chisholm D, Dua T, et al., eds. *Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, Third Edition (Volume 4)*. . Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2016.
201. WHO. Global health estimates. Geneva: World Health Organization; 2018. http://www.who.int/healthinfo/global_burden_disease/en (accessed Jan 7 2019 Access 2018).
202. Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. *World Psychiatry* 2014; **13**(2): 153-60.
203. Cavanagh JT, Carson AJ, Sharpe M, Lawrie SM. Psychological autopsy studies of suicide: a systematic review. *Psychol Med* 2003; **33**(3): 395-405.
204. Ferrari AJ, Norman RE, Freedman G, et al. The burden attributable to mental and substance use disorders as risk factors for suicide: findings from the Global Burden of Disease Study 2010. *PLoS One* 2014; **9**(4): e91936.
205. Knipe D, Williams AJ, Hannam-Swain S, et al. Psychiatric morbidity and suicidal behaviour in low- and middle-income countries: A systematic review and meta-analysis. *PLoS Med* 2019; **16**(10): e1002905.
206. Vijayakumar L. Suicide prevention: the urgent need in developing countries. *World Psychiatry* 2004; **3**(3): 158-9.
207. Nock MK, Hwang I, Sampson NA, Kessler RC. Mental disorders, comorbidity and suicidal behavior: results from the National Comorbidity Survey Replication. *Molecular psychiatry* 2010; **15**(8): 868-76.
208. Dong M, Zeng LN, Lu L, et al. Prevalence of suicide attempt in individuals with major depressive disorder: a meta-analysis of observational surveys. *Psychol Med* 2019; **49**(10): 1691-704.
209. Hawton K, Casanas ICC, Haw C, Saunders K. Risk factors for suicide in individuals with depression: a systematic review. *J Affect Disord* 2013; **147**(1-3): 17-28.
210. Harwood D, Hawton K, Hope T, Jacoby R. Psychiatric disorder and personality factors associated with suicide in older people: a descriptive and case-control study. *Int J Geriatr Psychiatry* 2001; **16**(2): 155-65.
211. Wang X, Cheng S, Xu H. Systematic review and meta-analysis of the relationship between sleep disorders and suicidal behaviour in patients with depression. *BMC Psychiatry* 2019; **19**(1): 303.
212. McGirr A, Renaud J, Seguin M, Alda M, Turecki G. Course of major depressive disorder and suicide outcome: a psychological autopsy study. *J Clin Psychiatry* 2008; **69**(6): 966-70.
213. Salomon JA, Haagsma JA, Davis A, et al. Disability weights for the Global Burden of Disease 2013 study. *Lancet Glob Health* 2015; **3**(11): e712-23.
214. Kieling C, Adewuya A, Fisher HL, et al. Identifying depression early in adolescence. *Lancet Child Adolesc Health* 2019; **3**(4): 211-3.

215. Haagsma JA, Polinder S, Cassini A, Colzani E, Havelaar AH. Review of disability weight studies: comparison of methodological choices and values. *Popul Health Metr* 2014; **12**: 20.
216. Nord E. Uncertainties about disability weights for the Global Burden of Disease study. *Lancet Glob Health* 2015; **3**(11): e661-2.
217. Voigt K, King NB. Disability weights in the global burden of disease 2010 study: two steps forward, one step back? *Bull World Health Organ* 2014; **92**(3): 226-8.
218. Stewart WF, Ricci JA, Chee E, Morganstein D. Lost productive work time costs from health conditions in the United States: results from the American Productivity Audit. *J Occup Environ Med* 2003; **45**(12): 1234-46.
219. Verbrugge LM, Patrick DL. Seven chronic conditions: their impact on US adults' activity levels and use of medical services. *Am J Public Health* 1995; **85**(2): 173-82.
220. Ormel J, Petukhova M, Chatterji S, et al. Disability and treatment of specific mental and physical disorders across the world. *Br J Psychiatry* 2008; **192**(5): 368-75.
221. Alonso J, Petukhova M, Vilagut G, et al. Days out of role due to common physical and mental conditions: results from the WHO World Mental Health surveys. *Molecular psychiatry* 2011; **16**(12): 1234-46.
222. Alonso J, Vilagut G, Chatterji S, et al. Including information about co-morbidity in estimates of disease burden: results from the World Health Organization World Mental Health Surveys. *Psychol Med* 2011; **41**(4): 873-86.
223. Breslau J, Miller E, Joanie Chung WJ, Schweitzer JB. Childhood and adolescent onset psychiatric disorders, substance use, and failure to graduate high school on time. *J Psychiatr Res* 2011; **45**(3): 295-301.
224. Vaughn MG, Wexler J, Beaver KM, Perron BE, Roberts G, Fu Q. Psychiatric correlates of behavioral indicators of school disengagement in the United States. *Psychiatr Q* 2011; **82**(3): 191-206.
225. Woodward LJ, Fergusson DM. Life course outcomes of young people with anxiety disorders in adolescence. *J Am Acad Child Adolesc Psychiatry* 2001; **40**(9): 1086-93.
226. Kawakami N, Abdulghani EA, Alonso J, et al. Early-life mental disorders and adult household income in the World Mental Health Surveys. *Biological psychiatry* 2012; **72**(3): 228-37.
227. Insel TR. Assessing the economic costs of serious mental illness. *Am J Psychiatry* 2008; **165**(6): 663-5.
228. Levinson D, Lakoma MD, Petukhova M, et al. Associations of serious mental illness with earnings: results from the WHO World Mental Health surveys. *Br J Psychiatry* 2010; **197**(2): 114-21.
229. Muntaner C, Eaton WW, Miech R, O'Campo P. Socioeconomic position and major mental disorders. *Epidemiol Rev* 2004; **26**: 53-62.
230. Goodman A, Joyce R, Smith JP. The long shadow cast by childhood physical and mental problems on adult life. *Proceedings of the National Academy of Sciences of the United States of America* 2011; **108**(15): 6032-7.
231. Smith JP, Smith GC. Long-term economic costs of psychological problems during childhood. *Soc Sci Med* 2010; **71**(1): 110-5.
232. Evans-Lacko S, Knapp M. Global patterns of workplace productivity for people with depression: absenteeism and presenteeism costs across eight diverse countries. *Soc Psychiatry Psychiatr Epidemiol* 2016; **51**(11): 1525-37.
233. Stewart WF, Ricci JA, Chee E, Hahn SR, Morganstein D. Cost of lost productive work time among US workers with depression. *Jama* 2003; **289**(23): 3135-44.

234. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? *J Clin Psychiatry* 2003; **64**(12): 1465-75.
235. Forthofer MS, Kessler RC, Story AL, Gotlib IH. The effects of psychiatric disorders on the probability and timing of first marriage. *J Health Soc Behav* 1996; **37**(2): 121-32.
236. Butterworth P, Rodgers B. Mental health problems and marital disruption: is it the combination of husbands and wives' mental health problems that predicts later divorce? *Soc Psychiatry Psychiatr Epidemiol* 2008; **43**(9): 758-63.
237. Breslau J, Miller E, Jin R, et al. A multinational study of mental disorders, marriage, and divorce. *Acta Psychiatr Scand* 2011; **124**(6): 474-86.
238. Culp LN, Beach SR. Marriage and depressive symptoms: The role and bases of self-esteem differ by gender. *Psychology of Women Quarterly* 1998; **22**(4): 647-63.
239. Whisman MA. Marital dissatisfaction and psychiatric disorders: results from the National Comorbidity Survey. *J Abnorm Psychol* 1999; **108**(4): 701-6.
240. Whisman MA. The association between depression and marital dissatisfaction. Marital and family processes in depression: A scientific foundation for clinical practice. Washington: American Psychological Association; 2001.
241. Mamun AA, Clavarino AM, Najman JM, Williams GM, O'Callaghan MJ, Bor W. Maternal depression and the quality of marital relationship: a 14-year prospective study. *Journal of women's health (2002)* 2009; **18**(12): 2023-31.
242. Whisman MA, Uebelacker LA. Prospective associations between marital discord and depressive symptoms in middle-aged and older adults. *Psychology and aging* 2009; **24**(1): 184-9.
243. Proulx CM, Helms HM, Buehler C. Marital Quality and Personal Well-Being: A Meta-Analysis. *Journal of Marriage and Family* 2007; **69**(3): 576-93.
244. Kronmuller KT, Backenstrass M, Victor D, et al. Quality of marital relationship and depression: results of a 10-year prospective follow-up study. *J Affect Disord* 2011; **128**(1-2): 64-71.
245. Pearson KA, Watkins ER, Kuyken W, Mullan EG. The psychosocial context of depressive rumination: ruminative brooding predicts diminished relationship satisfaction in individuals with a history of past major depression. *Br J Clin Psychol* 2010; **49**(Pt 2): 275-80.
246. Riggs DS, Caulfield MB, Street AE. Risk for domestic violence: factors associated with perpetration and victimization. *J Clin Psychol* 2000; **56**(10): 1289-316.
247. Miller E, Breslau J, Petukhova M, et al. Premarital mental disorders and physical violence in marriage: cross-national study of married couples. *Br J Psychiatry* 2011; **199**(4): 330-7.
248. Yu R, Nevado-Holgado AJ, Molero Y, et al. Mental disorders and intimate partner violence perpetrated by men towards women: A Swedish population-based longitudinal study. *PLoS Med* 2019; **16**(12): e1002995.
249. Shen H, Magnusson C, Rai D, et al. Associations of Parental Depression With Child School Performance at Age 16 Years in Sweden. *JAMA Psychiatry* 2016; **73**(3): 239-46.
250. Bauer A, Pawlby S, Plant DT, King D, Pariante CM, Knapp M. Perinatal depression and child development: exploring the economic consequences from a South London cohort. *Psychol Med* 2015; **45**(1): 51-61.
251. Weissman MM. Postpartum Depression and Its Long-term Impact on Children: Many New Questions. *JAMA Psychiatry* 2018; **75**(3): 227-8.
252. Lovejoy MC, Graczyk PA, O'Hare E, Neuman G. Maternal depression and parenting behavior: a meta-analytic review. *Clin Psychol Rev* 2000; **20**(5): 561-92.

253. Wilson S, Durbin CE. Effects of paternal depression on fathers' parenting behaviors: a meta-analytic review. *Clin Psychol Rev* 2010; **30**(2): 167-80.
254. Tronick E, Reck C. Infants of depressed mothers. *Harv Rev Psychiatry* 2009; **17**(2): 147-56.
255. Eckardt JP. Caregivers of people with severe mental illness in the COVID-19 pandemic. *Lancet Psychiatry* 2020; **7**(8): e53.
256. Kim-Cohen J, Caspi A, Moffitt TE, Harrington H, Milne BJ, Poulton R. Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-longitudinal cohort. *Arch Gen Psychiatry* 2003; **60**(7): 709-17.
257. Pine DS, Cohen P, Gurley D, Brook J, Ma Y. The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. *Arch Gen Psychiatry* 1998; **55**(1): 56-64.
258. Rice F, Riglin L, Thapar AK, et al. Characterizing Developmental Trajectories and the Role of Neuropsychiatric Genetic Risk Variants in Early-Onset Depression. *JAMA Psychiatry* 2018.
259. Meier SM, Pavlova B, Dalsgaard S, et al. Attention-deficit hyperactivity disorder and anxiety disorders as precursors of bipolar disorder onset in adulthood. *Br J Psychiatry* 2018; **213**(3): 555-60.
260. Rasic D, Hajek T, Alda M, Uher R. Risk of mental illness in offspring of parents with schizophrenia, bipolar disorder, and major depressive disorder: a meta-analysis of family high-risk studies. *Schizophrenia bulletin* 2014; **40**(1): 28-38.
261. Kendler KS, Ohlsson H, Sundquist K, Sundquist J. Sources of Parent-Offspring Resemblance for Major Depression in a National Swedish Extended Adoption Study. *JAMA Psychiatry* 2018; **75**(2): 194-200.
262. Wray NR, Ripke S, Mattheisen M, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nature genetics* 2018; **50**(5): 668-81.
263. Howard DM, Adams MJ, Clarke TK, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. *Nature neuroscience* 2019; **22**(3): 343-52.
264. Levey DF, Stein MB, Wendt FR, et al. Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. *Nature neuroscience* 2021; **24**(7): 954-63.
265. Musliner KL, Mortensen PB, McGrath JJ, et al. Association of Polygenic Liabilities for Major Depression, Bipolar Disorder, and Schizophrenia With Risk for Depression in the Danish Population. *JAMA Psychiatry* 2019.
266. Li M, D'Arcy C, Meng X. Maltreatment in childhood substantially increases the risk of adult depression and anxiety in prospective cohort studies: systematic review, meta-analysis, and proportional attributable fractions. *Psychol Med* 2016; **46**(4): 717-30.
267. Nanni V, Uher R, Danese A. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. *Am J Psychiatry* 2012; **169**(2): 141-51.
268. Klein DN, Kotov R, Bufferd SJ. Personality and depression: explanatory models and review of the evidence. *Annu Rev Clin Psychol* 2011; **7**: 269-95.
269. Disner SG, Beevers CG, Haigh EA, Beck AT. Neural mechanisms of the cognitive model of depression. *Nat Rev Neurosci* 2011; **12**(8): 467-77.
270. Dobson KS, Dozois DJA. Risk Factors in Depression. Cambridge: Academic Press; 2008(2008).

271. Meaney R, Hasking P, Reupert A. Borderline Personality Disorder Symptoms in College Students: The Complex Interplay between Alexithymia, Emotional Dysregulation and Rumination. *PLoS One* 2016; **11**(6): e0157294.
272. Ellison WD, Rosenstein L, Chelminski I, Dalrymple K, Zimmerman M. The Clinical Significance of Single Features of Borderline Personality Disorder: Anger, Affective Instability, Impulsivity, and Chronic Emptiness in Psychiatric Outpatients. *J Pers Disord* 2016; **30**(2): 261-70.
273. Zimmerman M, Rothschild L, Chelminski I. The prevalence of DSM-IV personality disorders in psychiatric outpatients. *Am J Psychiatry* 2005; **162**(10): 1911-8.
274. Schuch FB, Vancampfort D, Firth J, et al. Physical Activity and Incident Depression: A Meta-Analysis of Prospective Cohort Studies. *Am J Psychiatry* 2018; **175**(7): 631-48.
275. Li Y, Lv M-R, Wei Y-J, et al. Dietary patterns and depression risk: A meta-analysis. *Psychiatry Research* 2017; **253**: 373-82.
276. Gobbi G, Atkin T, Zytynski T, et al. Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis. *JAMA Psychiatry* 2019.
277. Luger TM, Suls J, Vander Weg MW. How robust is the association between smoking and depression in adults? A meta-analysis using linear mixed-effects models. *Addict Behav* 2014; **39**(10): 1418-29.
278. Keyes KM, Galea S. Population health science. Oxford: Oxford University Press; 2016(2016).
279. Lund C, Brooke-Sumner C, Baingana F, et al. Social determinants of mental disorders and the Sustainable Development Goals: a systematic review of reviews. *Lancet Psychiatry* 2018; **5**(4): 357-69.
280. Trevillion K, Oram S, Feder G, Howard LM. Experiences of domestic violence and mental disorders: a systematic review and meta-analysis. *PLoS One* 2012; **7**(12): e51740.
281. Oram S, Khalifeh H, Howard LM. Violence against women and mental health. *Lancet Psychiatry* 2017; **4**(2): 159-70.
282. Stockl H, Devries K, Rotstein A, et al. The global prevalence of intimate partner homicide: a systematic review. *Lancet* 2013; **382**(9895): 859-65.
283. Patel V, Burns JK, Dhingra M, Tarver L, Kohrt BA, Lund C. Income inequality and depression: a systematic review and meta-analysis of the association and a scoping review of mechanisms. *World Psychiatry* 2018; **17**(1): 76-89.
284. Morina N, Akhtar A, Barth J, Schnyder U. Psychiatric Disorders in Refugees and Internally Displaced Persons After Forced Displacement: A Systematic Review. *Front Psychiatry* 2018; **9**: 433.
285. Berk M, Williams LJ, Andreazza AC, et al. Pop, heavy metal and the blues: secondary analysis of persistent organic pollutants (POP), heavy metals and depressive symptoms in the NHANES National Epidemiological Survey. *BMJ Open* 2014; **4**(7): e005142.
286. van den Bosch M, Meyer-Lindenberg A. Environmental Exposures and Depression: Biological Mechanisms and Epidemiological Evidence. *Annu Rev Public Health* 2019; **40**: 239-59.
287. Rutter M. Annual Research Review: Resilience--clinical implications. *J Child Psychol Psychiatry* 2013; **54**(4): 474-87.
288. Herrman H, Stewart DE, Diaz-Granados N, Berger EL, Jackson B, Yuen T. What is resilience? *Can J Psychiatry* 2011; **56**(5): 258-65.
289. Southwick SM, Charney DS. The science of resilience: implications for the prevention and treatment of depression. *Science* 2012; **338**(6103): 79-82.
290. Rutter M. Implications of resilience concepts for scientific understanding. *Ann NY Acad Sci* 2006; **1094**: 1-12.

291. Ungar M, Ghazinour M, Richter J. Annual Research Review: What is resilience within the social ecology of human development? *J Child Psychol Psychiatry* 2013; **54**(4): 348-66.
292. Klengel T, Mehta D, Anacker C, et al. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. *Nature neuroscience* 2013; **16**(1): 33-41.
293. Hammen C. Risk Factors for Depression: An Autobiographical Review. *Annu Rev Clin Psychol* 2018; **14**: 1-28.
294. Nolen-Hoeksema S, Wisco BE, Lyubomirsky S. Rethinking Rumination. *Perspect Psychol Sci* 2008; **3**(5): 400-24.
295. Monroe SM, Simons AD. Diathesis-stress theories in the context of life stress research: implications for the depressive disorders. *Psychol Bull* 1991; **110**(3): 406-25.
296. Fang Y, Scott L, Song P, Burmeister M, Sen S. Genomic prediction of depression risk and resilience under stress. *Nature Human Behaviour* 2020; **4**(1): 111-8.
297. Hankin BL, Abramson LY. Development of gender differences in depression: an elaborated cognitive vulnerability-transactional stress theory. *Psychol Bull* 2001; **127**(6): 773-96.
298. Belsky J, Pluess M. Beyond diathesis stress: differential susceptibility to environmental influences. *Psychol Bull* 2009; **135**(6): 885-908.
299. Clarke TK, Zeng Y, Navrady L, et al. Genetic and environmental determinants of stressful life events and their overlap with depression and neuroticism. *Wellcome open research* 2018; **3**: 11.
300. Schoeler T, Choi SW, Dudbridge F, et al. Multi-Polygenic Score Approach to Identifying Individual Vulnerabilities Associated With the Risk of Exposure to Bullying. *JAMA Psychiatry* 2019.
301. Hammen C. Stress and depression. *Annu Rev Clin Psychol* 2005; **1**: 293-319.
302. Arnau-Soler A, Adams MJ, Clarke TK, et al. A validation of the diathesis-stress model for depression in Generation Scotland. *Translational psychiatry* 2019; **9**(1): 25.
303. Colodro-Conde L, Couvy-Duchesne B, Zhu G, et al. A direct test of the diathesis-stress model for depression. *Molecular psychiatry* 2018; **23**(7): 1590-6.
304. Keers R, Coleman JR, Lester KJ, et al. A Genome-Wide Test of the Differential Susceptibility Hypothesis Reveals a Genetic Predictor of Differential Response to Psychological Treatments for Child Anxiety Disorders. *Psychotherapy and psychosomatics* 2016; **85**(3): 146-58.
305. Marzi SJ, Sugden K, Arseneault L, et al. Analysis of DNA Methylation in Young People: Limited Evidence for an Association Between Victimization Stress and Epigenetic Variation in Blood. *Am J Psychiatry* 2018; **175**(6): 517-29.
306. Danese A, Pariante CM, Caspi A, Taylor A, Poulton R. Childhood maltreatment predicts adult inflammation in a life-course study. *Proceedings of the National Academy of Sciences of the United States of America* 2007; **104**(4): 1319-24.
307. Valles-Colomer M, Falony G, Darzi Y, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. *Nature microbiology* 2019; **4**(4): 623-32.
308. Kelly JR, Borre Y, C OB, et al. Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. *J Psychiatr Res* 2016; **82**: 109-18.
309. Meyer JH, Wilson AA, Segrati S, et al. Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. *Arch Gen Psychiatry* 2009; **66**(12): 1304-12.
310. Setiawan E, Wilson AA, Mizrahi R, et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. *JAMA Psychiatry* 2015; **72**(3): 268-75.

311. Wise T, Radua J, Via E, et al. Common and distinct patterns of grey-matter volume alteration in major depression and bipolar disorder: evidence from voxel-based meta-analysis. *Molecular psychiatry* 2017; **22**(10): 1455-63.
312. Miller CH, Hamilton JP, Sacchet MD, Gotlib IH. Meta-analysis of Functional Neuroimaging of Major Depressive Disorder in Youth. *JAMA Psychiatry* 2015; **72**(10): 1045-53.
313. Baxter LR, Jr., Schwartz JM, Phelps ME, et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. *Arch Gen Psychiatry* 1989; **46**(3): 243-50.
314. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. *Proceedings of the National Academy of Sciences of the United States of America* 1996; **93**(9): 3908-13.
315. Mayberg HS. Limbic-cortical dysregulation: a proposed model of depression. *The Journal of neuropsychiatry and clinical neurosciences* 1997; **9**(3): 471-81.
316. Williams LM. Defining biotypes for depression and anxiety based on large-scale circuit dysfunction: a theoretical review of the evidence and future directions for clinical translation. *Depression and anxiety* 2017; **34**(1): 9-24.
317. Drevets WC, Price JL, Bardgett ME, Reich T, Todd RD, Raichle ME. Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. *Pharmacology, biochemistry, and behavior* 2002; **71**(3): 431-47.
318. Dunn RT, Kimbrell TA, Ketter TA, et al. Principal components of the Beck Depression Inventory and regional cerebral metabolism in unipolar and bipolar depression. *Biological psychiatry* 2002; **51**(5): 387-99.
319. Friston KJ. Functional and effective connectivity in neuroimaging: A synthesis. *Human Brain Mapping* 1994; **2**(1-2): 56-78.
320. Arfanakis K, Cordes D, Haughton VM, Moritz CH, Quigley MA, Meyerand ME. Combining independent component analysis and correlation analysis to probe interregional connectivity in fMRI task activation datasets. *Magnetic resonance imaging* 2000; **18**(8): 921-30.
321. Smith SM, Fox PT, Miller KL, et al. Correspondence of the brain's functional architecture during activation and rest. *Proceedings of the National Academy of Sciences of the United States of America* 2009; **106**(31): 13040-5.
322. Biswal BB, Mennes M, Zuo XN, et al. Toward discovery science of human brain function. *Proceedings of the National Academy of Sciences of the United States of America* 2010; **107**(10): 4734-9.
323. Drysdale AT, Grosenick L, Downar J, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. *Nature medicine* 2017; **23**(1): 28-38.
324. Ferenczi EA, Zalocusky KA, Liston C, et al. Prefrontal cortical regulation of brainwide circuit dynamics and reward-related behavior. *Science* 2016; **351**(6268): aac9698.
325. Duman CH, Duman RS. Spine synapse remodeling in the pathophysiology and treatment of depression. *Neuroscience letters* 2015; **601**: 20-9.
326. Hamani C, Amorim BO, Wheeler AL, et al. Deep brain stimulation in rats: different targets induce similar antidepressant-like effects but influence different circuits. *Neurobiology of disease* 2014; **71**: 205-14.
327. Watters AJ, Carpenter JS, Harris AWF, Korgaonkar MS, Williams LM. Characterizing neurocognitive markers of familial risk for depression using multi-modal imaging, behavioral and self-report measures. *J Affect Disord* 2019; **253**: 336-42.
328. Gee DG, Gabard-Durnam LJ, Flannery J, et al. Early developmental emergence of human amygdala-prefrontal connectivity after maternal deprivation. *Proceedings of the National Academy of Sciences of the United States of America* 2013; **110**(39): 15638-43.

329. Gatt JM, Nemeroff CB, Dobson-Stone C, et al. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. *Molecular psychiatry* 2009; **14**(7): 681-95.
330. McEwen BS, Morrison JH. The brain on stress: vulnerability and plasticity of the prefrontal cortex over the life course. *Neuron* 2013; **79**(1): 16-29.
331. Russo SJ, Murrough JW, Han MH, Charney DS, Nestler EJ. Neurobiology of resilience. *Nature neuroscience* 2012; **15**(11): 1475-84.
332. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. *British medical bulletin* 2003; **65**: 193-207.
333. McGrath CL, Kelley ME, Holtzheimer PE, et al. Toward a neuroimaging treatment selection biomarker for major depressive disorder. *JAMA Psychiatry* 2013; **70**(8): 821-9.
334. Dunlop BW, Rajendra JK, Craighead WE, et al. Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder. *Am J Psychiatry* 2017; **174**(6): 533-45.
335. Kelley ME, Choi KS, Rajendra JK, et al. Establishing Evidence for Clinical Utility of a Neuroimaging Biomarker in Major Depressive Disorder: Prospective Testing and Implementation Challenges. *Biological psychiatry* 2021.
336. Riva-Posse P, Choi KS, Holtzheimer PE, et al. A connectomic approach for subcallosal cingulate deep brain stimulation surgery: prospective targeting in treatment-resistant depression. *Molecular psychiatry* 2018; **23**(4): 843-9.
337. Weigand A, Horn A, Caballero R, et al. Prospective Validation That Subgenual Connectivity Predicts Antidepressant Efficacy of Transcranial Magnetic Stimulation Sites. *Biological psychiatry* 2018; **84**(1): 28-37.
338. Raison CL, Rutherford RE, Woolwine BJ, et al. A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression. *JAMA Psychiatry* 2013; **70**(1): 31.
339. Vistorte AOR, Ribeiro WS, Jaen D, Jorge MR, Evans-Lacko S, Mari JdJ. Stigmatizing attitudes of primary care professionals towards people with mental disorders: A systematic review. *The International Journal of Psychiatry in Medicine* 2018; **53**(4): 317-38.
340. Farrelly S, Jeffery D, Ruesch N, Williams P, Thornicroft G, Clement S. The link between mental health-related discrimination and suicidality: service user perspectives. *Psychological medicine* 2015; **45**(10): 2013-22.
341. Schnyder N, Panczak R, Groth N, Schultze-Lutter F. Association between mental health-related stigma and active help-seeking: Systematic review and meta-analysis. *British Journal of Psychiatry* 2017; **210**(4): 261-8.
342. Pescosolido BA, Martin JK, Long JS, Medina TR, Phelan JC, Link BG. "A disease like any other"? A decade of change in public reactions to schizophrenia, depression, and alcohol dependence. *American Journal of Psychiatry* 2010; **167**(11): 1321-30.
343. Wood L, Birtel M, Alsawy S, Pyle M, Morrison A. Public perceptions of stigma towards people with schizophrenia, depression, and anxiety. *Psychiatry Research* 2014; **220**(1): 604-8.
344. Griffiths KM, Christensen H, Jorm AF. Predictors of depression stigma. *BMC Psychiatry* 2008; **8**(1): 25.
345. Hanisch SE, Twomey CD, Szeto AC, Birner UW, Nowak D, Sabariego C. The effectiveness of interventions targeting the stigma of mental illness at the workplace: a systematic review. *BMC Psychiatry* 2016; **16**(1): 1.

346. Elbogen EB, Johnson SC. The intricate link between violence and mental disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry* 2009; **66**(2): 152-61.
347. Reavley NJ, Jorm AF. Recognition of mental disorders and beliefs about treatment and outcome: findings from an Australian national survey of mental health literacy and stigma. *Aust N Z J Psychiatry* 2011; **45**(11): 947-56.
348. Scazufca M, MC PdPC, Huang H, et al. Public Stigma towards Older Adults with Depression: Findings from the São Paulo-Manaus Elderly in Primary Care Study. *PLoS One* 2016; **11**(6): e0157719.
349. Yang F, Yang BX, Stone TE, et al. Stigma towards depression in a community-based sample in China. *Compr Psychiatry* 2020; **97**: 152152.
350. Boti N, Hussen S, Ayele G, et al. Community Perception and Attitude towards people with Depression among Adults Residing in Arba Minch Health and Demographic Surveillance Site (AM-HDSS), Southern Ethiopia. *Ethiop J Health Sci* 2020; **30**(4): 567-78.
351. Kohrt BA, Harper I. Navigating diagnoses: understanding mind-body relations, mental health, and stigma in Nepal. *Culture, Medicine & Psychiatry* 2008; **32**(4): 462-91.
352. Singh S, Zaki RA, Farid NDN. A systematic review of depression literacy: Knowledge, help-seeking and stigmatising attitudes among adolescents. *Journal of Adolescence* 2019; **74**: 154-72.
353. Jorm AF. Mental health literacy: empowering the community to take action for better mental health. *Am Psychol* 2012; **67**(3): 231-43.
354. Angermeyer MC, Schomerus G. State of the art of population-based attitude research on mental health: a systematic review. *Epidemiology and psychiatric sciences* 2017; **26**(3): 252-64.
355. Thornicroft G, Chatterji S, Evans-Lacko S, et al. Undertreatment of people with major depressive disorder in 21 countries. *Br J Psychiatry* 2017; **210**(2): 119-24.
356. Furnham A, Swami V. Mental health literacy: A review of what it is and why it matters. *International Perspectives in Psychology: Research, Practice, Consultation* 2018; **7**(4): 240-57.
357. Dumesnil H, Verger P. Public awareness campaigns about depression and suicide: a review. *Psychiatric Services* 2009; **60**(9): 1203-13.
358. Loughman A, Haslam N. Neuroscientific explanations and the stigma of mental disorder: a meta-analytic study. *Cognitive Research: Principles and Implications* 2018; **3**(1): 43.
359. Andersson MA, Harkness SK. When Do Biological Attributions of Mental Illness Reduce Stigma? Using Qualitative Comparative Analysis to Contextualize Attributions. *Society and Mental Health* 2017; **8**(3): 175-94.
360. Cheng ZH. Asian Americans and European Americans' stigma levels in response to biological and social explanations of depression. *Social Psychiatry and Psychiatric Epidemiology* 2015; **50**(5): 767-76.
361. Gaebel W, Rössler W, Sartorius N. *The Stigma of Mental Illness—End of the Story?* . New York: Springer; 2016(2016).
362. Thornicroft G, Mehta N, Clement S, et al. Evidence for effective interventions to reduce mental-health-related stigma and discrimination. *The Lancet* 2015.
363. Gronholm PC, Henderson C, Deb T, Thornicroft G. Interventions to reduce discrimination and stigma: the state of the art. *Social Psychiatry and Psychiatric Epidemiology* 2017; **52**(3): 249-58.
364. Morgan AJ, Ross A, Reavley NJ. Systematic review and meta-analysis of Mental Health First Aid training: Effects on knowledge, stigma, and helping behaviour. *PLOS ONE* 2018; **13**(5): e0197102.

365. Heim E, Kohrt BA, Koschorke M, Milenova M, Thornicroft G. Reducing mental health-related stigma in primary health care settings in low- and middle-income countries: a systematic review. *Epidemiology and Psychiatric Sciences* 2018; 1-10.
366. Nyblade L, Stockton MA, Giger K, et al. Stigma in health facilities: why it matters and how we can change it. *BMC Medicine* 2019; **17**(1): 25.
367. Heim E, Henderson C, Kohrt BA, Koschorke M, Milenova M, Thornicroft G. Reducing mental health-related stigma among medical and nursing students in low- and middle-income countries: a systematic review. *Epidemiology and Psychiatric Sciences* 2020; **29**: e28.
368. Corrigan PW, Morris SB, Michaels PJ, Rafacz JD, Rüsçh N. Challenging the public stigma of mental illness: a meta-analysis of outcome studies. *Psychiatr Serv* 2012; **63**(10): 963-73.
369. Tergesen CL, Gurung D, Dhungana S, et al. Impact of Service User Video Presentations on Explicit and Implicit Stigma toward Mental Illness among Medical Students in Nepal: A Randomized Controlled Trial. *International Journal of Environmental Research and Public Health* 2021; **18**(4).
370. Sylwestrzak A, Overholt CE, Ristau KI, Coker KL. Self-reported barriers to treatment engagement: adolescent perspectives from the National Comorbidity Survey-Adolescent supplement (NCS-A). *Community mental health journal* 2015; **51**(7): 775-81.
371. Haller DM, Sanci LA, Sawyer SM, Patton GC. The identification of young people's emotional distress: a study in primary care. *Br J Gen Pract* 2009; **59**(560): e61-e70.
372. Wasserman C, Postuvan V, Herta D, Iosue M, Värnik P, Carli V. Interactions between youth and mental health professionals: The Youth Aware of Mental health (YAM) program experience. *PLoS One* 2018; **13**(2): e0191843.
373. Pescosolido BA, Jensen PS, Martin JK, Perry BL, Olafsdottir S, Fettes D. Public knowledge and assessment of child mental health problems: Findings from the National Stigma Study-Children. *Journal of the American Academy of Child & Adolescent Psychiatry* 2008; **47**(3): 339-49.
374. Johnco C, Rapee RM. Depression literacy and stigma influence how parents perceive and respond to adolescent depressive symptoms. *Journal of affective disorders* 2018.
375. Salerno JP. Effectiveness of Universal School-Based Mental Health Awareness Programs Among Youth in the United States: A Systematic Review. *Journal of school health* 2016; **86**(12): 922-31.
376. Kutcher S, Wei Y, Morgan C. Successful application of a Canadian mental health curriculum resource by usual classroom teachers in significantly and sustainably improving student mental health literacy. *The Canadian Journal of Psychiatry* 2015; **60**(12): 580-6.
377. Swartz KL, Kastelic EA, Hess SG, et al. The effectiveness of a school-based adolescent depression education program. *Health Education & Behavior* 2010; **37**(1): 11-22.
378. Ruble AE, Leon PJ, Gilley-Hensley L, Hess SG, Swartz KL. Depression knowledge in high school students: Effectiveness of the adolescent depression awareness program. *Journal of affective disorders* 2013; **150**(3): 1025-30.
379. Beaudry MB, Swartz K, Miller L, Schweizer B, Glazer K, Wilcox H. Effectiveness of the Adolescent Depression Awareness Program (ADAP) on depression literacy and mental health treatment. *Journal of school health* 2019; **89**(3): 165-72.
380. Wasserman D, Carli V, Wasserman C, et al. Saving and Empowering Young Lives in Europe (SEYLE): a randomized controlled trial. *BMC Public Health* 2010; **10**(1): 192.
381. Wei Y, Hayden JA, Kutcher S, Zygumnt A, McGrath P. The effectiveness of school mental health literacy programs to address knowledge, attitudes and help seeking among youth. *Early intervention in psychiatry* 2013; **7**(2): 109-21.

382. McLuckie A, Kutcher S, Wei Y, Weaver C. Sustained improvements in students' mental health literacy with use of a mental health curriculum in Canadian schools. *BMC psychiatry* 2014; **14**(1): 379.
383. Wasserman D, Hoven CW, Wasserman C, et al. School-based suicide prevention programmes: the SEYLE cluster-randomised, controlled trial. *Lancet* 2015; **385**(9977): 1536-44.
384. Gelhorn HL, Sexton CC, Classi PM. Patient preferences for treatment of major depressive disorder and the impact on health outcomes: a systematic review. *Prim Care Companion CNS Disord* 2011; **13**(5): PCC.11r01161.
385. McHugh RK, Whitton SW, Peckham AD, Welge JA, Otto MW. Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. *The Journal of clinical psychiatry* 2013; **74**(6): 595-602.
386. Churchill R, Khaira M, Gretton V, et al. Treating depression in general practice: factors affecting patients' treatment preferences. *Br J Gen Pract* 2000; **50**(460): 905-6.
387. Luck-Sikorski C, Stein J, Heilmann K, et al. Treatment preferences for depression in the elderly. *International Psychogeriatrics* 2017; **29**(3): 389-98.
388. Castaldelli-Maia JM, Scomparini LB, Andrade AGd, Bhugra D, de Toledo Ferraz Alves TC, D'Elia G. Perceptions of and Attitudes Toward Antidepressants: Stigma Attached to Their Use-A Review. *The Journal of Nervous and Mental Disease* 2011; **199**(11): 866-71.
389. Bradley KL, McGrath PJ, Brannen CL, Bagnell AL. Adolescents' Attitudes and Opinions about Depression Treatment. *Community Mental Health Journal* 2010; **46**(3): 242-51.
390. van Schaik DJF, Klijn AFJ, van Hout HPJ, et al. Patients' preferences in the treatment of depressive disorder in primary care. *General Hospital Psychiatry* 2004; **26**(3): 184-9.
391. Hanson K, Webb TL, Sheeran P, Turpin G. Attitudes and Preferences towards Self-help Treatments for Depression in Comparison to Psychotherapy and Antidepressant Medication. *Behavioural and Cognitive Psychotherapy* 2016; **44**(2): 129-39.
392. Partridge B, Lucke J, Hall W. Over-diagnosed and over-treated: a survey of Australian public attitudes towards the acceptability of drug treatment for depression and ADHD. *BMC Psychiatry* 2014; **14**(1): 74.
393. Dowrick C, Frances A. Medicalising unhappiness: new classification of depression risks more patients being put on drug treatment from which they will not benefit. *BMJ : British Medical Journal* 2013; **347**: f7140.
394. Reynolds CF, 3rd, Clayton PJ. Commentary: Out of the silence: confronting depression in medical students and residents. *Acad Med* 2009; **84**(2): 159-60.
395. Moutier C, Norcross W, Jong P, et al. The suicide prevention and depression awareness program at the University of California, San Diego School of Medicine. *Acad Med* 2012; **87**(3): 320-6.
396. Center C, Davis M, Detre T, et al. Confronting depression and suicide in physicians: a consensus statement. *Jama* 2003; **289**(23): 3161-6.
397. Henderson C, Noblett J, Parke H, et al. Mental health-related stigma in health care and mental health-care settings. *The Lancet Psychiatry* 2014; **1**(6): 467-82.
398. Fekadu A, Medhin G, Selamu M, et al. Recognition of depression by primary care clinicians in rural Ethiopia. *BMC Family Practice* 2017; **18**(1): 56.
399. Alexander CL, Arnkoff DB, Glass CR, Kaburu AW. Detecting depression in rural primary care clinics in central Kenya: Impact of a brief training intervention. *International Perspectives in Psychology: Research, Practice, Consultation* 2013; **2**(1): 14-28.

400. Leff MS, Vrublevska J, Lūse A, Rancāns E. Latvian family physicians' experience diagnosing depression in somatically presenting depression patients: A qualitative study. *European Journal of General Practice* 2017; **23**(1): 91-7.
401. Wilson DR, Widmer RB, Cadoret RJ, Judiesch K. Somatic symptoms: A major feature of depression in a family practice. *Journal of Affective Disorders* 1983; **5**(3): 199-207.
402. Herrman H, Saxena S, Moodie R. Promoting Mental Health: Concepts, Emerging Evidence and Practice. Geneva: WHO; 20052005).
403. National Academies of Sciences Engineering and Medicine. Fostering Healthy Mental, Emotional, and Behavioral Development in Children and Youth: A National Agenda. Washington, DC: The National Academies Press; 2019. <https://www.nap.edu/catalog/25201/fostering-healthy-mental-emotional-and4080-behavioral-development-in-children-and-youth2019>.
404. Mendelson T, Pas ET, Lee-Winn A, et al. The logic and practice of the prevention of mental disorders. In: Eaton WW, Fallin D, eds. Public mental health 2nd ed. New York: OUP; 2019: 489-547.
405. Jorm AF, Mulder RT. Prevention of mental disorders requires action on adverse childhood experiences. *Aust N Z J Psychiatry* 2018; **52**(4): 316-9.
406. Andrews G, Basu A, Cuijpers P, et al. Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: An updated meta-analysis. *J Anxiety Disord* 2018; **55**: 70-8.
407. Buntrock C, Ebert DD, Lehr D, et al. Effect of a Web-Based Guided Self-help Intervention for Prevention of Major Depression in Adults With Subthreshold Depression: A Randomized Clinical Trial. *Jama* 2016; **315**(17): 1854-63.
408. Cuijpers P, Donker T, van Straten A, Li J, Andersson G. Is guided self-help as effective as face-to-face psychotherapy for depression and anxiety disorders? A systematic review and meta-analysis of comparative outcome studies. *Psychol Med* 2010; **40**(12): 1943-57.
409. Jacka FN, Reavley NJ, Jorm AF, Toumbourou JW, Lewis AJ, Berk M. Prevention of common mental disorders: what can we learn from those who have gone before and where do we go next? *Aust N Z J Psychiatry* 2013; **47**(10): 920-9.
410. Mendelson T, Eaton WW. Recent advances in the prevention of mental disorders. *Soc Psychiatry Psychiatr Epidemiol* 2018; **53**(4): 325-39.
411. Deady M, Choi I, Calvo RA, Glozier N, Christensen H, Harvey SB. eHealth interventions for the prevention of depression and anxiety in the general population: a systematic review and meta-analysis. *BMC Psychiatry* 2017; **17**(1): 310.
412. Cuijpers P, Pineda BS, Quero S, et al. Psychological interventions to prevent the onset of depressive disorders: A meta-analysis of randomized controlled trials. *Clin Psychol Rev* 2021; **83**: 101955.
413. Knapp M, Wong G. Economics and mental health: the current scenario. *World Psychiatry* 2020; **19**(1): 3-14.
414. Duevel JA, Hasemann L, Peña-Longobardo LM, et al. Considering the societal perspective in economic evaluations: a systematic review in the case of depression. *Health Econ Rev* 2020; **10**(1): 32-.
415. US Preventive Services Task Force. Interventions to Prevent Perinatal Depression: US Preventive Services Task Force Recommendation Statement. *JAMA* 2019; **321**(6): 580-7.
416. Daley AJ, Foster L, Long G, et al. The effectiveness of exercise for the prevention and treatment of antenatal depression: systematic review with meta-analysis. *BJOG: An International Journal Of Obstetrics And Gynaecology* 2015; **122**(1): 57-62.
417. Freeman MP. Perinatal Depression: Recommendations for Prevention and the Challenges of Implementation. *Jama* 2019; **321**(6): 550-2.

418. Weissman MM, Markowitz JC. *The Guide to Interpersonal Psychotherapy: Updated and Expanded Edition Expanded, Updated Edition*: Oxford Press; 2018(2018).
419. Morrell CJ, Sutcliffe P, Booth A, et al. A systematic review, evidence synthesis and meta-analysis of quantitative and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and acceptability of interventions to prevent postnatal depression. *Health Technol Assess* 2016; **20**(37): 1-414.
420. Fuhr DC, Weobong B, Lazarus A, et al. Delivering the Thinking Healthy Programme for perinatal depression through peers: an individually randomised controlled trial in India. *Lancet Psychiatry* 2019; **6**(2): 115-27.
421. Sikander S, Ahmad I, Atif N, et al. Delivering the Thinking Healthy Programme for perinatal depression through volunteer peers: a cluster randomised controlled trial in Pakistan. *Lancet Psychiatry* 2019; **6**(2): 128-39.
422. Brugha TS, Morrell CJ, Slade P, Walters SJ. Universal prevention of depression in women postnatally: cluster randomized trial evidence in primary care. *Psychological Medicine* 2011; **41**(4): 739-48.
423. Henderson C, Dixon S, Bauer A, et al. Cost-effectiveness of PoNDER health visitor training for mothers at lower risk of depression: findings on prevention of postnatal depression from a cluster-randomised controlled trial. *Psychol Med* 2019; **49**(8): 1324-34.
424. Borschmann R, Molyneaux E, Spry E, et al. Pre-conception self-harm, maternal mental health and mother-infant bonding problems: a 20-year prospective cohort study. *Psychol Med* 2019; **49**(16): 2727-35.
425. Spry E, Moreno-Betancur M, Becker D, et al. Maternal mental health and infant emotional reactivity: a 20-year two-cohort study of preconception and perinatal exposures. *Psychol Med* 2019: 1-11.
426. Patton GC, Romaniuk H, Spry E, et al. Prediction of perinatal depression from adolescence and before conception (VIHCS): 20-year prospective cohort study. *Lancet* 2015; **386**(9996): 875-83.
427. Patton GC, Olsson CA, Skirbekk V, et al. Adolescence and the next generation. *Nature* 2018; **554**(7693): 458-66.
428. Ahlen J, Lenhard F, Ghaderi A. Universal Prevention for Anxiety and Depressive Symptoms in Children: A Meta-analysis of Randomized and Cluster-Randomized Trials. *J Prim Prev* 2015; **36**(6): 387-403.
429. Corrieri S, Heider D, Conrad I, Blume A, Konig HH, Riedel-Heller SG. School-based prevention programs for depression and anxiety in adolescence: a systematic review. *Health Promot Int* 2014; **29**(3): 427-41.
430. Hetrick SE, Cox GR, Merry SN. Where to go from here? An exploratory meta-analysis of the most promising approaches to depression prevention programs for children and adolescents. *Int J Environ Res Public Health* 2015; **12**(5): 4758-95.
431. Hetrick SE, Cox GR, Witt KG, Bir JJ, Merry SN. Cognitive behavioural therapy (CBT), third-wave CBT and interpersonal therapy (IPT) based interventions for preventing depression in children and adolescents. *The Cochrane Database Of Systematic Reviews* 2016; (8): CD003380.
432. Loechner J, Starman K, Galuschka K, et al. Preventing depression in the offspring of parents with depression: A systematic review and meta-analysis of randomized controlled trials. *Clin Psychol Rev* 2018; **60**: 1-14.
433. Rasing SPA, Creemers DHM, Janssens J, Scholte RHJ. Depression and Anxiety Prevention Based on Cognitive Behavioral Therapy for At-Risk Adolescents: A Meta-Analytic Review. *Front Psychol* 2017; **8**: 1066.

434. Werner-Seidler A, Perry Y, Calear AL, Newby JM, Christensen H. School-based depression and anxiety prevention programs for young people: A systematic review and meta-analysis. *Clinical Psychology Review* 2017; **51**: 30-47.
435. Yap MBH, Morgan AJ, Cairns K, Jorm AF, Hetrick SE, Merry S. Parents in prevention: A meta-analysis of randomized controlled trials of parenting interventions to prevent internalizing problems in children from birth to age 18. *Clinical Psychology Review* 2016; **50**: 138-58.
436. Arseneault L. Annual Research Review: The persistent and pervasive impact of being bullied in childhood and adolescence: implications for policy and practice. *J Child Psychol Psychiatry* 2018; **59**(4): 405-21.
437. Shinde S, Weiss HA, Khandeparkar P, et al. A multicomponent secondary school health promotion intervention and adolescent health: An extension of the SEHER cluster randomised controlled trial in Bihar, India. *PLoS Med* 2020; **17**(2): e1003021.
438. Rith-Najarian LR, Boustani MM, Chorpita BF. A systematic review of prevention programs targeting depression, anxiety, and stress in university students. *J Affect Disord* 2019; **257**: 568-84.
439. Lynch FL, Dickerson JF, Clarke GN, et al. Cost-Effectiveness of Preventing Depression Among At-Risk Youths: Postintervention and 2-Year Follow-Up. *Psychiatr Serv* 2019; **70**(4): 279-86.
440. Taylor RD, Oberle E, Durlak JA, Weissberg RP. Promoting Positive Youth Development Through School-Based Social and Emotional Learning Interventions: A Meta-Analysis of Follow-Up Effects. *Child Dev* 2017; **88**(4): 1156-71.
441. Knapp M, McDaid D, Parsonage M. Mental health promotion and mental illness prevention: The economic case. London: Department of Health; 2011(2011).
442. McDaid D, Park A-L, Knapp M, Wilson E, Rosen B, Beecham J. Commissioning cost-effective services for promotion of mental health and wellbeing and prevention of mental ill-health. London: Public Health England; 2017(2017).
443. van der Noordt M, Ijzelenberg H, Droomers M, Proper KI. Health effects of employment: a systematic review of prospective studies. *Occupational And Environmental Medicine* 2014; **71**(10): 730-6.
444. Modini M, Joyce S, Mykletun A, et al. The mental health benefits of employment: Results of a systematic meta-review. *Australasian Psychiatry: Bulletin Of Royal Australian And New Zealand College Of Psychiatrists* 2016; **24**(4): 331-6.
445. Joyce S, Modini M, Christensen H, et al. Workplace interventions for common mental disorders: a systematic meta-review. *Psychological medicine* 2016; **46**(4): 683-97.
446. Tan L, Wang M-J, Modini M, et al. Preventing the development of depression at work: a systematic review and meta-analysis of universal interventions in the workplace. *BMC Medicine* 2014; **12**: 74-.
447. Nigatu YT, Huang J, Rao S, Gillis K, Merali Z, Wang J. Indicated Prevention Interventions in the Workplace for Depressive Symptoms: A Systematic Review and Meta-analysis. *Am J Prev Med* 2019; **56**(1): e23-e33.
448. de Oliveira C, Cho E, Kavelaars R, Jamieson M, Bao B, Rehm J. Economic analyses of mental health and substance use interventions in the workplace: a systematic literature review and narrative synthesis. *Lancet Psychiatry* 2020; **7**(10): 893-910.
449. van Zoonen K, Buntrock C, Ebert DD, et al. Preventing the onset of major depressive disorder: a meta-analytic review of psychological interventions. *Int J Epidemiol* 2014; **43**(2): 318-29.
450. Conejo-Ceron S, Moreno-Peral P, Rodriguez-Morejon A, et al. Effectiveness of Psychological and Educational Interventions to Prevent Depression in Primary Care: A Systematic Review and Meta-Analysis. *Ann Fam Med* 2017; **15**(3): 262-71.

451. Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. *BMJ (Clinical Research Ed)* 2014; **348**: g1151-g.
452. Kvam S, Kleppe CL, Nordhus IH, Hovland A. Exercise as a treatment for depression: A meta-analysis. *Journal Of Affective Disorders* 2016; **202**: 67-86.
453. Cooney G, Dwan K, Mead G. Exercise for depression. *Jama* 2014; **311**(23): 2432-3.
454. Mammen G, Faulkner G. Physical activity and the prevention of depression: a systematic review of prospective studies. *American Journal Of Preventive Medicine* 2013; **45**(5): 649-57.
455. Pascoe MC, Parker AG. Physical activity and exercise as a universal depression prevention in young people: A narrative review. *Early Interv Psychiatry* 2019; **13**(4): 733-9.
456. Nakamura A, van der Waerden J, Melchior M, Bolze C, El-Khoury F, Pryor L. Physical activity during pregnancy and postpartum depression: Systematic review and meta-analysis. *J Affect Disord* 2019; **246**: 29-41.
457. Berk M, Jacka FN. Diet and Depression-From Confirmation to Implementation. *Jama* 2019; **321**(9): 842-3.
458. Howard LM, Trevillion K, Khalifeh H, Woodall A, Agnew-Davies R, Feder G. Domestic violence and severe psychiatric disorders: prevalence and interventions. *Psychol Med* 2010; **40**(6): 881-93.
459. Trevillion K, Hughes B, Feder G, Borschmann R, Oram S, Howard LM. Disclosure of domestic violence in mental health settings: a qualitative meta-synthesis. *International review of psychiatry (Abingdon, England)* 2014; **26**(4): 430-44.
460. Xiao CL, Gavrilidis E, Lee S, Kulkarni J. Do mental health clinicians elicit a history of previous trauma in female psychiatric inpatients? *Journal of mental health (Abingdon, England)* 2016; **25**(4): 359-65.
461. Feder G, Davies RA, Baird K, et al. Identification and Referral to Improve Safety (IRIS) of women experiencing domestic violence with a primary care training and support programme: a cluster randomised controlled trial. *Lancet* 2011; **378**(9805): 1788-95.
462. Stewart DE, Chandra PS. WPA International Competency-Based Curriculum for Mental Health Providers on Intimate Partner Violence and Sexual Violence Against Women. *World Psychiatry* 2017; **16**(2): 223-4.
463. Gu J, Huang H, Chen K, Huang G, Huang Y, Xu H. Are they necessary? Preventive therapies for post-stroke depression: A meta-analysis of RCTs. *Psychiatry Res* 2020; **284**: 112670.
464. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose vitamin D3 and mental well-being: randomised controlled trial. *Br J Psychiatry* 2011; **198**(5): 357-64.
465. Berk M, Woods RL, Nelson MR, et al. Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial. *JAMA Psychiatry* 2020.
466. Courtin E, Knapp M. Social isolation, loneliness and health in old age: a scoping review. *Health Soc Care Community* 2017; **25**(3): 799-812.
467. National Institute for Health and Care Excellence. Older people: independence and mental wellbeing. London: NICE; 20152015).
468. Masi CM, Chen HY, Hawkey LC, Cacioppo JT. A meta-analysis of interventions to reduce loneliness. *Pers Soc Psychol Rev* 2011; **15**(3): 219-66.
469. Figueroa CA, Aguilera A. The Need for a Mental Health Technology Revolution in the COVID-19 Pandemic. *Front Psychiatry* 2020; **11**: 523.
470. Armitage R, Nellums LB. COVID-19 and the consequences of isolating the elderly. *Lancet Public Health* 2020; **5**(5): e256.

471. Dias A, Azariah F, Anderson SJ, et al. Effect of a Lay Counselor Intervention on Prevention of Major Depression in Older Adults Living in Low- and Middle-Income Countries: A Randomized Clinical Trial. *JAMA Psychiatry* 2019; **76**(1): 13-20.
472. Institute of Medicine. Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research. Washington, D.C. : The National Academies Press; 1994. <https://www.nap.edu/catalog/2139/reducing-risks-for-mental-disorders-frontiers-for-preventive-intervention-research1994>).
473. Council;; NR, Medicine;; Io. Preventing Mental, Emotional, and Behavioral Disorders Among Young People: Progress and Possibilities. Washington, D.C.: National Academies Press; 2009. <https://www.nap.edu/catalog/12480/preventing-mental-emotional-and-behavioral-disorders-among-young-people-progress2009>).
474. Beddington J, Cooper CL, Field J, et al. The mental wealth of nations. *Nature* 2008; **455**(7216): 1057-60.
475. Frieden TR. A framework for public health action: the health impact pyramid. *Am J Public Health* 2010; **100**(4): 590-5.
476. Masters R, Anwar E, Collins B, Cookson R, Capewell S. Return on investment of public health interventions: a systematic review. *J Epidemiol Community Health* 2017; **71**(8): 827-34.
477. Patel V. Reimagining outcomes requires reimagining mental health conditions. *World Psychiatry* 2019; **18**(3): 286-7.
478. Angeles G, de Hoop J, Handa S, Kilburn K, Milazzo A, Peterman A. Government of Malawi's unconditional cash transfer improves youth mental health. *Soc Sci Med* 2019; **225**: 108-19.
479. Yu S. Uncovering the hidden impacts of inequality on mental health: a global study. *Translational psychiatry* 2018; **8**(1): 98-.
480. Hyde JS, Mezulis AH. Gender Differences in Depression: Biological, Affective, Cognitive, and Sociocultural Factors. *Harv Rev Psychiatry* 2020; **28**(1): 4-13.
481. Seedat S, Scott KM, Angermeyer MC, et al. Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys. *Arch Gen Psychiatry* 2009; **66**(7): 785-95.
482. Nishtar S, Niinistö S, Sirisena M, et al. Time to deliver: report of the WHO Independent High-Level Commission on NCDs. *Lancet* 2018; **392**(10143): 245-52.
483. Hutter RV. At last - worldwide agreement on the staging of cancer: presidential address. *Arch Surg* 1987; **122**(11): 1235-9.
484. Fava GA, Kellner R. Staging: a neglected dimension in psychiatric classification. *Acta Psychiatr Scand* 1993; **87**(4): 225-30.
485. McGorry PD. Issues for DSM-V: clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. *Am J Psychiatry* 2007; **164**(6): 859-60.
486. Shah JL, Scott J, McGorry PD, et al. Transdiagnostic clinical staging in youth mental health: a first international consensus statement. *World Psychiatry* 2020; **19**(2): 233-42.
487. Davey CG, McGorry PD. Early intervention for depression in young people: a blind spot in mental health care. *Lancet Psychiatry* 2019; **6**(3): 267-72.
488. Monroe SM, Harkness KL. Recurrence in major depression: a conceptual analysis. *Psychol Rev* 2011; **118**(4): 655-74.
489. MacQueen GM, Campbell S, McEwen BS, et al. Course of illness, hippocampal function, and hippocampal volume in major depression. *Proceedings of the National Academy of Sciences of the United States of America* 2003; **100**(3): 1387-92.
490. Schmaal L, Veltman DJ, Van Erp TGM, et al. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA major depressive disorder working group. *Molecular psychiatry* 2016; **21**(6): 806-12.

491. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. *Molecular psychiatry* 2013; **18**(5): 595-606.
492. Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: A primer on neuron death. *Biological psychiatry* 2000; **48**(8): 755-65.
493. McGorry P, Bates T, Birchwood M. Designing youth mental health services for the 21st century: examples from Australia, Ireland and the UK. *Br J Psychiatry* 2013; **202**(SUPPL. 54): s30-s5.
494. McGorry PD, Goldstone SD, Parker AG, Rickwood DJ, Hickie IB. Cultures for mental health care of young people: an Australian blueprint for reform. *Lancet Psychiatry* 2014; **1**(7): 559-68.
495. Kilpatrick DG, Ruggiero KJ, Acierno R, Saunders BE, Resnick HS, Best CL. Violence and risk of PTSD, major depression, substance abuse/dependence, and comorbidity: results from the national survey of adolescents. *J Consult Clin Psychol* 2003; **71**(4): 692-700.
496. Scott JG, Moore SE, Sly PD, Norman RE. Bullying in children and adolescents: a modifiable risk factor for mental illness. *Aust N Z J Psychiatry* 2014; **48**(3): 209-12.
497. McGorry P, Nelson B. Why we need a transdiagnostic staging approach to emerging psychopathology, early diagnosis, and treatment. *JAMA Psychiatry* 2016; **73**(3): 191-2.
498. World Health Organization. Mental Health Global Action Programme Humanitarian Intervention Guide (mhGAP-HIG): Clinical Management of Mental, Neurological and Substance Use Conditions in Humanitarian Emergencies. Geneva: World Health Organization, 2015.
499. Watanabe N, Furukawa TA, Shimodera S, et al. Brief behavioral therapy for refractory insomnia in residual depression: an assessor-blind, randomized controlled trial. *J Clin Psychiatry* 2011; **72**(12): 1651-8.
500. Christensen H, Batterham PJ, Gosling JA, et al. Effectiveness of an online insomnia program (SHUTi) for prevention of depressive episodes (the GoodNight Study): a randomised controlled trial. *Lancet Psychiatry* 2016; **3**(4): 333-41.
501. Cuijpers P, Noma H, Karyotaki E, Cipriani A, Furukawa TA. Effectiveness and Acceptability of Cognitive Behavior Therapy Delivery Formats in Adults With Depression: A Network Meta-analysis. *JAMA Psychiatry* 2019; **76**(7): 700-7.
502. Karyotaki E, Riper H, Twisk J, et al. Efficacy of Self-guided Internet-Based Cognitive Behavioral Therapy in the Treatment of Depressive Symptoms: A Meta-analysis of Individual Participant Data. *JAMA Psychiatry* 2017; **74**(4): 351-9.
503. Karyotaki E, Efthimiou O, Miguel C, et al. Internet-Based Cognitive Behavioral Therapy for Depression: A Systematic Review and Individual Patient Data Network Meta-analysis. *JAMA Psychiatry* 2021.
504. Lund C, De Silva M, Plagerson S, et al. Poverty and mental disorders: breaking the cycle in low-income and middle-income countries. *Lancet* 2011; **378**(9801): 1502-14.
505. Barth J, Munder T, Gerger H, et al. Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis. *PLoS Med* 2013; **10**(5): e1001454.
506. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet* 2018; **391**(10128): 1357-66.
507. Leucht S, Hierl S, Kissling W, Dold M, Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. *Br J Psychiatry* 2012; **200**(2): 97-106.

508. Furukawa TA, Weitz ES, Tanaka S, et al. Initial severity of depression and efficacy of cognitive-behavioural therapy: individual-participant data meta-analysis of pill-placebo-controlled trials. *Br J Psychiatry* 2017; **210**(3): 190-6.
509. Furukawa TA, Cipriani A, Atkinson LZ, et al. Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. *Lancet Psychiatry* 2016; **3**(11): 1059-66.
510. Furukawa TA. From effect size into number needed to treat. *Lancet* 1999; **353**(9165): 1680.
511. Furukawa TA. Measuring Clinical Importance in a Trial of Interventions for Mixed Urinary Incontinence. *Jama* 2020; **323**(5): 479.
512. Cuijpers P, Turner EH, Koole SL, van Dijke A, Smit F. What is the threshold for a clinically relevant effect? The case of major depressive disorders. *Depression and anxiety* 2014; **31**(5): 374-8.
513. Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. *Lancet Psychiatry* 2019; **6**(7): 601-9.
514. Furukawa TA, Salanti G, Cowen PJ, Leucht S, Cipriani A. No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review. *Acta Psychiatr Scand* 2020; **141**(5): 401-9.
515. Cuijpers P, Noma H, Karyotaki E, Vinkers CH, Cipriani A, Furukawa TA. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. *World Psychiatry* 2020; **19**(1): 92-107.
516. Dunlop BW, Binder EB, Cubells JF, et al. Predictors of remission in depression to individual and combined treatments (PREdict): study protocol for a randomized controlled trial. *Trials* 2012; **13**: 106.
517. Mufson L, Dorta KP, Moreau D, Weissman MM. *Interpersonal Psychotherapy for Depressed Adolescents*: Guilford Publications; 2005(2005).
518. Zhou X, Teng T, Zhang Y, et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. *Lancet Psychiatry* 2020; **7**(7): 581-601.
519. Cuijpers P, Karyotaki E, Eckshtain D, et al. Psychotherapy for Depression Across Different Age Groups: A Systematic Review and Meta-analysis. *JAMA Psychiatry* 2020; **77**(7): 694-702.
520. Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. 1995. *CMAJ* 1998; **159**: 1245-52.
521. Zhou C, Fang L, Chen Y, Zhong J, Wang H, Xie P. Effect of selective serotonin reuptake inhibitors on bone mineral density: a systematic review and meta-analysis. *Osteoporos Int* 2018; **29**(6): 1243-51.
522. NHS. <https://www.nhs.uk/conditions/ssri-antidepressants/side-effects/>.
523. Dragioti E, Solmi M, Favaro A, et al. Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review. *JAMA Psychiatry* 2019.
524. Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? *Addict Behav* 2019; **97**: 111-21.
525. Taylor S, al. e. *Dependence and Withdrawal Associated with Some Prescribed Medicines: An Evidence Review*. . London: Public Health England; 2019(2019).

526. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review. *Psychotherapy and psychosomatics* 2015; **84**(2): 72-81.
527. Jauhar S, Hayes J. Corrigendum to "The war on antidepressants: What we can, and can't conclude, from the systematic review of antidepressant withdrawal effects by Davies and Read" [Addictive Behaviors (2019)]. *Addict Behav* 2019; **97**: 126.
528. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms - Authors' reply. *Lancet Psychiatry* 2019; **6**(7): 562-3.
529. Fava GA, Cosci F. Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs. *J Clin Psychiatry* 2019; **80**(6).
530. Marsden J, White M, Annand F, et al. Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England. *Lancet Psychiatry* 2019; **6**(11): 935-50.
531. Luo Y, Kataoka Y, Ostinelli EG, Cipriani A, Furukawa TA. National Prescription Patterns of Antidepressants in the Treatment of Adults With Major Depression in the US Between 1996 and 2015: A Population Representative Survey Based Analysis. *Frontiers in Psychiatry* 2020; **11**(35).
532. Brown S, Rittenbach K, Cheung S, McKean G, MacMaster FP, Clement F. Current and Common Definitions of Treatment-Resistant Depression: Findings from a Systematic Review and Qualitative Interviews. *Can J Psychiatry* 2019; **64**(6): 380-7.
533. McAllister-Williams RH, Arango C, Blier P, et al. The identification, assessment and management of difficult-to-treat depression: An international consensus statement. *Journal of Affective Disorders* 2020; **267**: 264-82.
534. Dold M, Bartova L, Rupprecht R, Kasper S. Dose Escalation of Antidepressants in Unipolar Depression: A Meta-Analysis of Double-Blind, Randomized Controlled Trials. *Psychotherapy and psychosomatics* 2017; **86**(5): 283-91.
535. Bschor T, Kern H, Henssler J, Baethge C. Switching the Antidepressant After Nonresponse in Adults With Major Depression: A Systematic Literature Search and Meta-Analysis. *J Clin Psychiatry* 2018; **79**(1).
536. Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. *J Clin Psychiatry* 2009; **70**(9): 1219-29.
537. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. *Am J Psychiatry* 2006; **163**(11): 1905-17.
538. Uher R, Frey BN, Quilty LC, et al. Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report. *J Clin Psychiatry* 2020; **81**(4).
539. Furukawa TA, Efthimiou O, Weitz ES, et al. Cognitive-Behavioral Analysis System of Psychotherapy, Drug, or Their Combination for Persistent Depressive Disorder: Personalizing the Treatment Choice Using Individual Participant Data Network Metaregression. *Psychotherapy and psychosomatics* 2018; **87**(3): 140-53.
540. Cristancho P, Lenard E, Lenze EJ, et al. Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM): Study Design and Treatment Characteristics of the First 396 Participants Randomized. *Am J Geriatr Psychiatry* 2019; **27**(10): 1138-52.
541. Wijkstra J, Lijmer J, Burger H, Cipriani A, Geddes J, Nolen WA. Pharmacological treatment for psychotic depression. *Cochrane Database Syst Rev* 2015; (7): Cd004044.

542. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. *Jama* 2001; **285**(10): 1299-307.
543. Gunduz-Bruce H, Kaner SJ, Zorumski CF. Trial of SAGE-217 in Patients with Major Depressive Disorder. Reply. *N Engl J Med* 2019; **381**(22): 2179.
544. Meltzer-Brody S, Colquhoun H, Riesenber R, et al. Brexanolone injection in postpartum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet* 2018; **392**(10152): 1058-70.
545. Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. *JAMA Psychiatry* 2018; **75**(2): 139-48.
546. Salanti G, Dias S, Welton NJ, et al. Evaluating novel agent effects in multiple-treatments meta-regression. *Stat Med* 2010; **29**(23): 2369-83.
547. Hunot V, Moore TH, Caldwell DM, et al. 'Third wave' cognitive and behavioural therapies versus other psychological therapies for depression. *Cochrane Database Syst Rev* 2013; (10): Cd008704.
548. Newby JM, McKinnon A, Kuyken W, Gilbody S, Dalgleish T. Systematic review and meta-analysis of transdiagnostic psychological treatments for anxiety and depressive disorders in adulthood. *Clin Psychol Rev* 2015; **40**: 91-110.
549. Fodor LA, Georgescu R, Cuijpers P, et al. Efficacy of cognitive bias modification interventions in anxiety and depressive disorders: a systematic review and network meta-analysis. *Lancet Psychiatry* 2020; **7**(6): 506-14.
550. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. *Arch Gen Psychiatry* 1991; **48**(9): 851-5.
551. Kato M, Hori H, Inoue T, et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. *Molecular psychiatry* 2021; **26**(1): 118-33.
552. Furukawa TA, Shinohara K, Sahker E, et al. Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta-analysis. *World Psychiatry* In press.
553. Clarke K, Mayo-Wilson E, Kenny J, Pilling S. Can non-pharmacological interventions prevent relapse in adults who have recovered from depression? A systematic review and meta-analysis of randomised controlled trials. *Clin Psychol Rev* 2015; **39**: 58-70.
554. Guidi J, Fava GA. Sequential Combination of Pharmacotherapy and Psychotherapy in Major Depressive Disorder: A Systematic Review and Meta-analysis. *JAMA Psychiatry* 2021; **78**(3): 261-9.
555. Flint AJ, Meyers BS, Rothschild AJ, et al. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial. *Jama* 2019; **322**(7): 622-31.
556. Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). *Arch Gen Psychiatry* 2006; **63**(12): 1337-44.
557. Cuijpers P. Targets and outcomes of psychotherapies for mental disorders: an overview. *World Psychiatry* 2019; **18**(3): 276-85.
558. Cuijpers P, de Beurs DP, van Spijker BA, Berking M, Andersson G, Kerkhof AJ. The effects of psychotherapy for adult depression on suicidality and hopelessness: a systematic review and meta-analysis. *J Affect Disord* 2013; **144**(3): 183-90.

559. Kolovos S, Kleiboer A, Cuijpers P. Effect of psychotherapy for depression on quality of life: meta-analysis. *Br J Psychiatry* 2016; **209**(6): 460-8.
560. Renner F, Cuijpers P, Huibers MJ. The effect of psychotherapy for depression on improvements in social functioning: a meta-analysis. *Psychol Med* 2014; **44**(14): 2913-26.
561. Weitz E, Kleiboer A, van Straten A, Cuijpers P. The effects of psychotherapy for depression on anxiety symptoms: a meta-analysis. *Psychol Med* 2018; **48**(13): 2140-52.
562. Cristea IA, Huibers MJ, David D, Hollon SD, Andersson G, Cuijpers P. The effects of cognitive behavior therapy for adult depression on dysfunctional thinking: A meta-analysis. *Clin Psychol Rev* 2015; **42**: 62-71.
563. Park M, Cuijpers P, van Straten A, Reynolds CF, 3rd. The effects of psychotherapy for adult depression on social support: A meta-analysis. *Cognit Ther Res* 2014; **38**(6): 600-11.
564. Cuijpers P, Weitz E, Karyotaki E, Garber J, Andersson G. The effects of psychological treatment of maternal depression on children and parental functioning: a meta-analysis. *European Child & Adolescent Psychiatry* 2015; **24**(2): 237-45.
565. Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression. *Cochrane Database Syst Rev* 2012; **12**: Cd008381.
566. Stein A, Netsi E, Lawrence PJ, et al. Mitigating the effect of persistent postnatal depression on child outcomes through an intervention to treat depression and improve parenting: a randomised controlled trial. *Lancet Psychiatry* 2018; **5**(2): 134-44.
567. Pizzi C, Rutjes AW, Costa GM, Fontana F, Mezzetti A, Manzoli L. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. *Am J Cardiol* 2011; **107**(7): 972-9.
568. Cristea IA, Karyotaki E, Hollon SD, Cuijpers P, Gentili C. Biological markers evaluated in randomized trials of psychological treatments for depression: a systematic review and meta-analysis. *Neurosci Biobehav Rev* 2019; **101**: 32-44.
569. Sharpe M, Walker J, Holm Hansen C, et al. Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial. *Lancet* 2014; **384**(9948): 1099-108.
570. Walker J, Hansen CH, Martin P, Symeonides S, Gourley C, Wall L, Weller D, Murray G, Sharpe M; SMaRT (Symptom Management Research Trials) Oncology-3 Team. Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer. *Lancet Oncol*. 2014 Sep;15(10):1168-76. doi: 10.1016/S1470-2045(14)70343-2. Epub 2014 Aug 27. PMID: 25175097.
571. Mulick A, Walker J, Puntis S, et al. Does depression treatment improve the survival of depressed patients with cancer? A long-term follow-up of participants in the SMaRT Oncology-2 and 3 trials. *Lancet Psychiatry* 2018; **5**(4): 321-6.
572. Legg LA, Tilney R, Hsieh CF, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. *Cochrane Database Syst Rev* 2019; **2019**(11).
573. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICH) Randomized Trial. *Jama* 2003; **289**(23): 3106-16.
574. van Melle JP, de Jonge P, Honig A, et al. Effects of antidepressant treatment following myocardial infarction. *Br J Psychiatry* 2007; **190**: 460-6.

575. Glassman AH, O'Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. *JAMA* 2002; **288**(6): 701-9.
576. Katon WJ, Lin EH, Von Korff M, et al. Collaborative care for patients with depression and chronic illnesses. *N Engl J Med* 2010; **363**(27): 2611-20.
577. Gallo JJ, Morales KH, Bogner HR, et al. Long term effect of depression care management on mortality in older adults: follow-up of cluster randomized clinical trial in primary care. *BMJ* 2013; **346**: f2570.
578. Bruce ML, Ten Have TR, Reynolds CF, 3rd, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. *JAMA* 2004; **291**(9): 1081-91.
579. Naik AD, Hundt NE, Vaughan EM, et al. Effect of Telephone-Delivered Collaborative Goal Setting and Behavioral Activation vs Enhanced Usual Care for Depression Among Adults With Uncontrolled Diabetes: A Randomized Clinical Trial. *JAMA Netw Open* 2019; **2**(8): e198634-e.
580. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. *N Engl J Med* 2008; **358**(3): 252-60.
581. Driessen E, Hollon SD, Bockting CL, Cuijpers P, Turner EH. Does Publication Bias Inflate the Apparent Efficacy of Psychological Treatment for Major Depressive Disorder? A Systematic Review and Meta-Analysis of US National Institutes of Health-Funded Trials. *PLoS One* 2015; **10**(9): e0137864.
582. Zou CX, Becker JE, Phillips AT, et al. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study. *Trials* 2018; **19**(1): 581.
583. Yoder WR, Karyotaki E, Cristea IA, van Duin D, Cuijpers P. Researcher allegiance in research on psychosocial interventions: meta-research study protocol and pilot study. *BMJ Open* 2019; **9**(2): e024622.
584. Munder T, Gerger H, Trelle S, Barth J. Testing the allegiance bias hypothesis: a meta-analysis. *Psychother Res* 2011; **21**(6): 670-84.
585. Cuijpers P, Karyotaki E, Reijnders M, Purgato M, Barbui C. Psychotherapies for depression in low- and middle-income countries: a meta-analysis. *World Psychiatry* 2018; **17**(1): 90-101.
586. Blackburn TP. Depressive disorders: Treatment failures and poor prognosis over the last 50 years. *Pharmacol Res Perspect* 2019; **7**(3): e00472-e.
587. Kavanagh BE, Brennan-Olsen SL, Turner A, et al. Role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders: a protocol for a systematic review and meta-analysis. *BMJ Open* 2019; **9**(4): e025145.
588. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? *Am J Psychiatry* 2002; **159**(3): 469-73.
589. van der Lem R, de Wever WW, van der Wee NJ, van Veen T, Cuijpers P, Zitman FG. The generalizability of psychotherapy efficacy trials in major depressive disorder: an analysis of the influence of patient selection in efficacy trials on symptom outcome in daily practice. *BMC Psychiatry* 2012; **12**: 192.
590. van der Lem R, van der Wee NJ, van Veen T, Zitman FG. The generalizability of antidepressant efficacy trials to routine psychiatric out-patient practice. *Psychol Med* 2011; **41**(7): 1353-63.
591. Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. *Cochrane Database Syst Rev* 2004; (1): Cd003012.

592. Mohr DC, Spring B, Freedland KE, et al. The selection and design of control conditions for randomized controlled trials of psychological interventions. *Psychotherapy and psychosomatics* 2009; **78**(5): 275-84.
593. Furukawa TA, Noma H, Caldwell DM, et al. Waiting list may be a placebo condition in psychotherapy trials: a contribution from network meta-analysis. *Acta Psychiatr Scand* 2014; **130**(3): 181-92.
594. Cuijpers P, Quero S, Papola D, Cristea IA, Karyotaki E. Care-as-usual control groups across different settings in randomized trials on psychotherapy for adult depression: a meta-analysis. *Psychol Med* 2019: 1-11.
595. Watts SE, Turnell A, Kladnitski N, Newby JM, Andrews G. Treatment-as-usual (TAU) is anything but usual: a meta-analysis of CBT versus TAU for anxiety and depression. *J Affect Disord* 2015; **175**: 152-67.
596. Cuijpers P, Beekman AT, Reynolds CF, 3rd. Preventing depression: a global priority. *Jama* 2012; **307**(10): 1033-4.
597. Kendrick T, Chatwin J, Dowrick C, et al. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. *Health Technol Assess* 2009; **13**(22): iii-iv, ix-xi, 1-159.
597. Kato T, Furukawa TA, Mantani A, et al. Optimising first- and second-line treatment strategies for untreated major depressive disorder - the SUND study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial. *BMC Med* 2018; **16**(1): 103.
599. Furukawa TA, Debray TPA, Akechi T, et al. Can personalized treatment prediction improve the outcomes, compared with the group average approach, in a randomized trial? Developing and validating a multivariable prediction model in a pragmatic megatrial of acute treatment for major depression. *J Affect Disord* 2020; **274**: 690-7.
600. Vigo D, Haro JM, Hwang I, et al. Toward measuring effective treatment coverage: critical bottlenecks in quality- and user-adjusted coverage for major depressive disorder. *Psychol Med* 2020: 1-11.
601. Rodrigues M, Herrman H, Galderisi S, Allan J. WPA Position Statement and Call to Action: Implementing Alternatives to Coercion: A Key Component of Improving Mental Health Care. Position Statement. World Psychiatric Association, 2020.
602. Caneo C, Toro P, Ferreccio C, et al. Validity and Performance of the Patient Health Questionnaire (PHQ-2) for Screening of Depression in a Rural Chilean Cohort. *Community Mental Health Journal* 2020; **56**(7): 1284-91.
603. Fernandes BS, Williams LM, Steiner J, Leboyer M, Carvalho AF, Berk M. The new field of 'precision psychiatry'. *BMC Med* 2017; **15**(1): 80.
604. Macneil CA, Hasty MK, Conus P, Berk M. Is diagnosis enough to guide interventions in mental health? Using case formulation in clinical practice. *BMC Med* 2012; **10**: 111.
605. Newton-Howes G, Tyrer P, Johnson T. Personality disorder and the outcome of depression: meta-analysis of published studies. *Br J Psychiatry* 2006; **188**: 13-20.
606. Thota AB, Sipe TA, Byard GJ, et al. Collaborative care to improve the management of depressive disorders: a community guide systematic review and meta-analysis. *Am J Prev Med* 2012; **42**(5): 525-38.
607. Rao U, Ryan ND, Birmaher B, et al. Unipolar depression in adolescents: clinical outcome in adulthood. *J Am Acad Child Adolesc Psychiatry* 1995; **34**(5): 566-78.
608. Drake RE, Bond GR. The future of supported employment for people with severe mental illness. *Psychiatr Rehabil J* 2008; **31**(4): 367-76.

609. Patel V, Weiss HA, Chowdhary N, et al. Effectiveness of an intervention led by lay health counsellors for depressive and anxiety disorders in primary care in Goa, India (MANAS): a cluster randomised controlled trial. *Lancet* 2010; **376**(9758): 2086-95.
610. Guo T, Xiang YT, Xiao L, et al. Measurement-Based Care Versus Standard Care for Major Depression: A Randomized Controlled Trial With Blind Raters. *Am J Psychiatry* 2015; **172**(10): 1004-13.
611. Panagioti M, Bower P, Kontopantelis E, et al. Association Between Chronic Physical Conditions and the Effectiveness of Collaborative Care for Depression: An Individual Participant Data Meta-analysis. *JAMA Psychiatry* 2016; **73**(9): 978-89.
612. van Eck van der Sluijs JF, Castelijn H, Eijsbroek V, Rijnders CAT, van Marwijk HWJ, van der Feltz-Cornelis CM. Illness burden and physical outcomes associated with collaborative care in patients with comorbid depressive disorder in chronic medical conditions: A systematic review and meta-analysis. *Gen Hosp Psychiatry* 2018; **50**: 1-14.
613. Coventry P, Lovell K, Dickens C, et al. Integrated primary care for patients with mental and physical multimorbidity: cluster randomised controlled trial of collaborative care for patients with depression comorbid with diabetes or cardiovascular disease. *Bmj* 2015; **350**: h638.
614. Camacho EM, Davies LM, Hann M, et al. Long-term clinical and cost-effectiveness of collaborative care (versus usual care) for people with mental-physical multimorbidity: cluster-randomised trial. *Br J Psychiatry* 2018; **213**(2): 456-63.
615. Ali MK, Chwastiak L, Poonthai S, et al. Effect of a Collaborative Care Model on Depressive Symptoms and Glycated Hemoglobin, Blood Pressure, and Serum Cholesterol Among Patients With Depression and Diabetes in India: The INDEPENDENT Randomized Clinical Trial. *JAMA* 2020; **324**(7): 651-62.
616. Green C, Richards DA, Hill JJ, et al. Cost-effectiveness of collaborative care for depression in UK primary care: economic evaluation of a randomised controlled trial (CADET). *PLoS One* 2014; **9**(8): e104225.
617. Buttorff C, Hock RS, Weiss HA, et al. Economic evaluation of a task-shifting intervention for common mental disorders in India. *Bull World Health Organ* 2012; **90**(11): 813-21.
618. Chevance A, Ravaud P, Tomlinson A, et al. Identifying outcomes for depression that matter to patients, informal caregivers, and health-care professionals: qualitative content analysis of a large international online survey. *Lancet Psychiatry* 2020; **7**(8): 692-702.
619. Simon GE, Perlis RH. Personalized medicine for depression: can we match patients with treatments? *Am J Psychiatry* 2010; **167**(12): 1445-55.
620. Cuijpers P, van Straten A, Schuurmans J, van Oppen P, Hollon SD, Andersson G. Psychotherapy for chronic major depression and dysthymia: a meta-analysis. *Clin Psychol Rev* 2010; **30**(1): 51-62.
621. Holsboer F. How can we realize the promise of personalized antidepressant medicines? *Nat Rev Neurosci* 2008; **9**(8): 638-46.
622. Crisafulli C, Fabbri C, Porcelli S, et al. Pharmacogenetics of antidepressants. *Front Pharmacol* 2011; **2**: 6.
623. DeRubeis RJ, Cohen ZD, Forand NR, Fournier JC, Gelfand LA, Lorenzo-Luaces L. The Personalized Advantage Index: translating research on prediction into individualized treatment recommendations. A demonstration. *PLoS One* 2014; **9**(1): e83875.
624. Kessler RC. The potential of predictive analytics to provide clinical decision support in depression treatment planning. *Curr Opin Psychiatry* 2018; **31**(1): 32-9.

625. Trivedi MH, McGrath PJ, Fava M, et al. Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. *J Psychiatr Res* 2016; **78**: 11-23.
626. Massoudi B, Holvast F, Bockting CLH, Burger H, Blanker MH. The effectiveness and cost-effectiveness of e-health interventions for depression and anxiety in primary care: A systematic review and meta-analysis. *J Affect Disord* 2019; **245**: 728-43.
627. Wu Q, Li J, Parrott S, et al. Cost-Effectiveness of Different Formats for Delivery of Cognitive Behavioral Therapy for Depression: A Systematic Review Based Economic Model. *Value Health* 2020; **23**(12): 1662-70.
628. Iacoviello BM, Murrough JW, Hoch MM, et al. A randomized, controlled pilot trial of the Emotional Faces Memory Task: a digital therapeutic for depression. *NPJ digital medicine* 2018; **1**.
629. Furukawa TA, Mchem AS, Ostinelli EG, et al. Dismantling, optimising and personalising internet cognitive-behavioural therapy for depression: A systematic review and individual participant data component network meta-analysis. *in press* 2021.
630. Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. *J Clin Epidemiol* 2010; **63**(11): 1179-94.
631. Muke SS, Shrivastava RD, Mitchell L, et al. Acceptability and feasibility of digital technology for training community health workers to deliver brief psychological treatment for depression in rural India. *Asian J Psychiatr* 2019; **45**: 99-106.
632. Van de Velde S, Heselmans A, Delvaux N, et al. A systematic review of trials evaluating success factors of interventions with computerised clinical decision support. *Implement Sci* 2018; **13**(1): 114.
633. Vitger T, Austin SF, Petersen L, Tonder ES, Nordentoft M, Korsbek L. The Momentum trial: the efficacy of using a smartphone application to promote patient activation and support shared decision making in people with a diagnosis of schizophrenia in outpatient treatment settings: a randomized controlled single-blind trial. *BMC Psychiatry* 2019; **19**(1): 185.
634. Tomlinson A, Furukawa TA, Efthimiou O, et al. Personalise antidepressant treatment for unipolar depression combining individual choices, risks and big data (PETRUSHKA): rationale and protocol. *Evid Based Ment Health* in press.
635. Vigod SN, Hussain-Shamsy N, Stewart DE, et al. A patient decision aid for antidepressant use in pregnancy: Pilot randomized controlled trial. *J Affect Disord* 2019; **251**: 91-9.
636. Onnela JP, Rauch SL. Harnessing Smartphone-Based Digital Phenotyping to Enhance Behavioral and Mental Health. *Neuropsychopharmacology* 2016; **41**(7): 1691-6.
637. Seppala J, De Vita I, Jamsa T, et al. Mobile Phone and Wearable Sensor-Based mHealth Approaches for Psychiatric Disorders and Symptoms: Systematic Review. *JMIR Ment Health* 2019; **6**(2): e9819.
638. Faurholt-Jepsen M, Frost M, Busk J, et al. Differences in mood instability in patients with bipolar disorder type I and II: a smartphone-based study. *Int J Bipolar Disord* 2019; **7**(1): 5.
639. Kumagai N, Tajika A, Hasegawa A, et al. Predicting recurrence of depression using lifelog data: an explanatory feasibility study with a panel VAR approach. *BMC Psychiatry* 2019; **19**(1).
640. Institute of Medicine (Edited by Olsen L, Aisner, D. & McGinnis, J. M.). Learning Healthcare System: Workshop Summary. Washington, DC: The National Academies Press; 2007(2007).

641. May C, Gask L, Atkinson T, Ellis N, Mair F, Esmail A. Resisting and promoting new technologies in clinical practice: the case of telepsychiatry. *Soc Sci Med* 2001; **52**(12): 1889-901.
642. Gilbody S, Littlewood E, Hewitt C, et al. Computerised cognitive behaviour therapy (cCBT) as treatment for depression in primary care (REEACT trial): large scale pragmatic randomised controlled trial. *BMJ* 2015; **351**: h5627.
643. Furukawa TA, Onishi Y, Hinotsu S, et al. Prescription patterns following first-line new generation antidepressants for depression in Japan: a naturalistic cohort study based on a large claims database. *J Affect Disord* 2013; **150**(3): 916-22.
644. Torous J, Wisniewski H, Liu G, Keshavan M. Mental Health Mobile Phone App Usage, Concerns, and Benefits Among Psychiatric Outpatients: Comparative Survey Study. *JMIR Ment Health* 2018; **5**(4): e11715.
645. Ben-Zeev D, Drake R, Marsch L. Clinical technology specialists. *BMJ* 2015; **350**: h945.
646. Faden RR, Beauchamp TL, Kass NE. Informed consent, comparative effectiveness, and learning health care. *N Engl J Med* 2014; **370**(8): 766-8.
647. Doraiswamy PME, London P, Varnum B, et al. Empowering 8 Billion Minds: Enabling Better Mental Health for All via the Ethical Adoption of Technologies. Washington, DC: National Academy of Medicine; 2019(2019).
648. Kapur N, Ibrahim S, While D, et al. Mental health service changes, organisational factors, and patient suicide in England in 1997-2012: a before-and-after study. *Lancet Psychiatry* 2016; **3**(6): 526-34.
649. Hampton T. Depression care effort brings dramatic drop in large HMO population's suicide rate. *JAMA* 2010; **303**(19): 1903-5.
650. Gusmão R, Quintão S, McDaid D, et al. Antidepressant Utilization and Suicide in Europe: An Ecological Multi-National Study. *PLoS One* 2013; **8**(6): e66455.
651. Abou-Saleh MT, Müller-Oerlinghausen B, Coppen AJ. Lithium in the episode and suicide prophylaxis and in augmenting strategies in patients with unipolar depression. *Int J Bipolar Disord* 2017; **5**(1): 11.
652. Murrough JW, Soleimani L, DeWilde KE, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. *Psychol Med* 2015; **45**(16): 3571-80.
653. Ionescu DF, Swee MB, Pavone KJ, et al. Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study. *J Clin Psychiatry* 2016; **77**(6): e719-25.
654. Stanley B, Brown GK. Safety Planning Intervention: A Brief Intervention to Mitigate Suicide Risk. *Cognitive and Behavioral Practice* 2012; **19**(2): 256-64.
655. Horowitz MA, Moncrieff J. Are we repeating mistakes of the past? A review of the evidence for esketamine. *Br J Psychiatry* 2020: 1-4.
656. Jayaram G, Sporney H, Perticone P. The Utility and Effectiveness of 15-minute Checks in Inpatient Settings. *Psychiatry (Edgmont)* 2010; **7**(8): 46-9.
657. Bschor T. Lithium in the treatment of major depressive disorder. *Drugs* 2014; **74**(8): 855-62.
658. McDaid D. Making an economic case for investing in suicide prevention: quo vadis? . In: O'Connor RC, Pirkis J, eds. *The International Handbook of Suicide Prevention*. Chichester, UK: Wiley-Blackwell; 2016: 775-90.
659. Dunlap LJ, Orme S, Zarkin GA, et al. Screening and Intervention for Suicide Prevention: A Cost-Effectiveness Analysis of the ED-SAFE Interventions. *Psychiatric Services* 2019; **70**(12): 1082-7.
660. Woodford R, Spittal MJ, Milner A, et al. Accuracy of Clinician Predictions of Future Self-Harm: A Systematic Review and Meta-Analysis of Predictive Studies. *Suicide & life-threatening behavior* 2019; **49**(1): 23-40.

661. Carter G, Milner A, McGill K, Pirkis J, Kapur N, Spittal MJ. Predicting suicidal behaviours using clinical instruments: systematic review and meta-analysis of positive predictive values for risk scales. *Br J Psychiatry* 2017; **210**(6): 387-95.
662. Large M, Myles N, Myles H, et al. Suicide risk assessment among psychiatric inpatients: a systematic review and meta-analysis of high-risk categories. *Psychol Med* 2018; **48**(7): 1119-27.
663. Runeson B, Odeberg J, Pettersson A, Edbom T, Jildevik Adamsson I, Waern M. Instruments for the assessment of suicide risk: A systematic review evaluating the certainty of the evidence. *PLoS One* 2017; **12**(7): e0180292.
664. Hosmer DW. Applied logistic regression. Third edition / David W. Hosmer, Jr., PhD, Stanley Lemeshow, PhD, Rodney X. Sturdivant, PhD. ed. Hoboken, New Jersey: Wiley; 2013(2013).
665. Belsher BE, Smolenski DJ, Pruitt LD, et al. Prediction Models for Suicide Attempts and Deaths: A Systematic Review and Simulation. *JAMA Psychiatry* 2019; **76**(6): 642-51.
666. Wortzel HS, Nazem S, Bahraini NH, Matarazzo BB. Why Suicide Risk Assessment Still Matters. *Journal of psychiatric practice* 2017; **23**(6): 436-40.
667. Kessler RC. Clinical Epidemiological Research on Suicide-Related Behaviors-Where We Are and Where We Need to Go. *JAMA Psychiatry* 2019; **76**(8): 777-8.
668. Kessler RC, Bossarte RM, Luedtke A, Zaslavsky AM, Zubizarreta JR. Suicide prediction models: a critical review of recent research with recommendations for the way forward. *Molecular psychiatry* 2020; **25**(1): 168-79.
669. Bernecker SL, Zuromski KL, Curry JC, et al. Economic Evaluation of Brief Cognitive Behavioral Therapy vs Treatment as Usual for Suicidal US Army Soldiers. *JAMA Psychiatry* 2020; **77**(3): 256-64.
670. EL R, Zuromski KL, Reis B, Nock MK, Kessler RC, Smoller J. Accuracy requirements for cost-effective suicide risk prediction in the United States. *JAMA Psychiatry* In press.
671. Gingrich JA, Malm H, Ansorge MS, et al. New Insights into How Serotonin Selective Reuptake Inhibitors Shape the Developing Brain. *Birth Defects Res* 2017; **109**(12): 924-32.
672. Khalifeh H, Hunt IM, Appleby L, Howard LM. Suicide in perinatal and non-perinatal women in contact with psychiatric services: 15 year findings from a UK national inquiry. *Lancet Psychiatry* 2016; **3**(3): 233-42.
673. Stewart DE, Vigod SN. Postpartum Depression: Pathophysiology, Treatment, and Emerging Therapeutics. *Annu Rev Med* 2019; **70**: 183-96.
674. Keynejad RC, Hanlon C, Howard LM. Psychological interventions for common mental disorders in women experiencing intimate partner violence in low-income and middle-income countries: a systematic review and meta-analysis. *Lancet Psychiatry* 2020; **7**(2): 173-90.
675. Clarke K, King M, Prost A. Psychosocial interventions for perinatal common mental disorders delivered by providers who are not mental health specialists in low- and middle-income countries: a systematic review and meta-analysis. *PLoS Med* 2013; **10**(10): e1001541.
676. Weissman MM, Pilowsky DJ, Wickramaratne PJ, et al. Remissions in maternal depression and child psychopathology: a STAR*D-child report. *Jama* 2006; **295**(12): 1389-98.
677. Wickramaratne P, Gameroff MJ, Pilowsky DJ, et al. Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. *Am J Psychiatry* 2011; **168**(6): 593-602.

678. Weissman MM, Wickramaratne P, Pilowsky DJ, et al. Treatment of maternal depression in a medication clinical trial and its effect on children. *Am J Psychiatry* 2015; **172**(5): 450-9.
679. Grote NK, Simon GE, Russo J, Lohr MJ, Carson K, Katon W. Incremental Benefit-Cost of MOMCare: Collaborative Care for Perinatal Depression Among Economically Disadvantaged Women. *Psychiatr Serv* 2017; **68**(11): 1164-71.
680. Swartz HA, Cyranowski JM, Cheng Y, et al. Brief Psychotherapy for Maternal Depression: Impact on Mothers and Children. *J Am Acad Child Adolesc Psychiatry* 2016; **55**(6): 495-503.e2.
681. Swartz HA, Fournier J. Can Network Meta-analysis Substitute for Direct Comparisons in Psychotherapy Trials? *JAMA Psychiatry* 2019; **76**(7): 678-9.
682. Gunlicks ML, Weissman MM. Change in child psychopathology with improvement in parental depression: a systematic review. *J Am Acad Child Adolesc Psychiatry* 2008; **47**(4): 379-89.
683. Howard LM, Challacombe F. Effective treatment of postnatal depression is associated with normal child development. *Lancet Psychiatry* 2018; **5**(2): 95-7.
684. McTavish JR, MacGregor JC, Wathen CN, MacMillan HL. Children's exposure to intimate partner violence: an overview. *International review of psychiatry (Abingdon, England)* 2016; **28**(5): 504-18.
685. UNICEF. Measurement of mental health among adolescents at the population level (MMAP): an overview. 2021. Available at: <https://data.unicef.org/resources/mmap-august-2019/>
686. Wolpert M, Vostanis P, Martin K, et al. High integrity mental health services for children: focusing on the person, not the problem. *Bmj* 2017; **357**: j1500.
687. Kodish I, Richardson L, Schlesinger A. Collaborative and Integrated Care for Adolescent Depression. *Child Adolesc Psychiatr Clin N Am* 2019; **28**(3): 315-25.
688. Richardson LP, Ludman E, McCauley E, et al. Collaborative care for adolescents with depression in primary care: a randomized clinical trial. *Jama* 2014; **312**(8): 809-16.
689. Wright DR, Haaland WL, Ludman E, McCauley E, Lindenbaum J, Richardson LP. The Costs and Cost-effectiveness of Collaborative Care for Adolescents With Depression in Primary Care Settings: A Randomized Clinical Trial. *JAMA Pediatr* 2016; **170**(11): 1048-54.
690. Bear HA, Edbrooke-Childs J, Norton S, Krause KR, Wolpert M. Systematic Review and Meta-Analysis: Outcomes of Routine Specialist Mental Health Care for Young People With Depression and/or Anxiety. *J Am Acad Child Adolesc Psychiatry* 2019.
691. Weisz JR, Kuppens S, Eckshtain D, Ugueto AM, Hawley KM, Jensen-Doss A. Performance of evidence-based youth psychotherapies compared with usual clinical care: a multilevel meta-analysis. *JAMA Psychiatry* 2013; **70**(7): 750-61.
692. Weisz JR, Chorpita BF, Palinkas LA, et al. Testing standard and modular designs for psychotherapy treating depression, anxiety, and conduct problems in youth: a randomized effectiveness trial. *Arch Gen Psychiatry* 2012; **69**(3): 274-82.
693. Wolpert M, Dalzell K, Ullman R, et al. Strategies not accompanied by a mental health professional to address anxiety and depression in children and young people: a scoping review of range and a systematic review of effectiveness. *Lancet Psychiatry* 2019; **6**(1): 46-60.
694. Michelson D, Malik K, Parikh R, et al. Effectiveness of a brief lay counsellor-delivered, problem-solving intervention for adolescent mental health problems in urban, low-income schools in India: a randomised controlled trial. *Lancet Child Adolesc Health* 2020; **4**(8): 571-82.

695. Unutzer J, Katon W, Callahan CM, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. *JAMA* 2002; **288**(22): 2836-45.
696. United Nations Office for the Coordination of Humanitarian Affairs (OCHA). Global Humanitarian Overview for 2021. Available at: <https://gho.unocha.org/>
697. IASC. Guidelines on Mental Health and Psychosocial Support in Emergency Settings. Geneva: Inter-Agency Standing Committee; 2007. Available at: https://www.who.int/mental_health/emergencies/guidelines_iasc_mental_health_psychosocial_june_2007.pdf
698. Dawson KS, Bryant RA, Harper M, et al. Problem Management Plus (PM+): a WHO transdiagnostic psychological intervention for common mental health problems. *World Psychiatry* 2015; **14**(3): 354-7.
699. Tol WA, Leku MR, Lakin DP, et al. Guided self-help to reduce psychological distress in South Sudanese female refugees in Uganda: a cluster randomised trial. *Lancet Glob Health* 2020; **8**(2): e254-e63.
700. Barbui C, Purgato M, Abdulmalik J, et al. Efficacy of psychosocial interventions for mental health outcomes in low-income and middle-income countries: an umbrella review. *The Lancet Psychiatry* 2020.
701. Harris MG, Kazdin AE, Chiu WT, et al. Findings From World Mental Health Surveys of the Perceived Helpfulness of Treatment for Patients With Major Depressive Disorder. *JAMA Psychiatry* 2020; **77**(8): 1-13.
702. Weissman MM, Pathak J, Talati A. Personal Life Events-A Promising Dimension for Psychiatry in Electronic Health Records. *JAMA Psychiatry* 2019.
703. Wellcome Trust. Mental health programme strategy; 2019. <https://wellcome.ac.uk/what-we-do/our-work/mental-health-transforming-research-and-treatments/strategy2019>).
704. Brinsley J, Schuch F, Lederman O, et al. Effects of yoga on depressive symptoms in people with mental disorders: a systematic review and meta-analysis. *British Journal of Sports Medicine* 2020: bjsports-2019-101242.
705. Clark DM. Realizing the Mass Public Benefit of Evidence-Based Psychological Therapies: The IAPT Program. *Annual Review of Clinical Psychology* 2018; **14**(1): 159-83.